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Obesity is a chronic condition where the body’s ability to regulate energy balance 
is compromised. Prolonged consumption of saturated fatty acids triggers 
inflammation throughout the body, including the brain. Within the brain, 
astrocytes and microglia respond to nutrients and inflammatory signals with 
reactive gliosis. The mitochondrial translocator protein of 18 kDa (TSPO) is used 
to mark reactive glia. However, the function of TSPO – or its relevance to gliosis 
- is not well-understood. In vitro studies suggest involvement in mitochondrial 
metabolism, including altering substrate use. In vivo work suggests a role for 
TSPO modulating systemic glucose homeostasis. The hypothesis underlying my 
project was: TSPO is involved in metabolic flexibility and is regulated in states of 
energy imbalance, and manipulation of TSPO expression will alter energy 
homeostasis. 
I validated a common TSPO antibody, which proved it to be unreliable for 
immunohistochemical characterisation of TSPO in the mouse brain. Comparison 
between brain tissue taken from TSPO knock-out (-/-) and wild-type mice 
indicated a low level of immunoreactivity throughout the mouse brain that was 
specific. This included immunoreactivity around the ventricles of the brain that 
was attributed to tanycytes. However, the majority of the immunoreactivity was 
not specific to TSPO and confounds results that use this antibody.  
I characterised the metabolic phenotype of the germline global TSPO -/- mice. 
These mice did not exhibit differences in body weight or food intake in response 
to an overnight fast compared to littermate controls. Male TSPO -/- mice 
consumed less high-fat diet than controls in the first week of exposure, but there 
were no long-term differences. Basal blood glucose levels or glucose clearance 
in the glucose tolerance test were also unaffected by genotype, though female 
TSPO -/- mice may have enhanced protection against diet-induced loss of 
glucose tolerance compared to wild-type. These data were consistent with 
experiments using PK11195, a TSPO ligand. These findings are important for 
comparisons across the literature that involve different knock-out mouse models. 
In conclusion, global modulation of TSPO does not impact energy homeostasis 
on the organismal level and its functions are likely cell-type specific. Therefore, 
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systemic modulation of TSPO signalling it is unlikely to offer translational potential 
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ICD-11 International Classification of Diseases 





IMPC International Mouse Phenotyping Consortium 
LCFA Long-chain fatty acid 
LH Lateral hypothalamic nucleus 
LPS Lipopolysaccharide 
LSN Lateral septal nucleus 
LV Lateral ventricle 
M Male 
MBH Mediobasal hypothalamus 
MC4R Melanocortin-4 receptors 
MCH Melanin-concentrating hormone 
ME Median eminence 
mRNA Messenger ribonucleic acid 
MSH Melanocyte-stimulating hormone 
NAcc Nucleus accumbens 
NaCl Sodium chloride 
NaF Sodium fluoride 
NaPPi Sodium pyrophosphate tetrabasic decahydrate 
NaOH Sodium hydroxide 




Normal donkey serum 
Nuclear factor kappa-light-chain-enhancer of 
activated B cells 
NNT Nicotinamide nucleotide transhydrogenase 
NPY Neuropeptide Y 
NTS Nucleus of the Solitary Tract 
ODN Octadecaneuropeptide 
Opt Optic tract 
PAGE Poly-acrylamide gel electrophoresis 
PBR Peripheral benzodiazepine receptor 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline with Triton-X 
Pck1 Phosphoenolpyruvate carboxykinase 1 
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PCR Polymerase chain reaction 
Pe Periventricular hypothalamic nucleus 
PET Positron emission tomography 
PFA Paraformaldehyde 
PMSF Phenylmethanesulfonyl fluoride 
POMC Pro-opiomelanocortin 
PVH Paraventricular nucleus of the hypothalamus 
qPCR Quantitative PCR 
ROI Region of interest 
SD Standard chow diet 
SDS Sodium dodecyl sulphate 
SF-1 Steroidogenic factor 1 
SFA Saturated fatty acid 
SFO Subfornical organ 
SIRT1 Sirtuin 1 
StAR Steroidogenic acute regulatory protein 
TBS-T Tris-buffered saline with Tween 
TEMED N,N,N′,N′-Tetramethylethylenediamine 
Tm1b Targeted mutation 
TNFα Tumour necrosis factor α 
TRH Thyrotropin releasing hormone 
TSPO Mitochondrial translocator protein 18 kDa 
TTN Triakontatetraneuropeptide 
VDAC Voltage-dependent anion channel 
VMH Ventromedial hypothalamic nucleus 
VOLT Vascular organ of the lamina terminalis 
WAT White adipose tissue 







The order in which the work is presented in this thesis is in three thematic 
chapters. However, this does not reflect the order in which the studies were 
conducted. It is essential to note that the acquisition of the TSPO global knock-
out mouse line, the data in which contributed to chapter five, meant that in-house 
validation could be performed on the antibody which produced the data used in 
chapters three and four. Unfortunately, this internal validation did not confirm the 
expected specificity of the antibody used. This altered the conclusions of the 
results described in chapters three and four. Therefore, the chapters in this thesis 
are described with as they were conducted – prior to the knowledge of the lack 
of specificity in the antibody. The chapter conclusions then consider this particular 
finding and its contribution to the interpretation of my data but also the 
conclusions of data produced by other research groups.  
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Chapter 1: General Introduction 
1.1 Obesity is a progressive disease with few 
therapeutic interventions 
 
Obesity is a physiological state that is typically a result of excess calorie intake 
not offset by a sufficient increase in energy expenditure. This leads to an increase 
in weight gain, attributed primarily to fat mass. The World Health Organisation 
(WHO) defines obesity as an accumulation of excessive fat that might impair 
health, and a body-mass index of over 30 (1,2). Increased fat storage occurs 
primarily within the adipose tissue, but also in the other metabolic organs of the 
body such as the liver (3,4). In addition to the excess weight that the body is 
bearing, increased fat stores predispose individuals to other health complications 
(5). Furthermore, individuals find it difficult to lose the excess weight and maintain 
the weight loss regardless of dietary or physical interventions (6). As well as a 
predisposing factor for other diseases, obesity is becoming acknowledged as a 
pathology in its own right and the international classification of diseases (ICD-11) 
considers obesity to be under the heading of endocrine, nutrient or metabolic 
diseases (7). The World Obesity Federation has proposed that obesity is a 
chronic relapsing and progressive disease (8). The idea that obesity is 
progressive is consistent with the knowledge of the metabolic changes underlying 
obesity, which is discussed in detail below. 
The mechanisms underlying obesity have gained a lot of research interest, due 
to it being a predisposing factor for other serious illnesses: cardiovascular 
illnesses (heart disease, stroke), metabolic diseases (type 2 diabetes mellitus), 
and musculoskeletal disorders (arthritis, osteoporosis) (5). Non-communicable 
diseases such as these, are estimated to be the cause of 70% of early deaths 
world-wide (9) and obesity is also associated with premature death and disability 
(10–13). Obesity is hugely prevalent throughout the world; although it is at greater 
incidence in countries of high-income and income-disparity (13,14). As well as 
socio-economic status, genetics and heritability contribute to obesity. Due to its 
high incidence and comorbidities, obesity places a considerable burden on public 
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health and the economy. While reduction of obesity would not eliminate other 
diseases, it has potential to alleviate them and their cost.  
Current strategies to conquer the obesity epidemic primarily involve educational 
approaches and changes in government policy (1,2,13,15,16). Dietary limitations 
are the most accessible and easy to implement, but are difficult to maintain long-
term compliance and benefits (6). These measures have been reinforced by 
societal changes in advertisement and taxes on foods deemed unhealthy. The 
hope is that these measures would facilitate an individual-based response that 
results in behavioural changes and reduction in consumption of high-sugar/high-
fat foods. However, to date no nation has been successful in reducing the 
prevalence of obesity (17). While the blame could be attributed to the individual, 
obesity is a multi-factorial challenge and such factors likely limit an individuals’ 
effort regardless of reinforcements provided by governmental policy. Even with 
societal support, responsibility cannot be placed solely upon on the individual to 
reduce the incidence of obesity as many causative factors lay outside of one’s 
control. Further investigation into these factors is required. 
Clinical interventions in individuals with obesity presenting with comorbidities has 
gained some success. Gastric bypass surgery remains the most effective, 
improving blood glucose control in patients with type-2 diabetes almost 
immediately (18). Pharmaceutical approaches have had varying successes but 
tend to only produce relatively small weight loss (19). Some drugs developed to 
treat type-2 diabetes, such as liraglutide (20), have been repurposed following 
promise in weight-loss. These drugs target one of many possible mechanisms 
underlying obesity-associated pathology and provide some insight to the 
pathophysiology.  
 
1.2 Cross-organ communication regulates energy 
balance 
 
The goal of energy homeostasis mechanisms is to maintain a steady state of 
energy reserves respective of energy intake and expenditure. These processes 
occur throughout the organism (Fig 1.2.1). Communications from tissues 
regarding energy and nutrient availability converge in the homeostatic hub of the 
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brain: the hypothalamus (21) (Fig 1.2.2). This information must be integrated to 
consequently inform the body of how to proceed: to initiate or cease food intake 
or regulate expenditure of energy. While the entire body is involved, I will focus 
on key hypothalamic and non-hypothalamic brain regions and the contribution 
from the gut, adipose tissue, and the liver. 
 
1.2.1 Peripheral signals contributing to the regulation of energy balance  
One of the initial sensors of energy intake is within the gastrointestinal (GI) tract. 
The gut contains the enteric nervous system, which consists of multiple cell types 
with different morphological, electrophysical and chemical properties (22–24). 
Cells of the GI lining respond depending on the nutrients absorbed and in turn 
secrete associated hormones. These hormones not only act locally to induce 
digestion, but also act in an endocrine manner across the body including the 
brain. One example, cholecystokinin, is secreted from the duodenum in response 
to fat and protein intake (25–27). It acts locally to inhibit gastric emptying, 
stimulates the pancreas to release digestive enzymes, and also acts in the brain 
to inhibit appetite. In acute absence of sufficient nutrition, the GI system secretes 
ghrelin to stimulate appetitive behaviour via the brain (28–31). As well as blood-
borne signals, the gut is capable of signalling directly to the brain by means of 
the vagus nerve (32–40). This nerve conveys signals between the medulla 
oblongata and organs within the abdomen. The vagal afferents are sensitive to 
mechanosensors in the gut, which sense gastric stretch due to food consumption, 
and are responsive to nutrients (36,37). Gut-released peptides can also enhance 
vagal transmission in relation to nutritional status (25). These two means of gut-
brain communication provide temporally dynamic information regarding food 
intake. 
The vagus nerve also innervates the liver, another important metabolic organ. 
The liver is crucial for the regulation of whole-body glucose levels and lipid 
metabolism (41). It receives information regarding nutrient intake from the gut 
directly, via circulating hormones and nutrient transport, and indirectly through 
the central nervous system (CNS) (41,42). It is also sensitive to the homeostatic 
output of the brain and regulates glucose levels accordingly. In the post-prandial 
state, hepatocytes condense glucose into glycogen for storage. In response to 
low energy availability/glucose deprivation, the liver is the primary site of glucose 
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production through glycogenolysis and gluconeogenesis. In addition to glucose 
metabolism, hepatocytes also provide a storage site for fatty acids (FAs). Excess 
FAs lead to lipid accumulation and liver damage in the form of hepatic steatosis 
(43). This also impairs the livers’ ability to maintain glucose homeostasis and so 
contributes to the pathology associated with obesity (44). Consequently, liver 
dysfunction is a key player in the progression of obesity. 
Adipose tissue is the primary designated fat storage organ of the organism. Since 
the discovery of the hormone leptin, an adipokine that conveys information on 
levels of fat storage, adipose tissue has been considered a crucial organ in 
energy homeostasis (45,46). In turn, adipose tissue receives innervation from the 
sympathetic nervous system which influence fat storage and lipolysis (47,48). 
There are two main types of adipose depot: energy-storing white adipose tissue 
(WAT), which is the most abundant within an organism, and energy-expending 
thermogenic brown adipose tissue (BAT) (49–51). White adipocytes take up un-
catabolized glucose and FAs in the circulation to store within the tissue as 
triglycerides (46). In states of negative energy balance these are catabolised into 
free FAs (FFAs) and released into the circulation to provide a source of energy 
(52).  
In obesity, white adipocytes try to compensate for the increased FFAs in the 
circulation through an increase in cell size (53–55). This increase in adipocyte 
mass leads to competition for oxygen, resulting in hypoxia across the tissue 
(56,57). During hypoxia, the adipocytes shift their metabolism and nutrient up-
take to focus on glycolysis (58,59). Considering the metabolic shift to glycolysis 
in WAT, as well as the increased calorie intake, FFAs in the circulation become 
elevated (54). This is a key driver for obesity-induced inflammation in adipose 
tissue. As well as being an important endocrine organ, adipose tissue is a host to 
many resident immune cells; such as macrophages, mast cells, and natural killer 
cells (60,61). Cellular debris from the dying adipocytes attracts additional 
macrophages and other immune cells to infiltrate the WAT and produce pro-
inflammatory cytokines (62–64). WAT infiltrating immune cells are associated 
with early-stage onset of insulin resistance, which is a metabolic complication of 
obesity (65). Adipocyte expansion and apoptosis is alleviated in absence of pro-
inflammatory signalling in adipose tissue (66). This indicates that impaired 
function of adipose tissue, as observed in nutrient excess, is exacerbated by its 
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Figure 1.2.1 A snapshot of the communication pathways between the brain, 
digestive organs, and adipose tissue relevant in the regulation of energy 
homeostasis. 
The brain receives signals from adipose tissue through chemical signals such as 
adipokines, including leptin, and cytokines. Free fatty acids released from adipose 
tissue also act as messenger signals to the brain. Adipose tissue is innervated by 
noradrenergic nervous transmission. Communication between the brain, liver and 
gastrointestinal tract is mediated by cholinergic transmission at the vagus nerve. The 
gastrointestinal system also secretes hormones that are received by the brain, such 




1.2.2 Hypothalamic regulation of energy balance 
As mentioned above, energy homeostasis incorporates communication of 
information on energy intake and storage across multiple organs. Pathways 
sensing and responding to nutritional state and energy expenditure require 
organisation and integration of the information to produce an appropriate output. 
The hub for integration relies on the brain, primarily the hypothalamic nuclei.  
The hypothalamus is an incredibly diverse and heterogeneous region of the 
forebrain. It supervises the regulation of multiple systems, including energy 
homeostasis, and its outputs are widespread throughout the CNS and the 
periphery. Energy homeostasis is primarily regulated by the nuclei immediately 
surrounding the third ventricle (3V) due to the ability of appetitive information 
relayed by nutrients and hormones to readily access this area (68). Below the 3V 
is the median eminence (ME), a circumventricular organ and an area in which the 
blood-brain barrier (BBB) has relatively increased permeability and so chemical 
signals and nutrients are able to  more readily penetrate to the brain regions that 
lie in immediate proximity (69–73). Hypothalamic nuclei are perfectly situated to 
receive signals regarding the energetic state of the body. The nuclei of focus in 
this project were the arcuate hypothalamic nucleus (Arc), ME, the paraventricular 
hypothalamic nucleus (PVH), and the dorsomedial hypothalamic nucleus (DMH). 
Other hypothalamic nuclei involved in energy homeostasis - that will not be 
covered in as much detail here - are the lateral hypothalamic nucleus (LH) and 
the ventromedial hypothalamic nucleus (VMH). 
Response to appetitive information is primarily controlled within the arcuate 
nucleus of the hypothalamus (Arc). There are six categorised neuronal types 
within the mouse Arc, from which further subtypes have been delineated (74). 
Appetitive behaviour is controlled by two major well-characterised neuronal 
populations: neurons that co-express both neuropeptide-Y (NPY) and agouti-
related peptide (AgRP), and those producing pro-opiomelanocortin (POMC). 
These neurons are differentially-activated in response to negative or positive 
energy states respectively, and promote feeding or meal termination (75). NPY 
is an appetite-stimulating peptide, and AgRP is an inverse agonist at appetite-
inhibiting melanocortin-4 receptors (MC4R) (76,77). Together, neurons that 
express these peptides are orexigenic. NPY/AgRP-expressing neurons also 
express the neurotransmitter GABA, and in turn directly inhibit the activity of 
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anorexigenic POMC-expressing neurons (78). POMC is post-translationally 
cleaved to form adrenocorticotropic hormone (ACTH) and melanocyte-
stimulating hormones (MSH) which are agonists at the MC4R (79–81). Axons of 
both Arc AgRP/NPY and POMC neurons project to multiple hypothalamic and 
non-hypothalamic regions of the brain to evoke their effects (82). These neurons 
also receive efferent signals from across the brain.  
The paraventricular nucleus of the hypothalamus (PVH) is one of the direct 
targets of Arc neuronal projections, as well as conveying signals down to the Arc 
itself. The PVH is an important nucleus in the regulation of energy intake through 
termination of feeding (83–86). As with the Arc, the PVH consists of a 
heterogeneous mix of peptidergic and non-peptidergic neurons. This enables it 
to regulate multiple different homeostatic mechanisms, including stress as well 
as energy balance (87). Neurosecretory neuronal projections from the PVH to the 
ME and on to the pituitary gland are critical regulators of endocrine function. It is 
a key projection target for melanocortin neurons from the Arc, and MC4R is highly 
expressed in the PVH (88). As well as appetite, the PVH is sensitive to 
information regarding adiposity through leptin-sensitive connections from the Arc 
(89,90) and leptin receptors expressed on PVH neurons (91–93). The PVH is an 
important hub of hypothalamic homeostatic control, crucial for mediating feeding 
termination as well as potentially energy balance. 
The dorsomedial hypothalamic nucleus (DMH) is an intermediate point in the 
hypothalamus, in which inputs from other regions in the brain are integrated and 
their afferents sent to the corresponding brain nuclei. Lesion studies have 
implicated the DMH in promoting appetite and energy expenditure, indicative of 
a role in energy homeostasis. The DMH is sensitive to ghrelin signalling (94), 
from which it regulates meal size, energy expenditure, and food anticipatory 
activity (95,96). It also mediates the thermogenic effect of leptin signalling, as a 
mode of energy expenditure (97). The DMH is also reported to be involved in the 
adaptive physiological response to food restriction (98). It is home to several 
groups of peptidergic neurons, some of which are also found in the Arc and other 
hypothalamic and non-hypothalamic regions. However, within the DMH these 
peptides have different functions. For example, a key set of neuropeptide-
expressing neurons in the DMH is that of NPY. Unlike NPY neurons of the Arc, 
DMH NPY cells are not sensitive to leptin and NPY in the DMH is expressed at 
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low levels under basal conditions but upregulated in energy imbalance (99,100). 
The output of DMH NPY neurons is important in communicating orexigenic 
signals that influence meal-size (100,101). DMH signalling is crucial in regulation 
of body weight, likely through balancing food intake and energy expenditure. 
 
 
Figure 1.2.2 Hypothalamic and other brain regions that are involved in energy 
homeostasis. 
Mouse brain figure adapted from Sci-Draw (67), depicting a sagittal view of the mouse 
brain and the key nuclei involved in energy homeostasis that are relevant to this study 
(a). Hypothalamic nuclei communicate amongst each other, as well as with other brain 
regions, to regulate energy balance (b). 
 
1.2.3 Extra-hypothalamic regions that influence energy balance 
Hypothalamic communication spans throughout the brain, including to the 
periphery, and so extra-hypothalamic regions are also capable of influencing 
homeostatic output. The network of brain nuclei that communicate with the 
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hypothalamus is extensive, but for the purpose of this project the focus here will 
be on a select few regions. 
As aforementioned, the vagus nerve rapidly relays information from the gut to the 
brain via the nucleus of the solitary tract (NTS). The NTS is a small  nucleus in 
the medulla oblongata that consists of multiple heterogeneous neuronal groups, 
which respond to different signals (38,102–104). The NTS is directly sensitive to  
signals relating to food consumption from the gut via the vagus nerve (105,106). 
The NTS can also directly detect blood-borne signals such as nutrients, as it lies 
beneath the area postrema (AP) – a circumventricular organ (107–109). In turn, 
the NTS relays information from the gut to higher brain regions – such as the 
hypothalamus and the parabrachial nucleus – usually to terminate feeding (110). 
The bed nucleus of the stria terminalis (BNST), nucleus accumbens (NAcc) and 
the lateral septal nuclei (LSN) are forebrain targets of hypothalamic signalling that 
have been implicated in energy homeostasis. The BNST receives input from the 
Arc and also innervates the LH, and is thought to play a role in the emotional 
modulation of appetite control (111). Identification of BNST inputs and outputs 
has suggested a potential role in coordination of autonomic, somatic, and 
behavioural networks with endocrine regulation of energy homeostasis (112). 
The NAcc receives input from the Arc, and is thought to be involved in the 
rewarding aspects of feeding motivation (113). The LSN can inhibit food intake 
via the LH, which has led to the proposal that it is also involved in the emotional 
aspect of food intake (114). Consequently, multiple brain regions are involved in 
regulating different aspects of energy homeostasis– including that of emotion and 
reward.  
The regulation of energy homeostasis is appropriately controlled by the balance 
of different systems, communicating through both blood-borne and neuronal 
messages. While it may be surprising that its efforts are overcome in the case of 
chronic energy excess, a preference for high-fat and high-sugar foods carries an 
evolutionary advantage (115). As observed in peripheral metabolic organs, the 
brain’s compensatory mechanisms in excessive energy intake can inflict damage 




1.2.4 Energy state affects cell function in the regulation of energy 
homeostasis  
Prolonged high-fat intake leads to reduced capacity to store or metabolise FAs in 
adipose and hepatic tissue, increasing the levels of FAs in the circulation. FAs 
are able to access the brain via the circulatory system and cerebrospinal fluid 
(116–119), and this forms one route by which the brain can sense nutrient intake 
(120). During chronic high-fat feeding, lipid droplets accumulate in the brain tissue 
and this can impair its function (121). This is dependent on FA type: FAs are a 
diverse group of molecules and exert different effects, exemplified by differential 
distribution and uptake by different cell types, in mouse hypothalamic ex vivo 
slices (121). Furthermore, injection of saturated FAs (SFAs) into the 3V induces 
upregulation of hypothalamic pro-inflammatory cytokines – such as tumour 
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) – while unsaturated FAs do 
not (122). While the brain senses energy intake through the level of circulating 
FAs, excessive SFAs can induce pro-inflammatory signalling pathways which 
may be detrimental to the brain tissue if prolonged. 
As described previously, lipid accumulation in peripheral tissues due to high-fat 
diet leads to damage: macrophage infiltration and production of pro-inflammatory 
cytokines. In diet-induced obesity, pro-inflammatory immune cells are able to 
cross the BBB and permeate the CNS (123). This includes infiltrating 
macrophages, which enhance secretion of pro-inflammatory mediators and also 
augment BBB permeability (124). Upregulation of pro-inflammatory cytokine 
mRNA - including Tnfα and Il-1b - is observed in hypothalamic tissue of obese 
mice fed high-fat chow (125). Diet-induced upregulation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), toll-like receptor 4, TNF-α and 
IL-1β signalling has also been observed in other brain regions including the 
hindbrain (126–131). Genetic and pharmacological manipulation of inflammatory 
signalling mediators, such as NF-κB and toll-like receptor 4, influence animal food 
intake and weight gain (122,132,133). The inflammatory response to excess 
nutrient intake is an innate mechanism by which the brain can regulate energy 
homeostasis, which is also influenced by peripheral metabolic tissues.  
There are sex-specific differences in FA metabolism and the neuroinflammatory 
response. Whole-brain tissue of high-fat fed female mice contains less SFA than 
the males of the cohort (134,135). Furthermore, exposure to high-fat diet 
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significantly increases uptake of SFA in brain tissue of male mice, while there is 
no difference in female mice (134). The sex-specific FA uptake is only observed 
in the brain tissue, and no differences between sexes are observed in plasma 
triglyceride levels between sexes. Furthermore, high-fat fed female mice have 
lower levels of Tnfα and Il-6 mRNA in hypothalamic tissue than their male 
counterparts (135). This indicates that female mice have an attenuated 
hypothalamic pro-inflammatory response to dietary FA consumption compared to 
male mice, in part, due to sex-specific differences in neural FA uptake. This 
sexual dimorphism is abolished through knock-out of the oestrogen α-receptor 
(135). This difference may contribute to the observation that female mice are less 
susceptible to diet-induced obesity than males. If this assumption is true, then the 
neural pro-inflammatory pathways triggered in response to SFAs are involved in 
the progression of obesity. 
The above studies suggest that the brain elicits complex regulation of energy 
status by communication between multiple peripheral organs and between brain 
regions. The brain decodes energetic status through a variety of means: 
hormones secreted by peripheral organs, neuronal communication via the vagus 
nerve, and pro-inflammatory responses to SFAs. In chronic high-calorie exposure 
the levels of circulating FAs are higher and may overwhelm the counter-
regulatory response to high-fat intake which then may lead to dysregulation and 
hypothalamic damage. 
 
1.3 A role for glia in regulating energy homeostasis in 
the hypothalamus 
 
Glia is the term for a group of specialised cells of the nervous system, which in 
the CNS collectively refers to astrocytes, microglia, oligodendrocytes, and 
tanycytes. The name ‘glia’ is derived from the Greek word for ‘glue’, originating 
from their roles in CNS structure and neuronal support. However, it has become 
clear that glial cells play a more active role in the brain and can even influence 
neuronal activity. Those of focus in the energy homeostasis field, so far, have 




1.3.1 Overview of glial cell types 
While macrophages can infiltrate the brain in some states (123), the brain is 
generally immune-privileged. The blood-brain barrier separates the brain from the 
peripheral immune system, so the brain forms its own defence against injury and 
disease (136). Microglia are the “macrophage-like” cells of the CNS. They are 
mobile, phagocytic and found throughout the brain; they are specially designed 
for detection and removal of pathogens, debris and apoptotic neurons (137,138). 
In experimental paradigms using the rodent brain, ‘at rest’ microglial cell bodies 
remain relatively static but their processes are ever extending and retracting – 
surveying the brain parenchyma (139). Microglia are a self-renewing population, 
coupling proliferation with apoptosis so that the overall cell density remains 
relatively stable (140,141). As well as housekeeping, microglia are important in 
neurogenesis and early brain development (137,142). 
Astrocytes are one of the larger forms of glial cell. Named after their star-like 
cytoskeletal structure, many astrocytes contain glial fibrillary acidic protein 
(GFAP) which is commonly used as an astrocyte cell marker. Astrocytes form the 
tripartite synapse with pre- and post-synaptic neurons (143). Here, they modulate 
neuronal communication and assist with neurotransmitter uptake from the 
synapse. Astrocytes also provide nearby neurons with nutrients, such as lactate 
and glutamate (144–147). Like microglia, astrocytes are plastic and dynamic 
(148–151). They are also motile, can proliferate and alter their morphology by 
increasing the number of processes and branching. 
Tanycytes are specialised ependymal cells that are interspersed within the walls 
of the ventricles, most notably the 3V. Here, the cell bodies align with the ventricle 
while the processes reach out into the hypothalamic nuclei. There are two sub-
types of tanycyte with different functions: α- and β-type. Tanycytes are involved 
in the interface between the  BBB and the blood-cerebrospinal fluid (CSF) barrier 
(152–154). Consequently they are well placed to mediate the communication of 
nutrients and signals from the CSF of the 3V to the hypothalamus (121,155–163). 
They also contribute to generation of new neural cells and hormone release 
(164,165). A role for tanycytes in neuroinflammation has been postulated but not 
well-characterised (166,167). Nonetheless, tanycytes are key neural cells for 




1.3.2 Glia and reactive gliosis 
Upon detection of brain injury or insult, microglia and astrocytes undergo 
structural and functional changes to minimise the damage. This process is 
referred to as reactive gliosis (Fig 1.3.1). It is characterised by increased 
complexity (termed ramification) of processes in astrocytes (168), and retraction 
of processes in microglia (169,170). In both glial types, proliferation and migration 
to the site of damage is common, alongside secretion of chemokines (171). 
Evidence suggests that microglia are the first responders to the insult and 
subsequently trigger activation of astrogliosis (172,173). 
Consumption of a high-fat diet (HFD) is a trigger for reactive gliosis. The 
microglial marker Cd68 (mRNA) has been demonstrated to be upregulated in the 
hypothalamus following one day of high-fat feeding in rats (125). An increase in 
number and size of microglia was observed after three days of HFD exposure 
and persists for up to two weeks. Increases in Gfap mRNA was also observed 
from day one of feeding a HFD, and GFAP protein expression in the Arc peaked 
after 7 days before reducing to baseline at week three. Moreover, GFAP 
upregulation was observed again at eight months exposure to a HFD: examined 
as increased densitometry, associated with increased number and size of the 
astrocyte cytoskeleton. Microglial markers were measured until 28 days of high-
fat feeding in this study (125), but also at 4 weeks (174,175), 8 weeks (176,177), 
10 weeks (178), and 8 months (179) by other groups. The study by Thaler et al 
(125) was the first indication that reactive gliosis (micro- and astrogliosis) in 
response to high-fat diet occurs in two waves, at acute and then at chronic dietary 
exposure. It has since been observed in different mouse strains (175,180,181) 
and in humans (125), but also contradicted by others (182,183). Increases in glial 
expression associated with diet-induced obesity are most prominent in 
hypothalamic regions such as the MBH, DMH and PVH – but have also been 
observed in other brain regions (178,180,184). High-fat feeding increases glial 
markers that are indicative of proliferation and morphological changes, the 
hallmarks of reactive gliosis (185). 
As covered previously, there are several means by which hypothalamic 
inflammation can be induced by diet. One route is by SFAs entering the brain 
through the circulation, another by peripheral immune cells and signals infiltrating 
the CNS, and also by cell stress and death of appetite-regulating neurons (125). 
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These paths are reflected in research uncovering the cellular mechanisms 
underlying diet-induced gliosis. Treatment of cultured primary astrocytes and 
primary microglia with SFAs induces secretion of pro-inflammatory cytokines 
(186–188). Diet-induced increases in GFAP expression are associated with the 
vasculature of the brain (178,180,184). Microglia of the Arc, taken from wild-type 
mice fed high-fat diet for 16 weeks, showed a marked accumulation in 
immunoglobulin-G (IgG)  (189). This was not observed in leptin-deficient ob/ob 
mice, indicating that a high-fat diet and not elevated body weight alone mediates 
the increase in microglial inflammatory signalling. These observations both imply 
regulation at the BBB, suggesting increased permeability and an influx of pro-
inflammatory signals. In addition, it has been suggested that circulating myeloid 
cells infiltrate the hypothalamus of diet-induced obese mice which may 
differentiate into microglia (123,174). Nonetheless, reactive gliosis in response to 
high-fat diet may occur through different means. 
Negative energy balance can also induce reactive gliosis. In a mouse model of 
pancreatic-ductal adenocarcinoma with cachexia, both reactive microglia and 
astrocytes were identified in the MBH and hippocampus (190). Pharmacological 
depletion of microglia is associated with accelerated cachexia physiology, 
indicating that increased microglial number and reactivity may be functionally 
protective against weight-loss in this model. Astrocyte activation, but not 
microglia, was observed in the MBH of mice that underwent weight-loss following 
diet-induced obesity (182). These studies provide further indication that there is 
a range of stimuli which may elicit the reactive gliosis response within the cells. 





Figure 1.3.1 Example images of reactive gliosis, in microglia and astrocytes, in 
the mouse brain. 
Ionised calcium-binding adaptor molecule 1 (IBA1) immuno-labelled microglia at 
resting state (a) and activated (b) in the mouse hippocampus. Increases in number 
and changes in cell morphology are apparent. GFAP-immunoreactive astrocytes at 
rest (c) and activated (d) in the mouse hippocampus show increases in number of 
processes. Images taken at 63x magnification and scale bars represent 50 μm. 
 
1.3.3 Glial contribution to nutrient sensing 
As described in brief above, tanycytes are important cells for nutrient sensing at 
the 3V and median eminence. Tanycytes take up lipid droplets from the 
circulation for metabolism (163). Manipulation of this process  influences weight 
gain in mouse models (156,163,191). It is possible that one of the mechanisms 
that influences weight gain is via the neurogenic tanycytes by the ME, which 
produce appetite-regulating neurons at the Arc (156). As well as lipids, tanycytes 
are capable of glucose sensing and amino acid detection (160,161). 
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Microglia are also responsive to FAs and glucose as sources of energy. They 
present lipid-associated receptors, express genes involved in lipid metabolism 
(192), and possess the enzymes required to process energy through glycolytic 
and oxidative means (193). This suggests that microglia have metabolic flexibility, 
a finding which has been recapitulated in vitro (194). Common with neurons, 
microglia predominantly express the glucose transporter 3 (GLUT3) isoform as 
well as being unique in their presentation of GLUT5 (195,196). The ability of 
microglia to use a wide range of substrates suggests that they are highly resilient 
in different energy states. 
Astrocytes are involved in nutrient sensing, working collectively to support 
neuronal function. They take up glucose in response to activation of receptors by 
insulin and insulin-like growth factor 1 (IGF-1) (197,198), and are considered to 
be crucial in mediating glucose transport across the BBB (198). Astrocytes can 
communicate amongst each other via gap junctions. Exposure to hyper- and 
hypoglycaemia in rats alters the level of proteins that form gap junctions – 
connexions-30 and -43 – which are enriched within the rat hypothalamus 
compared to other brain regions (199). Hereby, hypothalamic astrocyte crosstalk 
is responsive to whole-body glucose levels. Astrocytes are also responsive to 
lipid levels that reach the brain. Within the hippocampus, proteins responsible for 
lipid metabolism were identified in astrocytes but not in neurons (200). Astrocytes 
are also able to endocytose fatty acid products that are secreted from neurons 
(201). Consequently, astrocytes work with other astrocytes and also neurons to 
support nutrient sensing and uptake. 
 
1.3.4 Glial regulation of energy homeostasis 
As well as mediating the responses to nutrients, astrocytes can respond to 
feeding-associated hormones. Ablation of the insulin receptor in astrocytes 
impacts whole-body glucose homeostasis (198), which indicates a crucial role for 
astrocytes in conveying glucose levels as well as glucose sensing. This likely 
occurs through astrocyte-neuronal communication, as activation of astrocytic 
insulin receptors induces POMC neuron activity (198). Astrocytes express 
receptors for leptin and ghrelin; hormones which both downregulate expression 
of glucose transporters in the astrocytes (202,203). NTS astrocytes are 
responsive to glucagon-like peptide-1 (GLP-1) receptor agonists (204). In the 
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CNS, GLP-1 is a NTS neuropeptide involved in feeding termination, for which 
agonists have been developed as pharmaceutical interventions for weight-loss 
(205,206). Pharmacological inactivation of NTS astrocytes attenuates the 
feeding-suppressive effects that are mediated by synthetic GLP-1 agonists. In a 
separate study, chemogenetic activation of NTS astrocytes considerably reduced 
food intake in mice (207). These studies show that astrocytes are crucial in 
mediating whole-body effects of hormones and other peripheral factors. 
Glia are capable of communicating signals locally across the brain parenchyma 
through gliotransmission. Microglia, as the immune cells of the brain, typically 
convey messages through release of cytokines and inflammatory mediators. For 
instance, preventing microglial NF-κB signalling attenuated diet-induced food 
intake and weight gain in mice (174). It is likely that microglia can modulate 
neuronal function in other ways, such as through transient contact by processes 
(208), though little has been reported in relation to energy homeostasis. 
Meanwhile, astrocytes are known to use a range of transmitters to modulate 
neuronal function. For example, action at astrocyte insulin receptors causes 
release of adenosine-triphosphate (ATP) (209). Astrocytes express acyl-CoA-
binding protein (ACBP), a peptide that can bind to long-chain FAs (LCFAs) and 
the deletion of which induces food intake and obesity in mice (210,211). This is 
proposed to be mediated by melanocortin-expressing neurons (211). Other 
examples of astrocyte-neuronal communication are through calcium signalling, 
and release of D-serine and lactate (212–215). Astrocyte inflammatory signalling, 
such as IKKβ/NFκB pathways, is also crucial in mediating diet-induced gliosis 
and weight gain (216). Although the notion of gliotransmission has been disputed 
(217), many studies have demonstrated that glia communicate with neurons via 
a multitude of pathways to convey an effect such as regulating food intake. 
Glial protein expression and metabolism impacts the whole organism. Disruption 
of astrocytic lipid uptake, through knock-out of lipoprotein lipase in GFAP-positive 
cells, increases body weight gain (as fat mass) and food intake in high-fat fed 
mice (218). Increases in expression of ionised calcium-binding adaptor molecule 
1 (IBA1; a microglial cell marker) and AgRP are also observed in the MBH of the 
knock-out mice. These mice are less glucose-tolerant than the controls, indicating 
enhancement of adverse diet-induced obesity mediated effects. On the other 
hand, inactivation of Arc AgRP neurons was achieved by specific chemogenetic 
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activation of Arc astrocytes which also attenuated ghrelin-induced feeding (219). 
In microglia, selective deletion of uncoupling-protein 1 conveys resistance 
against diet-induced obesity (177). This is attributed to activation of Arc POMC 
neurons, which are anorexigenic. These studies suggest that glia of the Arc can 
modulate neuronal function to affect food intake, which may have other metabolic 
effects such as on glucose clearance. Other studies that support this notion 
include astrocytic over-expression of IL-6, which provides protection against diet-
induced obesity in mice (220). Overexpression of sirtuin-1, a cellular energy 
sensor, specifically in astrocytes results in hyperphagia and weight gain, while 
downregulation causes the inverse effect (221). 
The maladaptive comorbid effects of obesity are also potentially mediated by glia. 
A mouse model of Alzheimer’s disease, fed a chronic high-fat ‘Western’ diet, 
demonstrates plaque accumulation alongside increases in the number of IBA1-
positive microglia (181). Diet-induced microgliosis in rats is demonstrated to 
affect rhythmicity of circadian clock genes in the microglia and disrupt the 
expression profile of immune-related genes (222). Microglial dysfunction and 
inflammation through high-fat feeding is also proposed to be associated with age-
related neurodegeneration (223). Chronic, but not acute, high-fat exposure is 
linked to hippocampal microgliosis and impaired performance in object-location 
tasks in rats (178). Pharmacological inactivation of microglia with minocycline 
rescues hippocampal-associated cognitive impairment. No significant changes in 
GFAP-positive cell number or size were detected within the hippocampus in this 
experiment, and so the cognitive decline associated with high-fat intake was 
proposed to be a consequence of microglial activation. However, another 
research group has identified increased expression of GFAP in the hippocampus 
of mice fed high-fat diet for 12 weeks compared to mice maintained on standard 
chow (224). This group also observed reduced expression of connexin-43, with 
no impact on memory tasks but an increase in experimental measures of anxiety. 
Chronic high-fat diet consumption has been shown to reduce performance of rats 
in object-location tasks, which is rescued by pharmacological inactivation of 
hippocampal microglia (178). Although the neuro-circuitry linking hypothalamic 
inflammation to loss of cognitive performance is not yet identified, it is clear that 
inflammatory signalling mediated by both astrocytes and microglia throughout the 




Hypothalamic glia are responsive to a wide range of stimuli that infer energy 
levels. Manipulation of expression for a variety of glial proteins in the mouse brain 
can elicit changes in food intake and weight gain, even when the animals are 
exposed to an obesogenic diet (174,177,218,220,221). This indicates that glial 
function is crucial in the regulation of energy status. This is supported by selective 
activation of hypothalamic astrocytes reducing food intake, including when 
orexigenic stimuli are present (207,219). Together, these studies suggest that 
homeostatic regulation is facilitated by glial-invoked action on neurons. This may 
be achieved by morphological changes that are observed in reactive gliosis 
(125,180,182), such as increased glial process connections with neurons 
(198,225), and also glial-mediated signalling including cytokines and 
gliotransmitters (174,204,216,218,220,221,226). Therefore, glia are clearly 
heavily involved in the regulation of energy balance and are also implemented in 
the comorbid consequences of obesity. Nonetheless, the underlying mechanisms 
within and between the cells is yet to be fully understood. 
 
1.4 Overview of TSPO pharmacology 
 
The mitochondrial translocator protein of 18 kDa (henceforth referred to as 
TSPO) is a common cell marker used to identify reactive astrocytes and 
microglia. It is expressed at low levels in the healthy brain, but upregulated in glia 
during neuroinflammation (172,227,228). Presence of neuroinflammation is a 
crucial indicator for status and progression of brain disease or injury, as well as 
a target for treatment (229). Consequently, the ability to visualise the extent of 
neuroinflammation in vivo is a useful tool both for research and in clinical practice.  
Many synthetic ligands have been developed, bound to radioactive tracers, to 
identify sites of high TSPO expression in imaging with positron electron 
tomography (PET). These ligands have also been applied to study the elusive 
function of TSPO as well as treatment in neuropathology (230–234). They have 
also been used in pre-clinical studies examining TSPO function and identifying 
the structure of the TSPO protein. In addition, there are many endogenous small 
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molecules that are proposed to bind to TSPO (Fig 1.4.1) (235–237). Studying the 
function of these could help allude to the function of TSPO across tissues. 
TSPO is a channel protein formed of five transmembrane helices alongside 
cytosolic loops (Fig 1.4.1) (238). It demonstrates dynamic structural changes; its 
tertiary structure only stabilises following ligand binding and its able to transition 
from monomer to polymer in the mitochondrial outer membrane (238,239). 
Binding of the synthetic TSPO ligand, PK11195, has been associated with the 
monomeric form of TSPO (240) and its aromatic residues of the cytosolic loops 
(241). TSPO contains a cholesterol-binding amino acid consensus (CRAC) motif, 
which is associated with its primary structure (237) and at which binding is 
preferential when the protein is in its polymeric form (239,242). A polymorphism 
in TSPO has been identified, although its influence on ligand binding capabilities 
is debated (243,244). TSPO forms a complex with many other mitochondrial 
proteins - such as voltage-dependent anion channel (VDAC) (245), adenine 
nucleotide transporter 1 (ANT1) (Fig 1.4.1) (245), and steroidogenic acute 
regulatory protein (StAR) – which is likely to influence the protein structure and 
ligand binding capability. These studies suggest that TSPO is highly dynamic in 
its structure and ability to bind to ligands. 
 
1.4.1 Endogenous TSPO ligands 
The most studied endogenous ligand in relation to TSPO binding is cholesterol. 
Cholesterol is a type of lipid and contributes to the structure of the cell membrane, 
as well as being an essential molecule for synthesis of steroid hormones (246). 
A CRAC motif was identified in the structure of TSPO, and so it was considered 
that TSPO was involved in cholesterol transport to the inner mitochondrial 
membrane (236,237). Import of cholesterol to the mitochondria is the rate-limiting 
step of steroidogenesis. It was thought that the channel, formed by the 
transmembrane helices, enabled transport of cholesterol (247). Interestingly, the 
human rs6971 polymorphism is associated with alterations in cholesterol binding 
– which results in increased plasma cholesterol levels in humans (243,248). It is 




An additional endogenous ligand that was proposed to bind to TSPO, and since 
criticized, is haem. The porphyrin ring of haem was initially found to compete for 
binding with benzodiazepines (244,249–252), which was associated with a role 
for inducing haemoglobin synthesis (253,254). Interestingly, the authors here 
commented on a structure-activity relationship in this function for TSPO (253). 
However, in an additional study, TSPO -/- mice did not show any changes in 
haemoglobin levels or number of erythrocytes resulting from their genotype (255). 
This suggests that there may be a high level of compensation in TSPO deficiency, 
or another scenario in which TSPO binding and function is misunderstood. 
Originally identified as a benzodiazepine-like receptor, ligands of the 
benzodiazepine family are capable of binding to TSPO. Compounds that are 
synthesised in vivo and have benzodiazepine-like effects are typically referred to 
as ‘endozepines’ (235). These ligands are thought to be capable of anxiolytic 
features, are neuroprotective and can regulate metabolism (211,256–258). 
However, whether they require TSPO to elicit their effects is unknown. Acyl-CoA 
binding protein (ACBP), also known as diazepam-binding inhibitor, is an 
endozepine peptide that has been reported to bind to TSPO (235,259). ACBP is 
also crucial in fatty acid metabolism, as it can bind to esterified long-chain fatty 
acids (LCFAs) within the cell (256,260). It is strongly expressed in tissues with 
high lipid metabolism, and also in hypothalamic glia - including the 
tanycyte/ependymal cell layer of the 3V (261,262). ACBP activity in hypothalamic 
glia is proposed to be a route by which astrocytes can sense FAs and modulate 
appetite (210,211,262). However, there is contention as to whether ACBP elicits 
these functions via TSPO.  
ACBP is processed within the cell to form smaller ligands: octadecaneuropeptide 
(ODN) and triakontatetraneuropeptide (TTN). ODN is thought to be the subunit 
responsible for the appetite regulatory effects within the hypothalamus (263). 
Competition pharmacological assays with exogenous ligands detailed that ODN 
acts though a metabotropic receptor on astrocytes and co-administration with a 
TSPO inhibitor did not inhibit its effects, suggesting that ODN does not bind to 
TSPO to mediate its effects (258). Consequently, appetite modulation by ACBP 
is unlikely to act via TSPO either. TTN, on the other hand, can stimulate 
aggressive behaviour in rats and steroid synthesis in vitro – both of which were 
alleviated by treatment with synthetic TSPO ligands PK11195 and Ro5-4864 
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(264–266). This suggests that TTN, PK11195 and Ro5-4864 bind to the same 
site on the TSPO structure. TTN can also enhance the LPS-induced secretion of 
pro-inflammatory cytokines (267–269). A selective metabotropic endozepine 
receptor antagonist is able to compete with ODN, indicating specificity for such 
receptors. In conclusion, the appetite modulating effects of ACBP are unlikely to 
be mediated by TSPO. However, ACBP can influence TSPO signalling via its 
cleavage product TTN – which has consequences on steroidogenesis and 
inflammation. 
 
1.4.2 Synthetic TSPO ligands 
Ligands for TSPO have been tested for capabilities in treating neuroinflammatory 
disorders, such as Alzheimer’s disease (AD) as well as psychiatric illness (270–
278). Etifoxine, an anxiolytic drug that binds to TSPO, provides protective benefits 
in a model of neurodegeneration in Sprague-Dawley rats (279). Both PK11195 
and Ro5-4864 have therapeutic potential in a mouse model of AD and of diabetic 
neuropathy (230,233,280). With PK11195, the most notable changes in AD 
pathology are in tests of memory and less so in amyloid-β load (233) – contrary 
to the Ro5-4864 study (230). This suggest different pathways in which these 
TSPO ligands exert their effects, which may also not be mediated by TSPO. In 
an additional study where C57BL/6 mice were treated with LPS after PK11195 
administration, cognitive function is protected in the drug-treated mice, but in the 
absence of any attenuation in pro-inflammatory cytokine levels (281). Studies that 
have investigated therapeutic potential of TSPO provide some insight as to the 
function of TSPO. Further information is required on the binding and specificity of 
TSPO ligands prior to concluding functions from such studies. 
The specificity of TSPO ligands have been under scrutiny, considering their 
contradictory effects in downstream functions. For example, there are dose-
dependent changes in effects of PK11195 and Ro5-4864 which can cause both 
opposite and similar physiological changes (240). Importantly, the two drugs have 
different binding sites on the TSPO protein (282). Treatment with PK11195 in the 
steroidogenic MA-10 Leydig cells increased progesterone production, which was 
not attenuated following TSPO knock-down in the cells (283). Although 
compensatory effects could be present, this indicates that PK11195 can elicit 
effects outside of TSPO expression which clouds the inferences regarding TSPO 
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function. The contradictions in TSPO ligand effects amongst the literature not 
only indicate a lack of specificity, but also suggest dynamics in the structure of 
TSPO. This may also be influenced by complexes with other mitochondrial 
proteins and competitive-binding with endogenous ligands. 
 
The actions of both exogenous and endogenous ligands at TSPO indicate 
multiple functions for TSPO, but interpretation clouded by off-target effects of 
these ligands. Furthermore, it would appear that the structure of TSPO is dynamic 
– altering the exposure and ligand-affinity at its binding sites. The role of TSPO 
may be influenced by the extra- and intra-cellular environment at that time (Fig 
1.6.1). Furthermore, investigations of ligand binding have been performed 
through competitive-binding studies with other TSPO ligands – some of which 
have since been reported to have off-target effects. Consequently, there is much 




Figure 1.4.1 TSPO is identified to form complexes with multiple other 
mitochondrial proteins, as well as potentially bind to a wide range of ligands. 
Key: Acyl-CoA binding protein (ACBP); adenosine transporter protein 1 (ANT1); 
octadecaneuropeptide (ODN); steroidogenic acute regulatory protein (StAR); 
mitochondrial translocator protein 18 kDa (TSPO); triakontatetraneuropeptide (TTN); 





1.5 TSPO expression in the brain  
 
While TSPO expression in states of neuroinflammation is an important focus, 
there have been published attempts to identify expression and function of TSPO 
in neural cells. TSPO has been identified in regions of the mouse brain in absence 
of neuroinflammation: the olfactory bulb, choroid plexus, dentate gyrus, 
ependymal layers and in the cerebellum (284). TSPO immunoreactivity has also 
been identified in the endothelial cells surrounding the vasculature throughout the 
brain (284). TSPO expression across a range of neural cells may be a reflection 
of its involvement in different cellular processes. 
 
1.5.1 TSPO expression in microglia 
As previously discussed, microglia are the resident immune cells of the CNS. 
TSPO upregulation as a biomarker for neuroinflammation is commonly attributed 
to activated microglia (228,285–287). While microglia express TSPO, up-
regulation in microgliosis can occur in a heterogeneous and dynamic manner. In 
rats with dopaminergic neuronal degeneration to model Parkinson’s disease, 
radiolabelled ligand binding to TSPO increases alongside disease progression 
(288). This correlates with increased IBA1-positive immunoreactivity in ex vivo 
analysis. Interestingly, increases in TSPO radiolabelling occur in the rat striatum 
in the same study but in the absence of any changes in IBA1- or GFAP-
immunoreactive cells. This suggests that TSPO expression can be upregulated 
without changes in microglia number corresponding to gliosis, possibly reflecting 
changes in glial function instead. In age-associated neuroinflammation, with 
which microgliosis can be observed, TSPO expression is not upregulated in the 
cortex and hippocampus of aged mice compared to young (289). Nonetheless, 
TSPO still co-localises with IBA1. Co-localisation also occurs with the 
mitochondrial marker, ATP synthase, within and outside of microglia, implicating 
TSPO expression in other cells. In mice with neuroinflammation induced by 
trimethyltin, TSPO expression coincided with microglia that were deemed to be 
reactive (172). This expression of TSPO appears temporally dynamic, alongside 
reactivity of the microglia, as expression is not identifiable until 14 days post-
treatment. TSPO immunoreactivity also subsides by 6 weeks post-treatment, as 
does the reactive status of the microglia. These findings indicate that stimulus 
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and context are crucial for TSPO upregulation, and that upregulation in microglia 
can be dynamic.  
Less is known about TSPO expression in resting microglia of healthy brains, as 
its expression is much lower. A study looking in the brains of healthy C57BL/6 
mice did not identify any co-localisation between TSPO and the microglial 
markers, IBA1 and CD11b+ (284). However, this study only considered limited 
regions of the mouse brain and the published images taken at higher 
magnification appeared to focus on TSPO expression around blood vessels in 
the brain. This contrasts with a previous study in which TSPO was co-localised 
with CD11b in brain tissue from the study control group (227). It may be that 
expression of TSPO is not necessarily a marker of activated microglia, and could 
reflect other functions dependent on region and experimental model. 
Manipulation of TSPO expression or function can influence microglial activity. 
Such manipulation can be performed by altering TSPO gene expression or 
through application of TSPO ligands. In microglial BV-2 cell culture,  knock-down 
or over-expression of TSPO promotes and suppresses an inflammatory 
phenotype, respectively (286). Treatment of cells with TSPO ligands can also 
attenuate cytokine release stimulated by lipopolysaccharide (LPS), a component 
of bacterial endotoxins (290,291). Meanwhile, in a rodent model of 
neurodegeneration caused by injection of quinolinic acid into the striatum, TSPO 
ligands reduce neuronal cell death caused by the toxin as well as enhance the 
expression of the activated microglial marker OX-42 (285,292). The TSPO ligand, 
PK11195, also reduces the up-regulation of pro-inflammatory cytokine mRNA 
following quinolinic acid-induced damage (292). Modulation of either TSPO 
expression or activity can in turn influence the inflammatory phenotype of 
microglia. This occurs in both isolated cells and in vivo rodent models. 
 
1.5.2 TSPO expression in astrocytes 
TSPO expression in the brain is also attributed to astrocytes, where it is 
upregulated during neuroinflammation. Astrocytes contribute to multiple functions 
in the healthy brain, and cooperate with microglia during neuroinflammation. 
Induction of astrogliosis is associated with increases in TSPO expression levels. 
In the trimethyltin-induced neurodegenerative rat model previously discussed 
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(172), TSPO immunoreactivity was seen to coincide within the main cell bodies 
of the GFAP-positive astrocytes but not in the projections. Furthermore, the study 
also commented on the timeline of astrocytic reactivity in response to the toxin: 
Astrogliosis was observed later and over a longer period than microgliosis, and 
astrocytes expressed TSPO at all stages of activation unlike microglia (172). 
Other studies have alluded to a difference in glial dynamics regarding TSPO 
expression. In a model of neuroinflammation where rats received an injection of 
ciliary neurotrophic factor into the striatum, GFAP and TSPO expression were 
both upregulated and also colocalised (227). There were no changes in the level 
of microglial TSPO expression in these rats, indicating that upregulation of TSPO 
was specific to astrocytes in this experimental setting. In a mouse model of 
multiple sclerosis, TSPO and GFAP dual-immunohistochemical labelling showed 
minimal co-localisation in the corpus callosum and cortex of the mice and TSPO 
expression was absent in the control ‘healthy’ mice (293). When the researchers 
used a GFAP-eGFP reporter mouse line, which also received cuprizone 
treatment to model multiple sclerosis, the TSPO signal within the astrocytes was 
much clearer. In this experimental scenario the TSPO staining was localised to 
the astrocytic cell body as well as processes. This study emphasises that choice 
of cell markers and visualisation processes are very important to consider when 
studying co-immunoreactivity with proteins. Furthermore, the above studies 
collectively show that TSPO expression within astrocytes is upregulated in 
experimental settings of neuroinflammation. This can occur in absence of 
microglial expression of TSPO. 
While TSPO expression is prominent in reactive astrocytes from animal models 
of neuroinflammation, this does not reflect expression levels in the healthy brain. 
In the healthy C57BL/6 mouse brain, TSPO immunoreactivity was not observed 
to co-localise with that of GFAP  (284). As previously discussed with regards to 
microglia, this study appeared to focus on the vasculature of the brain and so glial 
expression elsewhere may have been overlooked. Meanwhile, in human brain 
tissue, coincidence of TSPO and GFAP immunoreactivity has been observed in 
post-mortem samples from both healthy individuals and patients with a range of 
brain diseases and injuries (294). With regards to brain disease, the level of 
TSPO expression in human astrocytoma has been associated with the grade of 
the tumour (295). These studies show that TSPO expression is present in 
50 
 
activated astrocytes, more so than astrocytes at rest, in the rodent and human 
brain. 
TSPO ligands influence astrocyte function. As many synthetic TSPO ligands can 
pass the BBB, this provides potential for treatment of neuroinflammation. In 
C57BL/6 mouse primary astrocytes cultured with pro-inflammatory toll-like 
receptor ligands, pre-treatment with TSPO ligands reduces the secretion of pro-
inflammatory cytokines (296). This reduction in the astrocyte cultures was modest 
compared to that in the cultured microglia from the same animals. In astrocytic 
T98G cells with glucose deprivation, pre-treatment with the TSPO ligand Ro5-
8464 reduces cell death compared to no ligand treatment (297). Ro5-8464 pre-
treatment also has protective effects on the astrocyte mitochondria, as production 
of reactive oxygen species were also reduced. With regard to in vivo markers of 
astrogliosis, co-injection of quinolinic acid with TSPO ligands to rats slightly 
reduces GFAP immunoreactivity compared to the quinolinic acid-only injected 
controls (285,292). PK11195, but not Ro5-4864, reduces vimentin 
immunoreactivity as a marker for reactive astrocytes in the rat hippocampus when 
co-injected into the cerebral ventricles with the bacterial endotoxin LPS (298). 
Furthermore, in a rat model of surgical-induced brain damage, intraperitoneal 
injection of Ro5-4864 had no effect on GFAP expression within the cortical injury 
compared to non-injected rats (299). Considering the above studies, the 
translational ability of targeting TSPO in reactive astrocytes appears to reflect the 
varied pharmacology of TSPO ligands. 
 
1.5.3 TSPO expression in other neural cell types 
TSPO expression in the brain has been reported in other neural cells, but there 
have been limited studies that provide insight into its function in these cells. Such 
cells include neurons, neural endothelial cells and tanycytes (294,300,301). It 
may be that there is minimal or no TSPO expression within these cells, or that 
the topic needs further investigation. A point to consider is what would be the 
function of TSPO in these cells. The possible role of TSPO in inflammation does 
not relate to the known roles of neurons, ependymal cells, nor tanycytes. 
Consequently, there may be processes involving TSPO in the brain that are 
outside of inflammation. 
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There have been minimal reports of TSPO expression in neurons. Co-
immunoreactivity of TSPO with NeuN is observed in both C57BL/6 mouse and in 
human hippocampal brain tissue (300,302). TSPO immunoreactivity is also 
identified in healthy human cortical brain tissue, and less so in brain tissue taken 
from patients with HIV (294). However, the authors commented that this was only 
observed with the polyclonal antibody they used, and not the monoclonal, though 
specificity of both antibodies had been previously confirmed. The authors 
proposed that neurons may contain a different isoform of TSPO, or a structurally 
related protein. Subsequently, there is currently not enough evidence to confirm 
nor reject the notion of TSPO expression in neurons.  
Although there has not been much focus on the role of TSPO in neural endothelial 
and ependymal cells, there is published qualitative research on expression 
around the ventricles and vasculature of the brain. Multiple studies that have 
investigated TSPO expression in glia have also identified TSPO co-
immunoreactivity with endothelial cell markers (294,300) or immunoreactivity in 
a pattern akin to the brain vasculature (284). In the choroidal endothelial cell line 
RF/6A, TSPO was co-localised to the mitochondria and application of TSPO 
ligands altered cholesterol efflux, lipid accumulation and reduced secretion of 
pro-inflammatory cytokines (303). TSPO immunoreactivity has been identified to 
coincide with markers of tanycytes and endothelial cells which layer the 3V, which 
runs through the hypothalamus (301). Here, TSPO was suggested to be involved 
in metabolism of lipids circulating in the cerebrospinal fluid. The proposed role of 
TSPO in these cells of the brain appear to pertain to the roles of the cells, 
implicating cell-dependent function of TSPO. 
 
TSPO imaging is a widespread application applied to many disease and injury 
states that involve inflammation, but cannot unpick the role of TSPO regulation in 
these disease states (300). Discrepancies between studies, in cases of TSPO 
regulation or disease paradigms, may be useful to resolve TSPO function and 
henceforth therapeutic translational potential. TSPO expression in the brain is 
attributed to multiple cell types, not all of which contribute to neuroinflammatory 
processes. Furthermore, the function of TSPO in these cells is not well 
understood. It is important to consider heterogeneity in TSPO expression, and 
that it may have functions in the brain outside of neuroinflammation. 
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Neuroinflammation puts a large metabolic demand on the tissue, and a positive 
correlation exists between neural uptake of fluorodeoxyglucose (FDG) and 
TSPO-ligand binding in mice (304). This suggests that areas of high glucose 
uptake in the murine brain are associated with relatively increased TSPO 
expression. The up-regulation of TSPO coinciding with high-glucose uptake may 
be involved at the interface of metabolism and neuroinflammation. 
 
1.6 TSPO in peripheral metabolic tissue 
 
As well as in the brain, TSPO is expressed to varying extents throughout the body 
(305). TSPO was first identified in the kidney, and named the peripheral 
benzodiazepine receptor (PBR) due to its ability to bind ligands of the 
benzodiazepine-like family. It is also strongly expressed in steroidogenic tissues, 
which implicated a role for TSPO in steroidogenesis (306,307). This is supported 
by its ability to bind cholesterol via a CRAC motif (236,237). In rodents, TSPO 
expression has been studied in white and brown adipose (308–312), cardiac 
(313–316), liver (317), macrophages (310,318,319), smooth muscle (320), and 
pancreatic tissue (321). TSPO is implicated in multiple different functions, and 
while the extent of TSPO function across tissues is not yet fully understood it is 
important to consider the overall functions of the cells and tissues in which it is 
expressed. Here, I will focus on TSPO expression and function in select metabolic 
organs. 
 
1.6.1 TSPO in mitochondrial metabolism 
One of the key roles for mitochondria is the regulation of energy production for 
cellular processes. Accordingly, they are responsible for a number of metabolic 
pathways. Important examples include oxidative phosphorylation - an aerobic 
process in which ATP is generated - and beta-oxidation of FAs to acetyl-CoA, 
which is then used to fuel the Krebs cycle and generate ATP. To complement 
these functions, mitochondria are highly dynamic and can undergo fission/fusion 
in response to energy demands. TSPO is implicated in mitochondrial processes 
relating to respiration and ATP production. This has been identified in a range of 
cell types (255,322–328). For example, knock-down of TSPO in mouse microglial 
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BV-2 cells impairs mitochondrial respiration and reduces ATP production (329). 
On the other hand, contradictory effects from Tspo manipulation have been 
measured in hepatocytes cultured from TSPO null mice (323) and in TSPO 
deficient MA-10 Leydig cells (330). In both studies, there was no alteration in 
mitochondrial respiration or ATP production resulting from absence of TSPO. 
This collection of studies suggest that presence of TSPO has an influence on 
ATP production and mitochondrial metabolism, although this effect appears to be 
cell and/or tissue dependent.  
FAs, circulating in the blood stream or stored as lipid droplets, are also a key 
source of fuel for metabolism and are of particular relevance to deviations in 
energy state. FAs are the primary energy substrate in absence of glucose. 
Deletion of TSPO in mouse Leydig MA-10 cells resulted in a shift of fuel 
preference from glucose to FAs (330). In the hypothalamic neural cell line, A2/29, 
knock-down of Tspo enhanced FFA generation through lipophagy to produce 
ATP (301). As well as mitochondrial respiration, experiments in cell lines have 
alluded to an influence of TSPO on use of glucose as a fuel substrate. In a mouse 
adipocyte cell line, 3T3-L1, treatment with PK11195 increased glucose uptake 
following stimulation with insulin (311). TSPO expression can also be modulated 
by glucose treatment. In smooth muscle A10 cells, expression of TSPO increases 
in a dose-dependent manner with respect to glucose concentration (331). In 
addition, knock-out of TSPO expression in a human retinal pigment epithelial cell 
line resulted in an increase in glycolytic metabolites compared to wild-type cells 
(332). Cells, genetically manipulated to have reduced TSPO expression, exhibit 
increased glycolysis alongside reduced mitochondrial respiration as previously 
described (326,330). Some cell culture studies using immortalized cell lines may 
not fully represent of nutrient use in normal cells, for reasons involving altered 
metabolism in transformed cells and requirement for high glucose conditions in 
culture. If replicable in vivo, this could be indicative of a role for TSPO modulating 
glucose levels and metabolism in cells across different tissue types. 
 
1.6.2 Adipose tissue 
Adipose tissue is crucial for healthy storage of lipid reserves. It is also an 
important endocrine organ; it secretes adipokines – such as leptin – to convey 
the metabolic and health state of the tissue. Adipose tissue is an important site 
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of study for how metabolic disease can occur and progress. For instance, excess 
energy intake leads to adipose dysfunction which results in impaired fatty acid 
storage and leptin-mediated signalling. Furthermore, there are different forms of 
adipose tissue – white (WAT) and brown (BAT) – which have different 
contributions to energy regulation. TSPO expression has been identified in both 
of these forms (310,312,333). Imaging of TSPO has been applied to adipose 
tissue, in rodent and human studies. In female Balb/c mice that were treated with 
a β3 adrenergic agonist to induce browning of inguinal WAT, increased TSPO 
ligand binding in the browned WAT was observed while no change was measured 
in the interscapular BAT (312). TSPO-targeted imaging of BAT has also been 
used in healthy human participants (333).  
TSPO expression is regulated in rodent adipose tissue in response to energetic 
demands. In a study in Sprague-Dawley rats, chronic administration of the 
antipsychotic drug olanzapine resulted in increased inflammatory markers in 
WAT but no changes to TSPO expression (334). This reinforces that there is a 
role for TSPO expression regulation outside of inflammatory processes. A model 
of stress in Sprague-Dawley rats, which involved a 24-hour fast, significantly 
increased TSPO expression in the epididymal WAT from a below-detection 
baseline (335). Accordingly, it has been observed that TSPO expression in 
epididymal WAT and interscapular BAT reduces in diet-induced obese C57BL/6J 
mice (310). This has been replicated in the MC4R -/- obese mice. These studies 
suggest that TSPO expression in adipose tissue is dynamic and reflects the 
metabolic status of the tissue.  
 
1.6.3 Liver 
The liver is an important metabolic organ involved in glucose homeostasis, 
glycogen storage, and bile production for fat metabolism amongst other roles 
(41,336). It is a site of metabolism for a variety of nutrients. It assists in glucose 
homeostasis by converting glucose into glycogen, or vice-versa, according to 
blood glucose levels. The liver is also important for breakdown of hormones, such 
as insulin, and is a source of cholesterol production (52,337–340). TSPO is 
strongly expressed in the rodent and human liver, and upregulation has been 
associated with both disease and alterations in metabolism (341,342).  
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TSPO can be used as a biomarker for imaging liver damage. For instance, 
upregulation of TSPO has been associated with liver disease progression from 
steatosis to non-alcoholic steatohepatitis (343). In a model of liver cirrhosis in 
Sprague-Dawley rats, TSPO expression correlated with disease progression 
(344). Immunohistochemical analysis identified expression to be localised to 
macrophages and hepatic stellate cells. In relation to liver damage arising from 
high-fat intake, exposure to a high-fat and high-cholesterol diet markedly reduced 
TSPO expression in the liver of Wistar rats (345). It is possible that TSPO-
mediated signalling is involved in hepatic inflammation, depending on the 
stimulus, and may be a potential treatment target. 
In addition to serving as a biomarker, manipulation of TSPO has been 
investigated as a potential mechanism to treat liver injury or disease. Etifoxine, a 
TSPO ligand used clinically for treatment of anxiety disorders (346), has been 
shown to increase TSPO expression in a liver cell line inoculated with hepatitis-
C virus (342). The virus lowered mitochondrial membrane potential as well as 
liver lipid accumulation, both of which were recovered by etifoxine treatment. On 
the contrary, etifoxine enhanced the viral-induced insulin resistance measured in 
the cells. This may be situation dependent in the case of obesity versus 
injury/toxin induced hepatic inflammation. There may again be organism-
dependent differences in TSPO regulation in the liver. The TSPO ligand PK11195 
may be therapeutic in treating hepatic steatosis occurring from diet-induced 
obesity. Lipid accumulation in the liver was lower in high-fat fed obese mice that 
received chronic treatment of PK11195 (347). In addition to the reduced hepatic 
steatosis, chronic PK11195 treatment also improved glucose tolerance and 
reduced mRNA expression of pro-inflammatory markers, TNFα and Il-6, in the 
livers of the mice. This indicates that TSPO targeting has potential to improve 
liver disease state and glucose metabolism. 
Whole-organism screening in zebrafish identified a novel role for TSPO in 
gluconeogenesis, which translated to mouse models (347). In food deprived 
C57BL/6 mice, administration of PK11195 enhanced fast-induced up-regulation 
of liver mRNA for genes involved in metabolism. These included carnitine 
palmitoyltransferase-1 subunit-a (Cpt1a), an important enzyme for fatty acid 
oxidation, phosphoenolpyruvate carboxykinase 1 (Pck1), and the catalytic 
subunit for glucose-6-phosphatase (G6PC) – which are involved in glucose 
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production (347). This effect was not seen in satiated mice. PK11195 was also 
able to decrease baseline glucose levels for up to 4 hours post-injection in fasted 
mice, suggesting that targeting of TSPO reduces hepatic glucose production 
despite up-regulation of gluconeogenic enzymes. These experiments indicate a 
translational opportunity for targeting TSPO to modulate glucose levels, which 
could prove to be protective in obesity. 
 
1.6.4 Macrophages 
As discussed previously, TSPO is connected to inflammatory processes in 
multiple tissue types. It is therefore not surprising that its expression has been 
detected in peripheral immune cells, such as macrophages (310,318,348–350). 
Macrophages are a mobile, phagocytic class of immune cell that are a crucial 
first-line of defence against invading pathogens (351). They are capable of 
infiltrating and residing in a variety of tissue types, in which they can be 
differentiated into sub-classifications. 
Microglia, the resident macrophage-like cells of the CNS, have been 
demonstrated to upregulate TSPO expression in response to inflammatory stimuli 
(228,285–287,298,352). Subsequently, it is anticipated that macrophage 
expression of TSPO will also be pro-inflammatory. Radio-ligand PET imaging of 
TSPO has been shown to correlate with macrophage accumulation in patients of 
rheumatoid synovitis (353). However, in a study that used the cultured human 
monocytic THP-1 cell line as well as primary macrophage cultures from healthy 
people and patients with rheumatoid arthritis, TSPO expression was 
downregulated in the pro-inflammatory ‘M1’ macrophage state and unchanged in 
the anti-inflammatory ‘M2’ phenotype (318). This observation was repeated by 
another study comparing both rodent- and human-derived primary macrophage 
culture (350). Human-derived macrophage cells cultured into a pro-inflammatory 
state decreased their expression of TSPO, while rodent-derived macrophages 
increased their expression following pro-inflammatory stimulation. The 
controversy in these results suggest that there may be a species-dependent 
difference in macrophage TSPO regulation; Although, it could also depend on 
experimental setting – such as in vivo versus in vitro. Both studies used LPS as 
the primary pro-inflammatory stimulus, while TSPO regulation in human-derived 
macrophages could be more sensitive to pro-inflammatory cytokines. Meanwhile 
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an additional study demonstrated that the benzodiazepine, midazolam, exerted 
its anti-inflammatory effects in THP-1 cells through TSPO (354). The authors 
proposed that midazolam targeted TSPO, which in turn suppressed pro-
inflammatory signalling such as NF-κB. 
TSPO and high-fat diet intake is associated with inflammation throughout the 
organism. Macrophages have been seen to increase in number in metabolic 
organs such as WAT. Infiltrating macrophages in WAT of obese mice have been 
associated with increased TSPO expression (310). Although currently not 
investigated, inhibition of TSPO in models of obesity may reduce the pro-
inflammatory state of macrophages. This in turn may be protective against the 
comorbid effects of obesity. 
A breakdown of cholesterol homeostasis in macrophages can lead to lipid 
accumulation and the transition to a macrophage foam cell state (355–357). 
Macrophage foam cells are associated with cardiovascular disease, primarily 
atherosclerosis. Up- and down-regulation of TSPO in a human macrophage cell 
line increases and decreases cholesterol efflux, respectively (348). The reduction 
in intra-cellular cholesterol as caused by TSPO over-expression also resulted in 
a decrease in lipid accumulation within the macrophage cells. Consequently, it 
appears that TSPO expression in macrophages may be protective against 
cholesterol and lipid accumulation and reduce the negative impacts on 
atherosclerotic plaque formation in humans. Furthermore, there has been 
evidence to suggest that TSPO is a useful potential pharmacological target for 
atherosclerosis (358). 
 
1.6.5 Steroidogenic organs 
Steroidogenesis is a mitochondrial process that occurs in specific cell-types that 
contain the appropriate machinery. Steroidogenic cells produce steroids from 
cholesterol, obtained from either de novo synthesis or by intracellular transport of 
cholesterol bound to lipoproteins. Import of cholesterol into the cell is facilitated 
by low- or high-density lipoproteins. Once within the cell, cholesterol is either 
stored within lipid droplets or transported into the mitochondria. P450scc, located 
at the inner mitochondrial membrane, is the cholesterol side chain cleavage 
enzyme that metabolises cholesterol into pregnenolone. StAR is involved in 
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mitochondrial cholesterol import although some cases of steroidogenesis are 
StAR-independent, with TSPO implicated instead. Deletion of TSPO in Leydig 
MA-10 cells results in increased expression of StAR (359). This points to potential 
compensatory mechanisms for absence of TSPO that can be initiated through 
StAR expression. Adrenergic and gonadal cells are highly steroidogenic, as are 
neural cells. Steroids are an important class of signalling molecules, as well as 
crucial components of cell membranes.  
The first attempts to generate TSPO mutant knock-out mice resulted in embryonic 
lethality (247). This led to the hypothesis that TSPO is essential for transportation 
of intra-cellular cholesterol across the mitochondrial membrane - the rate-limiting 
step for steroidogenesis. However, upon the subsequent successful generation 
of viable TSPO-deficient mouse models, the importance of its role in 
steroidogenesis caused much controversy within the field (322,325,360). Global 
TSPO deficient mice have been used by several researchers to study the impact 
of loss of TSPO signalling on steroidogenesis. In one such study, TSPO knock-
out mice exhibited no difference in serum pregnenolone levels (325). Yet, in a 
different study, the TSPO null mice had significantly reduced production of 
steroids – particularly corticosterone (361). This study also emphasised a role for 
TSPO in maintaining androgen levels during aging. The TSPO knock-out mice 
were generated using the same method in both studies, but hormone collection 
and measurements differ. Methods of transgenic mouse generation and hormone 
measures may contribute to conflicting results between studies. 
In addition to global knock-outs, tissue-specific deletion of TSPO in steroidogenic 
cells has also alluded to an impairment in circulating steroid levels. Steroidogenic 
factor 1 (SF-1) driven conditional TSPO knock-out in male mice led to impaired 
stimulated corticosterone secretion, but no effects on basal corticosterone levels 
(362). TSPO deletion in these mice occurred primarily in the adrenal cortex, which 
resulted in a compensatory increase of TSPO in the adrenal medulla. Expression 
was also reduced by half in the gonads. Plasma adrenaline levels were also 
greater in the knock-out mice (363). The authors concluded that the higher 
circulating adrenaline levels resulted in a pre-diabetic phenotype in the male 
mice, as exhibited by hyperglycaemia and lower c-peptide levels than controls. It 
is apparent that selective reduction of TSPO in steroidogenic organs impairs 
ability to produce adrenaline, which may have a wider impact on the organism, 
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including potentially glucose homeostasis. In a separate study, conditional knock-
out of TSPO in the testicular Leydig cells of male mice did not alter plasma 
testosterone levels when compared to control mice with TSPO floxed alleles 
(360). Expression of StAR in the testes was also unchanged. Consequently, 
experimental methods applied to manipulate gene expression can have varying 
results – likely due to compensatory or tissue-specific mechanisms. 
While conflicting findings on a role for TSPO in steroidogenesis points to species-
, tissue- and method-dependant effects, it is also possible that TSPO is indirectly 
involved in steroid production. Application of PK11195 to astrocytic  
(steroidogenic) and fibroblast (non-steroidogenic) cell lines was able to modulate 
cholesterol import (364). Increased accumulation of cholesterol droplets and 
cholesterol efflux were observed, alongside reduced cholesterol esterification. 
Furthermore, the consideration that the structure of TSPO contains a CRAC motif 
(236,237) alludes to a role that involves cholesterol binding even if not transport. 
Sex-dependent effects have been found in mice with reduced TSPO expression 
in steroidogenic organs. Gonadectomy in Sprague-Dawley rats resulted in 
increased Tspo RNA within the cerebral cortex of female, and increased Tspo 
RNA in the cerebellum of male, rats (365). In the female SF-1 driven knock-out 
mice, both basal and stimulated corticosterone levels were significantly lower 
compared to control. This effect was not observed in the male cohort (362). While 
the male knock-out mice exhibited increased blood cholesterol and glucose 
levels, as described above, no such differences were observed in the female mice 
(363). Sex-specific effects following manipulation of steroid synthesis are 
expected but consideration must be made when exploring other potential roles of 
TSPO. 
 
The current literature regarding TSPO expression in tissues suggests a role in 
metabolism. This could be direct, such as in liver regulation of gluconeogenic 
enzymes, or indirect such as adrenal secretion of hormones that influence whole-
body glucose levels. Pharmacological manipulation of TSPO in studies of 
metabolism have also contributed conflicting data, which may be due to off-target 
effects. Genetic manipulation of TSPO in cells provides a good basis for 
understanding; however, contradictions in such experimental findings point to 
60 
 
tissue/cell specific functions. Consequently, manipulation of TSPO expression at 
the tissue or system level may provide further insight to its function. 
 
1.7 Summary of introduction 
 
Obesity is a complex and progressive disease that affects multiple organs (7). It 
impairs ability to effectively sense nutrients and energy availability via the 
homeostatic hub of the brain, the hypothalamus(366). This region integrates 
signals from across the brain and throughout the body to then respond 
accordingly to the energetic state of the organism. Obesity causes systemic low-
grade inflammation (123,125,367). This is observed in peripheral organs such as 
the adipose tissue and the liver, and also in the brain, where it is largely mediated 
by glial cells (125). Glia, primarily astrocytes and microglia, are dynamic cells that 
respond to brain injury or disease through structural and functional changes in 
order to mitigate the damage and maintain brain homeostasis. This process is 
termed reactive gliosis (368). Furthermore, these cells respond to saturated fatty 
acids (SFAs) with gliosis (175,187). This is accompanied with changes in 
mitochondrial metabolism of astrocytes and microglia. Prolonged exposure to the 
insult may lead the neuroinflammatory response to become maladaptive, which 
would explain energy balance dysregulation following excessive fat consumption. 
Reactive gliosis and the accompanying alterations in metabolism could provide 
insight into how homeostatic control of energy balance breaks down in obesity. 
The mitochondrial translocator protein of 18 kDa (TSPO) is expressed across the 
organism in a heterogeneous fashion, including glial cells in the brain 
(298,304,319,369,370). Neural expression of TSPO is upregulated in reactive 
gliosis (172,227,228). This is taken advantage of in the clinic as a proxy 
biomarker for imaging neuroinflammation with PET imaging (230–234). TSPO is 
also present in metabolic organs such as adipose tissue, liver, and steroidogenic 
tissues (306–312,343,344). TSPO has been implicated in various functions, 
including mitochondrial metabolism, though the TSPO literature is clouded by 
seemingly conflicting data. In vitro studies have demonstrated that TSPO up-
regulation alters the preferential route for cellular metabolism to glycolysis 
(326,330,332). In vivo, targeting TSPO expression has shown alterations in 
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glucose homeostasis and alterations in the susceptibility to metabolic 
consequences of obesity. Considering the roles of TSPO in neuroinflammation 
and metabolism, TSPO could be a fruitful link to study the mechanisms underlying 
the breakdown of energy homeostasis. 
 
 
1.8 Hypothesis and aims 
 
The overarching hypothesis of this research project is as follows: TSPO is 
involved in mitochondrial metabolic fuel preference and metabolic flexibility. 
TSPO is up- or downregulated in response to metabolic demand, which facilitates 
the tissue response to nutrient availability or pro-inflammatory stimuli. This 
hypothesis is tested using the following three research aims, which are 
investigated in the next three chapters. 
1. To characterise the distribution of TSPO in brain regions involved in 
energy homeostasis 
2. To examine the regulation of TSPO expression during energy imbalance 
3. To investigate whether modulation of TSPO will influence regulation of 




Chapter 2: Materials and Methods 
2.1 Chemicals 





Agarose Fisher 10688973 
Ammonium persulfate (APS) Sigma-Aldrich A3678 
Benzamidine Sigma-Aldrich 1207 
Bovine serum albumin Sigma-Aldrich A2153 





Dimethyl sulfoxide (DMSO) Sigma-Aldrich D2650-5X5ML 
DPX Mounting Medium Sigma-Aldrich 06522-500ML 
DreamTaq HS Green Master Mix Fisher 15689374 
Eosin-Y Sigma-Aldrich 1.02439 
Ethanol  Thermo Fisher E/0650DF/17 
Ethylenediaminetetraacetic acid 






Fluoroshield Mounting Medium Abcam Ab104135 
Fluoroshield Mounting Medium, 
with DAPI 
Abcam AB104139 




Generuler 1kb Plus Fisher 10101240 
Glucose Sigma-Aldrich G7021 
Glycerol Sigma-Aldrich 49767 
Glycine Melford G0709 
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Chemical Supplier Catalogue number 
Hematoxylin solution, Gill No. 2 Sigma-Aldrich GHS316 
Hydrochloric acid (HCl) Fisher 258148-500ML-D 





Normal donkey serum Sigma-Aldrich D9663 







PK11195 Tocris 0670 
Precision Plus Protein Dual Color 
Standards 
BioRad 1610374 
Primers (TSPO) IDT  
Protein Assay Dye Reagent BioRad 500-0006 
Proteinase K (recombinant), PCR 
grade 
Fisher 10308293 
REVERT™ Total Protein stain LI-COR 926-11021 
REVERT™ Wash Solution LI-COR 926-11012 
Skimmed milk powder Sigma-Aldrich 70166-500G 
Sodium azide Fisher 10592211 
Sodium Chloride (NaCl) Sigma-Aldrich S7653-5KG 
Sodium dodecyl sulphate (SDS) Melford B2008 
Sodium fluoride (NaF) Sigma-Aldrich  S7920 
Sodium hydroxide (NaOH) Fisher 10396240 
Sodium orthovanodate (NaVO4) Sigma-Aldrich S6508 
Sodium phosphate dibasic 
anhydrous 
Sigma-Aldrich RES20908-A702X 





Chemical Supplier Catalogue number 





Sucrose Melford S0809 
Tris Melford B2005 
Tris-acetate-EDTA Fisher 10041223 
Triton X-100 Fisher BP151-00 
Tween-20 Sigma-Aldrich P2287 
Xylenes Sigma-Aldrich 534056 
β-mercaptoethanol Sigma-Aldrich M3148 
 












Bioruptor Plus Diagenode 
Codefree™ Blood Glucose Monitor SD Biosensor 
Codefree™ Blood Glucose Test Strip SD Biosensor 
DM4000 B LED Fluorescent microscope Leica 
DMi8 TCS SP8 confocal microscope Leica 
PHERAstar® FS microplate reader BMG Labtech 
GelMax Imager UVP 
DFC340 FX Light microscope Leica 
8000 Retracting Sledge Microtome Bright Instruments 
Mini-PROTEAN tetra vertical hand-cast protein 
electrophoresis systems 
BioRad 
HistoCore BIOCUT Manual Rotary Microtome Leica 
Odyssey Clx imaging system LI-COR 
NanoDrop™ 8000 Spectrophotometer Thermo Scientific 
Sample Corer 17 Gauge InterFocus 
SimpliAmp Thermocycler Applied Biosystems 











Excel 2013 Microsoft 
FIJI ImageJ 1.52i National Institutes of Health 
Prism 8 & 9 GraphPad 
Image Studio Lite 5.2 LI-COR 
Leica Application Suite X Leica 
 
Table 2.3 List of software used in this research project. 
 
 
2.4 Ethics statement 
 
All procedures involving animals were carried out in accordance with the UK 
Animal (Scientific Procedures) Act 1986, and were approved by the University of 
Exeter Animal Welfare and Ethical Review Body. All steps were taken to minimise 
potential pain and suffering in the animals, as well as to follow the 3Rs as 
described by the National Centre for the Replacement, Refinement and 




All animals were housed on a 12:12 light/dark cycle, with environmental 
conditions at 22 (± 2) °C and 55% (± 2%) humidity. Animals had ad libitum access 
to standard laboratory chow (LabDiet, EURodent diet [5LF2]) – unless specified 
otherwise by the experiment – and water. Housing and experiments took place in 
either the Hatherly (low barrier) or the Living Systems Institute Biological Services 
Units (BSU; intermediate barrier), both based at the University of Exeter. Regular 
welfare checks were made on the experimental animals by the personal licence 
holder and the unit staff. 
The following transgenic and non-transgenic animals were used in the studies 




2.5.1 C57BL/6J mice 
These mice were bred in-house, except for two cohorts acquired from Charles 
River, UK (Table 2.2.1). The genome of C57BL/6J mice contains mutations in the 
gene that codes for nicotinamide nucleotide transhydrogenase (Nnt) (371–373). 
NNT is a mitochondrial protein involved in nicotinamide reduction which in turn 
contributes to ATP synthesis. These mice exhibit altered redox homeostasis, but 
their overall health is unaffected, with the exception of moderate impairment in 
glucose clearance in the glucose tolerance test (371,372). Accordingly, this strain 
is a common “wild-type” model for obesogenic and diabetes studies. These mice 
are prone to pronounced weight-gain, hyperinsulinemia and hyperglycaemia 
when fed high-fat diet (374).  
 
2.5.2 Tg(Trh-EGFP)FZ169Gsat/Mmucd mice 
Brain tissue from Tg(Trh-EGFP)FZ169Gsat/Mmucd (TRH-eGFP) mice was gifted 
by Prof Simon Luckman of the University of Manchester, and used to study 
distribution of TSPO around thyrotropin-releasing hormone (TRH) neurons. This 
strain enables visualisaton of TRH-positive cells using immunohistochemistry. 
The mice were bred on a mixed Swiss Webster and FVB/N mouse background. 
The mouse strain Tg(Trh-EGFP)FZ169Gsat/Mmucd, identification number 
030178-UCD, was originally obtained from the Mutant Mouse Regional Resource 
Center, a NCRR-NIH funded strain repository, and was donated to the MMRRC 
by Nathaniel Heintz at the Rockefeller University and the NINDS funded GENSAT 
BAC transgenic project (375).  
 
2.5.3 Crhtm1(cre)Zjh/J X Gt(ROSA)26Sortm1(EYFP)Cos/J mice 
Brain tissue from these mice was gifted by Prof Simon Luckman of the University 
of Manchester for immunohistochemical processing. These mice were used to 
study the distribution of TSPO in corticotropin-releasing hormone (CRH) neurons. 
The strain was formed from a cross of two different strains: 
Gt(ROSA)26Sortm1(EYFP)Cos/J, originally sourced from Jackson Labs, with 
originator Frank Costantini, Columbia University Medical Center, and 
Crhtm1(cre)Zjh/J – sourced from Jackson Labs, with originator Z. Josh Huang, 
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Cold Spring Harbour Laboratory (376). The offspring of this cross were then bred 
on a C57BL/6J background to generate Crhtm1(cre)Zjh/J X 
Gt(ROSA)26Sortm1(EYFP)Cos/J (CRH-eYFP) mice.  
 
2.5.4 Gad65-GFP mice 
Brain tissue from these mice was gifted by Prof Simon Luckman of from the 
University of Manchester for immunohistochemical processing. This mouse strain 
expresses GFP under the GAD65 promoter, and so allows the identification of 
GABA-expressing neurons. This mouse was originally produced by Szabo Gabor 
at the Department of Functional Neuroanatomy at the Institute of Experimental 
Medicine in Budapest, Hungary (377). These mice were bred on a C57BL/6J 
background. 
 
2.5.5 C57BL/6N-Tspotm1b(EUCOMM)Wtsi/leg mice 
The allele construct to knock-out TSPO was generated at the German Research 
Center for Environmental Health (GmbH) as part of the International Mouse 
Phenotyping Consortium (IMPC) (Fig 2.5.2a) (378). The protocol applied in this 
scenario is known as the “LacZ tagged null allele”. Here, exons 2 and 3 of the 
Tspo gene are labelled by a LacZ and a neomycin cassette. LoxP sites are 
spliced to either side. Following a cross with alleles expressing cre-recombinase, 
a knock-out of the neomycin cassette and exons 2 and 3 is made. This results in 
an allele that cannot produce a Tspo gene product, as the remaining exons (1 
and 4) do not contain a start codon (325). This knock-out affects all organs that 
would ordinarily express TSPO. This method is similar to the generation of a 
different global TSPO-KO mouse line, namely C57BL/6-Tspotm1GuMu(GuwiyangWurra). 
In this case, exons 2 and 3 were also removed and the authors indicated that the 
remaining exons may possibly produce an unrelated protein with no sequence 
similarity to that of TSPO (325). An additional global TSPO-KO mouse line has 
been generated from a conditional anti-Müllerian hormone type 2 receptor cre-
mediated TSPO-KO line (379). 
Following the creation of founder breeders by in vitro fertilization, transgenic mice 
were bred at MRC Harwell to a C57BL6/N mouse background to produce 
heterozygote offspring. These offspring were bred together in order to produce 
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the homozygous knock-out (TSPO -/-) and wild-type mice (TSPO +/+) used in 
this study. These – along with an additional cohort were then used for in-house 
breeding – arrived at the University of Exeter at ages 6-9 weeks old. The 
genotypes of all the mice used in the following experiments were confirmed using 
PCR from liver tissue collected following euthanisation (Fig 2.5.2b). The absence 
of protein expression in TSPO in the TSPO -/- mice was confirmed using Western 
blots of liver tissue from the experimental animals (Fig 2.5.2c). The experimental 
animal cohort were allowed to acclimatise to their surroundings for two weeks, 
and then individually-housed for monitoring of body weight and food intake. 
Individual housing was performed by the NACWO of the animal unit, to ensure 
that the investigators were blinded to the genotype of the animals during the 
study. 
 
2.5.6 Tg(Npy-hrGFP)1Lowl mice 
The wild-type offspring from heterozygous Tg(Npy-hrGFP)1Lowl (NPY-hrGFP) 
mice bred in-house were used in the diet-induced obese study of Chapter 4. 
Using wild-type offspring that were otherwise due to be destroyed reduces 
unnecessary breeding. This strain was originally generated on a FVB mouse 










3.2.1 Distribution C57BL/6J 
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Figure 2.5.1 Generation and validation of the TSPO -/- mice. 
A schematic diagram demonstrating the genetic manipulation that led to the generation 
of the TSPO -/- mutant allele (a). The targeted mutation (tm1b) is identifiable by 
splicing the cDNA to a LacZ and a neomycin (neo) cassette, and targeted by splicing 
to LoxP sites. Crossing the mutated allele with alleles expressing cre-recombinase 
resulted in knock-out of the neomycin cassette and exon 2, resulting in a null allele. 
PCR of liver samples taken from the experimental cohort of mice was used to confirm 
the presence of the wild-type (i; 128 bp) and knock-out (ii; 380 bp) alleles of the mice 
used in the study (b). Western blot was performed in brain tissue of animals bred in-
house to confirm absence of TSPO protein (c). Protein lysate from primary cultured 




2.6 In vivo experimental procedures 
 
2.6.1 Acute high-fat diet exposure 
These experiments were performed in the Hatherly BSU (low barrier facility). 
Male C57BL/6J mice were maintained in their holding room and post-weening 
cages with ad libitum access to water. Within 30 minutes of lights-out (1900 
hours), the mice were weighed and either provided with high-fat chow (TestDiet 
DIO 58Y1, 60% energy from fat) or maintained on their original standard chow 
used in-house (Table 2.6.1). After 12h, from lights-on (0700 hours), the mice were 
moved individually to the procedural room where they were injected via the intra-
peritoneal route with 100 μL of pentobarbitone sodium (1.6 g/kg) and food intake 
and body weights were measured. The mice then underwent either decapitation 
under anaesthesia or transcardial perfusion, depending on requirement for tissue 
analysis. 
 Nutritional profile (% from ingredients) 
Nutrient EURodent 5LF2 
(Standard chow) 
TestDiet DIO 58Y1 
(High-fat diet) 




Total monounsaturated  
Total polyunsaturated 










Fibre 3.7 6.5 






Table 2.6.1 The nutritional profile of the standard chow diet (EURodent 5LF2) 
and high-fat diet (TestDiet DIO 58Y1) used in this project. 
 
2.6.2 Acute food deprivation 
These experiments were performed in the Hatherly BSU (low barrier facility). 
Male C57BL/6J mice were maintained in their holding room and post-weening 
cages with ad libitum access to water. Within 30 minutes prior to lights-out, the 
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mice were weighed and randomly assigned to either the fasted or fed groups. 
The mice in the fast group had their food removed, and the empty tray returned, 
while the food for the mice in the fed condition went untouched. After 12 hours, 
from lights-on (0700 hours), the mice were moved individually to the procedural 
room where they were injected with 100 μL of pentobarbitone sodium (1.6 g/kg) 
into the peritoneum and body weights were measured. The mice then underwent 
either decapitation under anaesthesia or transcardial perfusion, depending on 
requirement for tissue analysis. 
 
2.6.3 Chronic high-fat diet exposure 
The mice used to analyse changes in TSPO and GFAP expression were male 
C57BL/6J. This study was undertaken in the Hatherly BSU (low barrier facility) 
with the mice kept in their original holding cages: group-housed at 2-3 animals 
per cage bar one cage in which a mouse was single-housed. The cages were 
randomly assigned to high-fat or standard chow. The cages allocated to the high-
fat group were provided with high-fat chow (TestDiet DIO 58Y1, 60% energy from 
fat; Table 2.6.1), and the control cages were maintained on the facility standard 
chow. For 12 weeks, body weights of the mice were measured weekly and high-
fat chow replaced twice a week. After the experimental period, mice were 
transported one at a time to the procedure room. Here, the animals were injected 
with 100 μL of pentobarbitone sodium (1.6 g/kg) to the peritoneum in preparation 
for transcardial perfusion.  
In the high-fat diet exposure of TSPO wild-type (+/+) and knock-out (-/-) mice, 
facility standard chow was replaced with high-fat diet (TestDiet, DIO 58Y1, 60% 
energy from fat; Table 2.6.1). Measurements of body weight and food intake were 
made on days 1, 2, 3 and 7 following diet change, and then weekly until 
experiment endpoint. Availability of high-fat chow within the cages was assessed 
every couple of days and animals were provided with more if current levels were 
insufficient. At week 6 the mice were weighed to complete measurements of body 
weight, then euthanised by overdose of pentobarbitone sodium (intra-peritoneal; 




2.6.4 Glucose tolerance test 
Different cohorts of mice underwent this experiment in separate studies, all 
performed in the Living Systems Institute BSU (intermediate barrier). In all cases, 
the mice were acclimatised to tail handling for at least a week before the 
experiment. At lights-on (0700 hours), the mice were moved to a procedure room 
and their food removed. After 6 hours, the mice received a topical anaesthetic 
(EMLA cream; 2.5% lidocaine, 2.5% prilocaine; AstraZeneca) to their tail and a 
small cut was made at the tip – from which blood glucose was measured by a 
handheld blood glucose monitor and testing strips (Table 2.2). The mice then 
received an intra-peritoneal injection of 2 g/kg glucose (Table 2.1) dissolved in 
100 μL saline (0.9% sodium chloride) and filter-sterilised. In the pharmacological 
experiments, mice were co-injected with sterile 5 mg/kg PK11195 or vehicle 
(DMSO; 3%) in sterile saline (Table 2.1). Blood glucose was measured from the 
tail tip cut at 15, 60, 90 and 120 minutes following glucose administration. 
 
2.6.5 Monitoring of nocturnal food intake 
The mice used in this study were also used in the fast-induced refeeding 
experiment, in agreement with PPL guidelines. This experiment occurred in the 
Hatherly BSU (low barrier). C57BL/6J mice were single-housed and handled daily 
for at least a week before the study, for acclimatisation, and randomly assigned 
to drug or control groups. Within 30 minutes prior to lights-out in the facility (1900 
hours), the mice assigned to the drug group were administrated with an intra-
peritoneal dose of sterile 1 mg/kg PK11195 or vehicle (DMSO; 3%) in 100 μL 
saline (0.9% sodium chloride dissolved in sterile water). The weight of the 
standard chow in each cage was recorded at the time of injection and also at 1, 
2, 3, 4, 12 and 24 hours post-injection. 
 
2.6.6 Monitoring of satiated food intake 
The mice used in this study were also used in the fast-induced refeeding 
experiment, in agreement with PPL guidelines. This experiment occurred in the 
Hatherly Biological Services Unit (low barrier). C57BL/6J mice were single-
housed and handled on a daily basis for at least a week before the study, for 
acclimatisation, and randomly assigned to drug or control groups. At lights-on 
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(0700 hours), the mice were injected with 1 mg/kg PK11195 or vehicle (DMSO; 
3%) in 100 μL saline (0.9% sodium chloride in sterile water) via the intra-
peritoneal route. The weight of standard chow was recorded at the time of 
injection and again at 90 minutes following injection, when the mice were then 
euthanised for tissue analysis. 
 
2.6.7 Fast-induced refeeding 
This procedure was performed on C57BL/6J, TSPO +/+ and TSPO -/- mice. Mice 
were single-housed for at least a week prior to the experimental day. Within 30 
minutes before lights-out (1900 hours), standard chow was removed from the 
cages and the body weight of each animal recorded. After 12 hours, from lights-
on (0700 hours), standard chow was weighed and returned to the respective 
cages. In the case of the pharmacological study on the C57BL/6J mice, the mice 
were randomly allocated to receive an intra-peritoneal injection of 1 or 5 mg/kg 
PK11195 or vehicle (DMSO; 3%) in 100 μL saline (0.9% sodium chloride in sterile 
water) alongside return of the standard chow. In all scenarios, the standard chow 
was weighed again at 1, 2, 3, 4, 12 and 24 hours post-injection/return of food. 
 
2.7 Ex vivo analysis 
 
2.7.1 Immunohistochemistry 
To collect brain tissue for immunohistochemical analysis, animals were perfused 
transcardially with 0.01M phosphate buffered saline (PBS; made from sodium 
phosphate; Table 2.1) containing heparin (0.01%) followed by 4% 
paraformaldehyde (PFA; Table 2.1) dissolved in 0.01M PBS. Brains were 
dissected and post-fixed in PFA for up to 18 hours – depending on quality of the 
perfusion. The brains were then placed in 30% sucrose (Table 2.1) dissolved in 
PBS, for 18 hours and stored at -80 °C until use. The brains were re-labelled 
accordingly by an independent observer, for blinding, before being sectioned in 
the coronal plane with a freezing-stage sledge microtome (Table 2.2) at 30 μm 
thickness. Free-floating sections were stored in 0.01% sodium azide in PBS until 
immunohistochemical processing.  
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For immunohistochemistry, sections were washed three times for 10 minutes in 
PBS, then incubated in a block of 5% normal donkey serum (NDS; Table 2.1) 
made in PBS plus 0.3% Triton X-100 (PBS-T; Table 2.1) for 1 hour at room 
temperature on an orbital shaker. Primary antibodies were diluted in 1% NDS, 
made in PBS-T, and free-floating sections were incubated for the duration and at 
the dilution previously optimised (Table 2.7.1.1). 
Sections were washed in three changes of PBS for 10 minutes each, before 
incubation with secondary antibody for 1 hour at room temperature (Table 
2.7.1.2). Secondary antibodies were made to 1:500 dilution in PBS-T. The 
sections were washed in an additional three changes of PBS for 10 minutes. In 
single immunohistochemical processing, the sections were then mounted. In dual 
immunohistochemistry, the incubations in primary and secondary antibodies 
were repeated accordingly. 
The sections were mounted onto glass slides from distilled water and allowed to 
air-dry overnight for 18 hours. Glass coverslips were then applied with fluorescent 
mounting medium (Table 2.1). Sections were examined and imaged using the 
fluorescent microscopes (Table 2.2) for analysis and figures. 
In immunohistochemical processing of white adipose tissue (WAT) the tissue was 
washed in PBS, weighed and then stored in 3% PFA at 4 °C until use. Tissue 
was cut into small sections of equal size using a scalpel, and were then washed 
in three changes of PBS for 10 minutes each. These were blocked in 20% NDS, 
diluted in PBS-T, for 1 hour at room temperature on an orbital shaker. This was 
followed by incubation in rat anti-F4/80 - diluted 1:250 in PBS-T with 20% NDS– 
overnight at 4 °C on an orbital shaker. The following morning, tissue sections 
were washed for 5 minutes in PBS for three changes and then incubated in 
donkey anti-ratalexa-594 – diluted 1:1000 in PBS-T containing 20% NDS - for 1 hour 
at room temperature. The tissue was washed in PBS for 10 minutes before 
incubation in rabbit anti-TSPO, 1:250 in PBS-T with 20% NDS, for 1 hour at room 
temperature. This was followed by three washes in PBS for 5 minutes each, and 
an incubation in donkey anti-rabbitalexa-488 – diluted 1:1000 in PBS-T with 20% 
NDS a– for 1 hour at room temperature. The tissue was washed for a further 10 
minutes in PBS before incubation in 1:1000 DAPI (Table 2.1) diluted in PBS. 
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Tissue was mounted onto glass slides, excess liquid dried by wicking away with 
tissue, and coverslips applied with fluorescent mounting medium. The sections 






Dilution Incubation Supplier 
Catalogue 
number 
F4/80 Rat 1:500 Overnight, 4 °C Abcam ab6640 
GFAP Rabbit 1:1000 Overnight, 4 °C Abcam ab7260 
GFAP Mouse 1:5000 Overnight, 4 °C Millipore mab360 
GFP Chicken 1:1000 Overnight, 4 °C Abcam ab13970 
IBA1 Goat 1:500 Overnight, 4 °C Abcam ab5076 
TSPO Rabbit 1:1000 
1 hour, room 
temperature 
Abcam ab109497 
Vimentin Chicken 1:500 Overnight, 4 °C Millipore ab5733 
 































































Table 2.7.1.2 Secondary antibodies, and their suppliers, used in this 
research project. 
 
2.7.2 Hematoxylin and eosin histological staining 
Liver tissue dissected from the TSPO +/+ and -/- mice was washed in 0.01M PBS, 
weighed and fixed in 4% PFA dissolved in PBS. Samples of equal sizes were 
paraffin embedded, by the Histopathology lab at the Royal Devon & Exeter 
Hospital. The paraffin embedded blocks were sliced using a rotary microtome 
(Table 2.2) into sections of 5 μm width and floated from a heat bath to 
Superfrost™ charged glass microscope slides. 
The slides were left overnight to air-dry, then deparaffinised in two changes of 10 
minutes incubation in xylene (Table 2.1). This was followed by re-hydration in two 
changes of 100% ethanol (Table 2.1) for 5 minutes each, then in 95% ethanol for 
2 minutes and 70% ethanol for 2 minutes. After a brief wash in distilled water, 
80 
 
slides were incubated in hematoxylin solution (Table 2.1) for 90 seconds. The 
solution was washed off in warm running water for 10 minutes, followed by a rinse 
in distilled water. The slides were briefly dipped into 95% ethanol 10 times, and 
then counter-stained in eosin-y solution (Table 2.1) for 30 seconds. Slides were 
dehydrated through 5 minutes incubation in fresh 95% ethanol, followed by 2 
changes in 100% ethanol. The slides were cleared in 2 changes of xylene for 5 
minutes each, and then coverslips applied with DPX mounting medium (Table 
2.1). 
The mounting media was left to dry and the slides were then imaged using light 
microscopy (Table 2.2). 
 
2.7.3 Quantification of protein expression  
Western blot analysis was performed on brain tissue from C57BL/6J mice that 
were exposed to high-fat diet, food deprivation or maintained on standard chow 
overnight (Chapter 2.6.1-2). Mice received an overdose by intra-peritoneal 
administration of pentobarbitone sodium (1.6 g/kg) and then were decapitated for 
dissection. Brains were removed and placed into the brain matrix (Table 2.2) from 
which micropunches containing the dorsomedial and arcuate hypothalamic nuclei 
were taken at approximately -1.70 mm from bregma (381). These were stored at 
-80 °C until use. 
20 μL of lysis buffer (Table 2.7.3.1) was added to the brain tissue micropunches, 
while on ice, and vortexed twice for 5 seconds. The Eppendorf tubes of brain 
tissue and lysis buffer were then lysed by sonication (Bioruptor Plus; Table 2.2): 
5 cycles of 30 seconds pulsing at high frequency, maintained at 4 °C. Tubes were 
vortexed again twice for 5 seconds each and then left for 2 hours at 4 °C on a 
rotary turner. Lysates were then centrifuged at 12,000 RPM for 20 minutes while 
maintained at 4 °C, and the supernatant containing the protein was transferred to 
a fresh pre-cooled Eppendorf tube. 
Liver tissue from TSPO +/+ and -/- mice was used for Western blot validation of 
TSPO genotype. Following tissue collection, samples were stored at -80 °C. 200 
μL of lysis buffer (Table 2.7.3.1) was added to the liver tissue. These were 
centrifuged at 12,000 RPM for 20 minutes at 4 °C and the supernatant transferred 
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to fresh pre-cooled Eppendorf tubes. This was repeated an additional 2 times to 
ensure removal of lipids from the lysates. 
 
Reagent Concentration (mM) 
Tris-HCl (pH 7.4) 25 
NaF 50 
NaCl 0.1 
EDTA (pH 8.0) 1 
EGTA (pH 8.0) 5 




Sodium orthovanadate 1 
Benzamidine 1 
Phenylmethylsulfonyl fluoride 0.1 
 
Table 2.7.3.1 Components, and concentration, of modified RIPA lysis 
buffer.  
 
Total protein quantification for all samples was conducted using the Bradford 
assay protocol (382). Protein assay dye reagent (Table 2.1) was diluted 
according to manufacturer’s instructions. Samples were incubated with 200 μL of 
reagent for 5 minutes on a plate shaker, and absorbance at 595 nm was 
measured using the PHERAstar microplate reader (Table 2.2). Total protein 
concentration was calculated by comparison to a standard curve plotted with 
known concentrations of bovine serum albumin (BSA; Table 2.1). 
For protein separation by SDS-PAGE, hand-cast gels were made with 15% 
acrylamide and a stacking section of 4% acrylamide (Table 2.7.3.2). Samples of 
equal protein concentration were prepared by dilution with sample buffer (Table 
2.7.3.3) and lysis buffer (Table 2.7.3.1) and heated to 90 °C for 5 minutes. 10 μL 
of sample, as well as Precision Plus protein ladder (Table 2.1), were loaded into 
the hand-cast gels in tanks containing running buffer (Table 2.7.3.3). 10 μg, in 10 
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μL, of cortical primary astrocyte cultured from neo-natal mouse brain was added 
as a positive control. Running conditions were set at 90 V for 15 minutes, then 
150 V for 90 minutes. 
 
Reagent Upper (4% acrylamide) Lower (15% acrylamide) 
ddH20 2.8 mL 2.3 mL 
0.5 M Tris (pH 6.8) 1.25 mL  
1.5 M Tris (pH 8.8)  3.15 mL 
30% acrylamide 850 μL 5.6 mL 
10% SDS 50 μL 110 μL 
20% APS 50 μL 55.4 μL 
TEMED 5.35 μL 11 μL 
Table 2.7.3.2 Components and concentrations to make 2x hand-cast gels 
for electrophoresis. 
 
The proteins, separated on the gel, were transferred onto a nitrocellulose 
membrane using the sandwich method. This was placed into a tank containing 
transfer buffer (Table 2.7.3.3) and a current of 100 V was applied for 70 minutes. 
For quantification of total protein transferred, the membrane was washed in water 
and then incubated in total protein stain (Table 2.1) for 5 minutes. The membrane 
was washed twice for 30 seconds in 5 mL Wash Solution (Table 2.1) and then 
imaged by the LI-COR Odyssey imaging system at 700 nm (Table 2.2). Total 
protein stain was removed by incubation in Reversal Solution (Table 2.1) for 10 
minutes, which was rinsed off in water. 
 
Buffer Components 
Sample 125 mM Tris-HCl (pH 6.8), 20% (v/v) glycerol, 4% (w/v) 
SDS, bromophenol blue, 0.1% β-mercaptoethanol 
Running 25 mM Tris, 192 mM glycine, 0.1% SDS 
Transfer 20% (v/v) methanol, 48 mM Tris, 39 mM glycine, pH 8.3 
 
Table 2.7.3.3 Buffers, and their components, used in gel electrophoresis. 
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The membranes were then blocked in 5% milk, dissolved in Tris-buffered saline 
with 0.1% Tween (TBS-T; Table 2.1). This was followed by three changes of 15 
mL TBS-T for 5 minutes each. The membranes were incubated in primary 
antibody; rabbit anti-TSPO (Table 2.7.3.4) diluted in TBS-T containing 2% BSA 
(Table 2.1), overnight at 4 °C. The membranes were washed again in three 
changes of 15 mL TBS-T for 5 minutes each, before incubation for 1 hour at room 
temperature in secondary antibody; goat anti-rabbit800 (Table 2.7.3.5) diluted in 
TBS-T. The membranes were washed in three changes of TBS-T, for 10 minutes 
each, and then imaged with the LI-COR Odyssey system.  
Where required, the membranes underwent further probing for GFAP 
quantification. After imaging, the membranes were incubated in mouse anti-
GFAP (Table 2.7.3.4) - diluted in 2% BSA in TBS-T - overnight at 4 °C. 
Membranes were washed three times in TBS-T for 5 minutes, then incubated in 
Goat anti-Mouse680 (Table 2.7.3.5) for 1 hour at room temperature. The 
membranes were washed in three changes of TBS-T for 10 minutes each, then 
imaged with the LI-COR Odyssey system. In the case of the liver samples to 
confirm TSPO expression and absence in TSPO +/+ and -/- mice, the membranes 
were incubated in mouse anti-GAPDH primary antibody (Table 2.7.3.4) for 1 hour 






Dilution Incubation Supplier 
Catalogue 
number 




GAPDH Rabbit 1:10,000 





TSPO Rabbit 1:1000 
1 hour, room 
temperature 
Abcam ab109497 






























Table 2.7.3.5 Secondary antibodies, and their suppliers, used in Western blot 
analysis. 
 
2.7.4 Confirmation of TSPO genotype by PCR 
Unfixed liver tissue from the high-fat fed TSPO +/+ and -/- mice were collected 
and stored at -80 °C. Equal-sized samples were taken and added to Eppendorf 
tubes containing 0.5 mL DNA digestion buffer (Table 2.7.4.1) with 0.5 mg/mL 
proteinase K (Table 2.1). These were incubated at 55 °C overnight, after which 
0.7 mL of Phenol:Chloroform:Isoamyl alcohol (Table 2.1) was added. The lysates 
were allowed to mix for 1 hour at 4 °C on an Eppendorf rotating rack. The tubes 
were then centrifuged at 14,000 RPM for 5 minutes and 0.5 mL of the supernatant 
was transferred into clean Eppendorf tubes. DNA was precipitated by addition of 
1 mL 100% ethanol, centrifuged at 14,000 RPM for 5 minutes to pellet the DNA 
and the supernatant discarded. To wash the pellet, 0.5 mL of ice-cold 70% 
ethanol was then added to the tubes and then they were centrifuged again. The 
supernatant was discarded, and the DNA pellet left to air-dry overnight until there 
was no ethanol remaining. Once dry, pellets were re-suspended in 200 μL Tris-
EDTA buffer (Table 2.7.4.1) and incubated at 65 °C for 15 minutes. The DNA 
yield was measured using the NanoDrop (Table 2.2) and diluted in Tris-EDTA 





DNA digestion 50 mM Tris-HCl (pH 8.0), 100 mM EDTA (pH 8.0), 100 
mM NaCl, 1% SDS in distilled water 
Tris-EDTA 10 mM Tris, 1 mM EDTA in distilled water (pH 8.0) 
 
Table 2.7.4.1 Buffers used for extraction of liver DNA for TSPO mouse 
genotyping. 
 
For PCR, reaction mix was prepared for the digests (Table 2.7.4.2) and cycling 
conditions optimised for the TSPO -/- allele (Table 2.7.4.3). A water-only negative 
control was included, with lysate replaced with DNA-free water, plus known TSPO 
+/+ and -/- samples for reference. The lysates were then separated by 
electrophoresis on a 1.5% agarose gel made in Tris-acetate-EDTA with 5 μL of 
GelRed nucleic acid stain (Table 2.1). 5 μL of Generuler DNA ladder (Table 2.1) 
and 5 μL of samples and control were loaded per lane. Samples were run at 90 
V for 70 minutes, and imaged using a GelMax Imaging system (Table 2.2). 
 
Component Volume (μL) 
DreamTaq PCR master mix 10 
DNA-free water 6 
5’ arm primer 5’>3’ [AGCAGAAGTAGGAAGAAGGTG] (10 
pmol/μL) 
1 
3’ arm primer 5’>3’ [GTCAACCCATCACTGCCTTCA] (10 
pmol/μL) 
1 
LAR3 primer 5’>3’ [CAACGGGTTCTTCTGTTAGTCC] (10 
pmol/μL) 
1 
DNA digest (50-100 ng) 1 
 





Temperature (°C) Time Number of cycles 
95 5 minutes 1 
94 30 seconds 39 
65 45 seconds 
72 45 seconds 
72 10 minutes 1 
4 hold 1 
 
Table 2.7.4.3 PCR cycling conditions for TSPO genotyping. 
 
 
2.8 Image acquisition and analysis 
 
Images were captured with the Leica fluorescent or confocal microscopes (Table 
2.2) unless stated otherwise. Images for display purpose were captured using 
confocal microscopy. HC PL APO CS2 20x/0.75 dry objective and HC PL APO 
CS2 63x/1.40 oil objective were used to capture images at for 20x and 63x 
magnification, respectively. Two photomultiplier tubes, which were sensitive to 
wavelengths between 597nm - 644nm and 763nm - 768nm, were used to detect 
emission peaks corresponding to Alexa Fluor 488, 568 and 594 dyes. A hybrid 
photodetector (Leica) was used to detect the emission peak corresponding to 
DAPI dye. For image capturing, pinhole size was kept at 95.5 μm, or 1 airy unit, 
and image resolution was consistently 1024 by 1024 pixels which equated to 0.18 
μm pixel-to-voxel size ratio. Image files were exported and processed for analysis 
using FIJI ImageJ (Table 2.3).  
2.8.1 Analysis of TSPO-immunoreactivity distribution in the mouse brain 
The distribution of TSPO-immunoreactivity in the mouse brain was assessed 
qualitatively using standard upright fluorescent microscopy (Table 2.2). This used 
a HC PL FLUOTAR 10x/0.30 dry objective, with a numerical aperture of 0.3, and 
a Leica L5 cube with a bandpass 480/40 excitation and 527/30 suppression filter. 
TSPO was identified in brain regions through comparison of sections to figures in 
the Mouse Brain in Stereotaxic Coordinates (381). Delineation of sub-region 
within nuclei was generally avoided except in cases of absolute clarity, for 
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instance the lateral septal nuclei. The intensity of immunoreactivity was 
qualitatively graded per brain region across sections for each animal (Table 
2.8.1.1). The values attributed to each region were averaged within brain nuclei 
for animals of the same sex. Co-immunoreactivity with neural cell markers, and 
TSPO immunoreactivity in TSPO -/- mice, was assessed qualitatively in both 
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For display purpose, 20x magnification images were captured using confocal 
microscopy (Table 2.2) with tile scanning and multiple z-slices. Tile scans were 
automatically merged by the Leica Application Suite (Table 2.3). Final images 
were formed from an average intensity projection of five z-slices using ImageJ 
(Table 2.3). One z-slice was captured for each image taken at 63x magnification. 
In order to assess potential co-localisation of TSPO with cell-markers, 10 z-slices 
were captured to assess coincidence of immunoreactivity but only one 
representative z-slice was used for display purpose. 
2.8.2 Assessment of TSPO regulation by dietary exposure using 
immunohistochemistry 
In brain sections of mice exposed to acute and chronic high-fat diet, as well as 
food deprivation, immunohistochemical processing was used to semi-
quantitatively assess changes in TSPO expression. Confocal microscopy and 
exposure settings for image acquisition were maintained within each cohort. FIJI 
ImageJ (Table 2.3) was used for measurement of intensity of anti-TSPO 
fluorophore-labelled immunoreactivity. Region of interest (ROI) was drawn 
around the brain nuclei assessed – DMH and Arc, as well as the wall of the third 
ventricle– in which intensity of immunohistochemical staining was measured. A 
ROI was measured outside of the brain nuclei of interest of the same slide, in 
which no immunoreactivity was detected, and this value was subtracted from the 
primary measurement to control for background fluorescence (Figure 2.8.2.1). 
This was performed on 1 slide per animal in each cohort, ensuring that the images 





Figure 2.8.2.1 The regions of interest used in semi-quantification of TSPO 
immunoreactivity. 
TSPO-positive immunoreactivity was semi-quantified in the dorsomedial (a) and the 
arcuate nucleus (b) of the hypothalamus. The regions of interest (ROI) were selected 
out of the nuclei to provide background fluorescence measurements (i). This was 
subtracted from the measurements made in the nuclei ROI (ii) and also in the wall of 
the third ventricle (iii). Images captured at 20x magnification. 
 
 
2.8.3 Analysis of GFAP-positive astrocyte morphology using 
immunohistochemistry 
Immunohistochemically processed brain sections of mice exposed to dietary 
manipulation were used to assess potential changes in GFAP expression – a 
marker for astrocytes. Measurements were made of cell counts and analysis of 
morphology, performed on the same sections of -1.70 mm from bregma as those 
used in the TSPO-immunoreactivity analysis. The cell counter plugin in FIJI 
ImageJ was used to measure the number of GFAP-expressing cells in a 
representative section per animal from each cohort. Inclusion criteria for the 
GFAP-expressing cells to be counted was to contain an observable cell body as 
well as cell processes.  
The ImageJ plugin, ‘Simple Neurite Tracer’ (383), was used to quantify 
morphology of five randomly selected GFAP-expressing cells per section and 
animal. The data acquired from the ‘Simple Neurite Tracer’ plugin is based on the 
linear quantitative analysis designed by Sholl (384). Sholl’s linear method 
measures the distribution of crossings made by cell processes at concentric 
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circles expanding from the cell body (383,384). This is used to characterise the 
morphology of the cell. In this research, the number of intersections of GFAP-
positive processes at each concentric circle were measured (Fig 2.5.3.1). 
Concentric circles were made at intersections of 3 μm. This data was averaged 
between the 5 selected cells for each circle of increasing radius by 3 μm. The 
average values were inputted to GraphPad Prism for analysis (Table 2.3), 
corresponding to each animal of dietary treatment and to each 3 μm radius. 
 
 
Figure 2.8.3.1 Representation of data collection from ‘Simple Neurite Tracer’ 
analysis of GFAP-expressing astrocytes. 
The cell body (pink) is centre of concentric circles of 3 μm apart. Data is extracted from 
the number of cell processes passing each expanding radius (green). Image taken at 





2.8.4 Analysis of white adipose tissue structure from 
immunohistochemical processing 
WAT structure was imaged at 20x magnification using the Leica confocal 
microscope (Table 2.2), and z-stacks were collected. A range of 6 z-stacks were 
processed using ImageJ and set to ‘maximum projection’, in order to visualise 
entire cells across the image. Using the ImageJ ‘Measure’ feature, the area of 
each adipocyte was measured in one image of WAT section per animal. The area 
of adipocytes was averaged per animal. 
The number of F4/80-positive macrophages was measured in the same image, 
per animal, using the ‘Cell Counter’ plugin of ImageJ.  
 
2.8.5 Analysis of liver tissue structure from haematoxylin & eosin 
histological processing 
Three images per liver sample were captured using light microscopy (Table 2.2). 
In ImageJ, images were converted to 8-bit and a threshold applied to convert 
them to black-and-white representations of the tissue structure. The same 
threshold adjustments were applied to all images. The images were inverted so 
that the stained area appeared black, and the ‘Analyse particles’ feature of 
ImageJ was applied. This provided information including the average area of 
black particles, which corresponded to the size of vacuolarised sites in the liver 
tissue. This was averaged again for each of the three images taken per animal 
and plotted accordingly. 
 
2.8.6 Analysis of TSPO and GFAP protein expression measured by 
Western Blot 
The membranes for TSPO and GFAP quantification were probed with Total 
Protein stain (Table 2.1). This was measured on the Image Studio Lite software 





2.9 Data presentation and statistical analysis 
 
Data were processed using Microsoft Excel 2013 (Table 2.3). Graphs were 
produced and statistical analysis was performed using GraphPad Prism versions 
8 and 9 (Table 2.3). Data were presented as individual points – where possible – 
with error bars indicating the range of standard error from the mean. Data were 
tested for normal distribution and the appropriate parametric or non-parametric 
statistical tests were applied. Where comparisons were made between treatment 
groups over time, two-way analysis of variance (ANOVA) tests with repeated-
measures were applied – and the non-parametric versions if data had unequal 
variances. For example, in cases where data collection at time points were 
missed or inaccurately recorded, a mixed-effects analysis model was used 
instead. An Area Under Curve (AUC) analysis was applied to measurements of 
glucose tolerance, where the analysis parameters included peaks greater than 
the baseline of “0” and ignored peaks that were less than 10% of the total distance 
from baseline to the maximum Y-value. In this case, where there were multiple 
comparisons across three groups (for example genotype, diet and sex in glucose 





Chapter 3: Characterisation of TSPO expression in the 




Enhanced neural expression of the mitochondrial translocator protein of 18 kDa 
(TSPO) is associated with neuroinflammation. This is attributed to up-regulation 
of TSPO in reactive astrocytes and microglia (228,240,298,370). TSPO is a target 
in the clinical setting to survey neuroinflammation, typically through positron 
emission tomography (PET) imaging (385). However, TSPO function in the 
healthy brain – human or rodent – is not well characterised. In addition to glia, 
TSPO has been identified in the vascular and ependymal cells (284), but also 
some neurons (300). In the context of PET imaging for clinical assessment of 
neuroinflammation, it is important to acknowledge that there are brain regions 
that have high levels of TSPO even in absence of an underlying pathology. For 
example, previous studies have identified TSPO expression in the dentate gyrus, 
olfactory bulb, choroid plexus as well as the neural vasculature system in healthy 
mouse models (284,325,369). Moreover, a more detailed understanding of the 
location of TSPO in the brain may provide an idea of the functions of this protein.  
The purpose of this study was to characterise the expression of TSPO using 
immunohistochemistry in the healthy adult mouse brain. To achieve this, three 
main objectives were investigated: 
 To examine the distribution of TSPO expression 
 To identify the cellular sources of TSPO localisation 







3.2.1 Distribution of TSPO immunoreactivity in regions of the mouse brain 
involved in energy homeostasis 
Single fluorescence immunohistochemistry was performed on formaldehyde-
fixed free-floating brain sections. I examined the distribution of TSPO 
immunoreactivity throughout the brain in both male and female mice (Table 
3.2.1.1). I focused on brain regions that are known to be involved in regulating 
energy homeostasis. Levels of immunoreactivity were qualitatively assessed 
according to a number scale of 0 to 4; in which 4 indicated the densest levels of 
immunoreactivity (Chapter 2, Table 2.8.1.1). The results of this semi-quantified 
immunoreactivity were averaged across three animals in both sexes.  
Tissue was examined from both sexes, to consider sexual dimorphism in 
neuroendocrine function (135,386–390). While the vast majority of TSPO 
immunoreactivity was very similar between male and female C57BL/6J mice, 
there were some small differences in immunoreactivity density. In some cases 
immunoreactivity was identified in brain regions of one sex and not in the other 
(Tables 3.2.1.1). For example, TSPO immunoreactivity was detected in the 
striohypothalamic nucleus in the female mice and not in the males, while 
immunoreactivity was observed in the septohypothalamic nucleus in the males 
only.  
In all animals the strongest levels of TSPO immunoreactivity were seen in the 
dorsomedial hypothalamic nucleus (DMH), median eminence (ME), and choroid 
plexus (Tables 3.2.1.1). High levels of TSPO-immunoreactivity were also seen in 
non-hypothalamic regions that are considered to be involved in energy 
homeostasis, such as the bed nucleus of the stria terminalis (BNST) (84,391–
393), the lateral septal nuclei (LSN) (92,114), and the nucleus of the solitary tract 
(NTS) (38,82,106,110) (Table 3.2.1.1). Other regions in which TSPO 
immunoreactivity was observed include the preoptic region, choroid plexus, 
subfornical organ (SFO), and amygdala (Table 3.2.1.1). The relative distribution 
of TSPO immunoreactivity in different brain regions will be described in more 
detail in the next sections. 
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3.2.1.1 TSPO immunoreactivity in the hypothalamus 
Throughout the hypothalamus, TSPO immunoreactivity was detected within the 
periventricular nucleus (Pe; Fig 3.2.1.1) surrounding the third ventricle (3V). The 
density of the observed immunoreactivity was variable throughout the coronal 
sections. Labelling in the Pe was in addition to the high levels of TSPO-positive 
immunoreactivity seen in the 3V wall. TSPO immunoreactivity was also seen in 
the paraventricular hypothalamic nucleus (PVH; Fig 3.2.1.1). TSPO 
immunoreactivity followed the transitions in the wing-like structure of the PVH in 
the coronal plane, from -0.58 to -1.22 mm from bregma (Table 3.2.1).  TSPO 
immunoreactivity also spread lateral of the PVH, towards the lateral hypothalamic 
nuclei and within the tuber cinereum (Fig 3.2.1.1). Immunoreactivity was also 
observed dorsal of the PVH, defined to a single focal point at the base of the 
reuniens thalamic nucleus either side of the 3V (Fig 3.2.1.1). 
As aforementioned, dense TSPO immunoreactivity was recorded throughout the 
DMH of both male and female mice (Fig 3.2.1.2). Minimal immunoreactivity was 
seen in the ventromedial hypothalamic nucleus (VMH; Fig 3.2.1.2). Moderate 
TSPO immunoreactivity was identified within the arcuate nucleus (Arc) of both 
male and female mice (Fig 3.2.1.2). Immunoreactivity here encompassed the 
entire nucleus and followed the trajectory by the 3V from anterior to posterior. 
TSPO immunoreactivity extended into the ME at the base of the 3V (Fig 3.2.1.2), 
of which strong immunoreactivity was observed particularly at the external layer.  
Weak TSPO immunoreactivity was noted in both the anterior and the lateral 
hypothalamic regions of male and female mice (Table 3.2.1.1). Here, 
immunoreactivity did not fill the entire nuclei. Within the lateral hypothalamic 
nucleus, immunoreactivity was mostly confined to the peduncular portion. TSPO 
immunoreactivity was also absent-to-weak in the ventrolateral hypothalamus. 
Light immunoreactivity was also reported within the septohypothalamic nucleus 
in the brains of male mice, and weak to moderate immunoreactivity in the females 
(Table 3.2.1.1). Weak to moderate immunoreactivity was observed in the 



















0.38 to 1.78 + + 
     
Nucleus 
Accumbens 
Shell 1.18 to 1.98 + + 
 Shell 0.74 to 1.18 +++ ++ 
 Core 1.98 to 0.74 +, +/- ++ 
     
Corpus Collosum  0.14 to 1.70 + + 
     
Vertical Limb of 
the Diagonal Band 
 0.74 to 1.34 0 + 
     
Septohippocampal 
Nucleus 
 0.74 to 1.18 + + 
     
Lateral Septal 
Nucleus 
Dorsal 0.38 to 1.42 + + 
 Intermediate 0.14 to 0.98 ++ +, +/- 
 Ventral 0.14 to 1.18 ++ ++ 
     
Bed Nucleus of the 
Stria Terminalis 
Dorsal 0.02 to 0.62 + ++ 
 Ventral 0.62 to -0.34 +++ +++ 
 Medial -0.46 to 0.02 + +, +/- 
 Lateral -0.10 0 ++ 
     
Medial Preoptic 
Area 
 -0.46 to 0.74 + +, +/- 
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Vascular Organ of 
the Lamina 
Terminalis 
 0.26 to 0.62 +++ +++ 




 -1.94 to 0.38 ++ ++ 
     
Striohypothalamic 
Nuclei 
 -0.10 to 0.62 0 ++ 
     
Septohypothalamic 
Nuclei 
 0.02 to 0.62 + 0 
     
Subfornical Organ  -0.58 to 0.02 ++, +/- ++ 




 -1.22 to -0.46 +++ ++ 








-2.06 to -0.22 + + 
     
Anterior 
Hypothalamic Area 
 -1.94 to -0.34 +, +/- +, +/- 
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Retrochiasmatic 
Nucleus 
 -1.34 to 0.94 0 + 




 -2.06 to -1.34 + + 




-1.70 to -0.58 +, +/- 0 
     
Arcuate Nucleus  -2.54 to -1.06 ++, +/- ++, +/- 




 -2.18 to -1.34 ++++ ++++ 







-2.06 to -1.70 + + 
     
Median Eminence  -2.30 to -1.58 ++++ ++++ 
     
Choroid Plexus   +++, +/- ++++ 




 -2.70 to -2.54 ++ + 
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-5.34 0 +. +/- 
     
Locus Coeruleus  -5.34 to -5.52 ++, +/- + 
     
Tegmental 
Nucleus 
Laterodorsal -5.40 0 + 
     
Medial Vestibular 
Nucleus 
Posterior part -5.80 + 0 
     
Parvicellular 
Reticular Nucleus 
Alpha part -6.36 ++ 0 
     
Pre-Botzinger 
Complex 
 -7.08 0 + 
     
Rostral Ventral 
Respiratory Group 
 -7.20 to -7.32 ++, +/- 0 
     
Raphe Pallidus 
Nucleus 
 -7.20 to -7.76 ++ + 
     
Raphe Obscurus 
Nucleus 
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-7.08 to -7.92 +, +/- ++ 
     
Dorsal Motor 
Nucleus of the 
Vagus Nerve 
 -7.08 to -7.92 ++ ++, +/- 
     
C1 adrenergic  & 
A1 noradrenergic 
cells 
 -7.56 to -7.92 +, +/- +, +/- 
     
Pyramidal Tract  -7.92 +, +/- ++ 
     
A2 noradrenergic 
cells 
 -8.24 + + 
 
Table 3.2.1.1 Semi-quantitative distribution of TSPO-immunoreactivity in the 
male mouse brain. 
Density of TSPO immunoreactivity was semi-quantified in the adult male and female 
mouse brain (n = 3), with a focus on neuroendocrine regions. 
Scale: 0 (no immunoreactivity), + (little immunoreactivity), ++ (moderate 








Figure 3.2.1.1 TSPO immunoreactivity around the third ventricle of brain tissue 
from a female C57BL/6J mouse, including the paraventricular nucleus of the 
hypothalamus. 
A coronal diagram (a), taken from the Mouse Brain atlas (381) at -1.06 mm from 
bregma, labelled to correspond with the captured images (b-c). Representative image 
capturing TSPO immunoreactivity (green) in the periventricular hypothalamic nucleus 
around the third ventricle (outlined) and paraventricular nucleus of the hypothalamus 
(outlined) (b). A magnified image taken within the paraventricular nucleus of the 
hypothalamus (outlined by the white box), showing TSPO immunoreactivity in the 
green (c). Images captured at 20x (b) and 63x (c) magnification, with scale bars 
representing 200 μm and 50 μm respectively. 






Figure 3.2.1.2 TSPO immunoreactivity around the third ventricle of brain tissue 
from a female C57BL/6J mouse, including the dorsomedial and mediobasal 
hypothalamic nuclei. 
A representative diagram, from the Mouse Brain atlas (381) at -1.70 mm from bregma, 
labelled to correspond with the captured images (a). Dense TSPO immunoreactivity 
(green) is observed around the third ventricle (b) and particularly within the 
hypothalamic dorsomedial nucleus (c), arcuate nucleus (d) and median eminence (e). 
Scale bar represents 200 μm in image captured at 20x magnification (b), and 50 μm 
in images taken at 63x magnification (c-e). 
Key: Third ventricle (3V). 
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3.2.1.2 TSPO immunoreactivity in non-hypothalamic regions that are 
involved in regulating energy homeostasis 
The BNST makes reciprocal connections with hypothalamic nuclei, of which 
some are able to influence food intake (394,395). TSPO immunoreactivity was 
variable within the BNST in all animals (Fig 3.2.1.3). Immunoreactivity was 
strongest in the ventral region (BNSTv), below the anterior commissure (acc). 
Immunoreactivity was not observed in the lateral BNST (BNSTl) in brains taken 
from male mice, but was observed at moderate intensity in female mice. Weak to 
moderate immunoreactivity was noted in the dorsal and medial parts of the BNST 
in all animals. 
Moderate immunoreactivity was also observed within the nucleus accumbens 
(NAcc; Table 3.2.1.1); mostly within the shell, but also in the core as the coronal 
sections moved caudally. The NAcc is involved in energy homeostasis, as well 
as implicated in modulating the reward response to sugar and fat intake (113). 
The NTS received input from the gastrointestinal tract, via the vagus nerve, 
regarding food intake and relays this to the hypothalamus to revoke feeding 
(106,110). TSPO immunoreactivity was also documented within the NTS (Fig 
3.2.1.4). This was found throughout the nucleus at moderate intensity – though 
weaker in brain sections from male mice compared to female. In many sections, 
immunoreactivity was identified at or across the border to the dorsal motor 







Figure 3.2.1.3 TSPO immunoreactivity around the anterior commissure, in the 
bed nucleus of the stria terminalis and in the medial preoptic area of brain tissue 
from a female C57BL/6J mouse. 
A representative coronal diagram (a), taken from the Mouse Brain atlas (381), 
highlighting the regions observed corresponding to 0.14 mm from bregma. TSPO 
immunoreactivity was dense below the anterior commissure and around the third 
ventricle (b). Immunoreactivity was also detected in the bed nucleus of the stria 
terminalis, above the anterior commissure (c), though reactivity was most dense below 
in the ventral region (d) and also in the medial preoptic area (e). Images taken at 20x 
(b) and 63x (c-e) magnification with scale bars representing 200 μm and 50 μm, 
respectively. 





Figure 3.2.1.4 TSPO immunoreactivity around the central canal of hindbrain 
tissue taken from a male C57BL/6J mouse. 
A representative coronal image, taken from the Mouse Brain atlas (381), labelling 
the regions corresponding to -7.76 mm from bregma at which the images were 
captured (a). TSPO immunoreactivity was observed around the central canal (b), 
and densely in the ventral part of the nucleus of the solitary tract (c) adjacent to the 
dorsal motor vagal nucleus.  Images taken at 20x magnification contain a scale bar 
representing 200 μm (b), and taken at 63x the scale bar represents 50 μm (c-e). 
Key: Hypoglossal nucleus (10N); Area postrema (AP); central canal (CC) dorsal 







3.2.1.3 TSPO within circumventricular organs 
TSPO immunoreactivity was detected in multiple circumventricular organs. As 
previously described, strong immunoreactivity was noted in the ME (Fig 3.2.1.2), 
but was weak-to-absent in the area postrema (AP; Fig 3.2.1.4). In addition, dense 
immunoreactivity was observed in the SFO (Table 3.2.1.1, Fig 3.2.2.2) and in the 
vascular organ of the lamina terminalis (VOLT; Table 3.2.1.1, Fig 3.2.2.9). The 
SFO contained TSPO immunoreactivity, of notably a ‘speckled’ pattern, to a 
moderate degree in brain slices from mice of both sexes. There were sex-
differences noted in TSPO immunoreactivity at the VOLT. Medium-level 
immunoreactivity was most notable in male animals (Table 3.2.1.1), while much 
more variable in brain tissue from female mice (Table 3.2.1.2). The 
subcommissural organ showed no TSPO immunoreactivity. The pituitary and the 
pineal gland were not immunohistochemically processed for TSPO. 
 
3.2.1.4 TSPO in other brain regions 
TSPO immunoreactivity was also observed in regions not known to be involved 
in energy homeostasis. Of most notable was strong immunoreactivity within the 
choroid plexus (Table 3.2.1.1). Immunoreactivity was also seen throughout the 
medial preoptic area (Fig 3.2.1.3) with weak to moderate intensity in both male 
and female mice. The same was observed in thalamic regions. With both of these 
areas, however, it was difficult to distinguish between sub-regions. Weak 
immunoreactivity was noted within a small region of the amygdala, which is 
considered to be within the posterior part of the medial amygdaloid nucleus 
(Table 3.2.1.1). Dense immunoreactivity was also identified in the 
noradrenaline/adrenaline cell group (C1/A1) of the hindbrain in both sexes (Table 
3.2.1.1). 
 
3.2.1.5 Controls for detection of TSPO immunoreactivity  
TSPO immunoreactivity was compared to sections, taken from the same mouse 
brain, which underwent an identical immuno-processing technique minus the 
primary antibody. The purpose of this was to identify non-specific binding of the 
secondary antibody used, for which none was identified in any of the brain regions 
observed (Fig 3.2.1.5). Western blot processing of mouse ventral hypothalamic 
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Figure 3.2.1.5 Validation of TSPO immunoreactivity in the mouse brain by 
immunohistochemical processing with secondary antibody only. 
Figures taken from the Mouse Brain in Stereotaxic Coordinates (381), indicating the 
regions in which the corresponding images are taken (i). Anti-rabbit488 
immunofluorescence in the absence of primary rabbit anti-TSPO (ii), showing DAPI 
nuclear staining (iii; blue) and anti-rabbit488 binding (iv; green). Images depict the bed 
nucleus of the stria terminalis (a; image 0.26 mm from bregma), the dorsomedial (b; 
image -1.70 mm from bregma) and arcuate (c; image -1.70 mm from bregma) nuclei 
of the hypothalamus, and in the dorsal vagal complex (d; image -7.48 from bregma). 
Images taken at 20x magnification, scale bars represent 100 μm. 
Key: Third ventricle (3V); anterior commissure (acc); area postrema (AP); central canal 
(CC); hypothalamic arcuate nucleus (Arc); hypothalamic dorsomedial nucleus (DMH); 
dorsal motor nucleus of the vagus nerve (DMX); median eminence (ME); medial 
preoptic area (MPA); nucleus of the solitary tract (NTS); bed nucleus of the stria 






Figure 3.2.1.6 Validation of TSPO antibody in Western blot. 
Western blot analysis of TSPO protein expression – indicated by a band identified at 
18 kDa - in the ventral portion of the hypothalamus of male C57BL/6J mice. Presence 




3.2.2 Cellular identity of TSPO immunoreactivity 
After identifying the regions of the male and female mouse brain with dense 
TSPO immunoreactivity, I then used dual-label immunohistochemistry to identify 
the cell type location within the brain. As glial cells are well documented to be 
responsible for most TSPO immunoreactivity (172,227,228,284), I used 
antibodies against common glial markers – glial fibrillary acidic protein (GFAP), 
ionised calcium binding adaptor molecule 1 (IBA1) and vimentin - to identify 
astrocytes, microglia and tanycytes respectively. However, considering the 
pattern of TSPO immunoreactivity and previous reports of TSPO in neurons 
(300), I also used transgenic reporter mice to label neuropeptide-expressing 
neurons. 
 
3.2.2.1 TSPO in GFAP-positive astrocytes 
I used dual-immunohistochemistry on forebrain sections from male C57BL/6J 
mice, to identify immunoreactivity of TSPO and of GFAP – a commonly used 
marker for astrocytes. GFAP is a cytoskeletal protein, and so antibodies label the 
astrocytic processes as well as the cell soma. GFAP expression is largely 
restricted to astrocytes and some tanycytes, but is not expressed by neurons. 
The activation state of astrocytes influences the level of GFAP expressed (396). 
Extensive immunoreactivity of TSPO was observed in the hypothalamus (Table 
3.2.1.1, Fig 3.2.1.1-2). Hypothalamic astrocytes have been implicated in 
regulating energy balance (204,207,219,397), as well as being activated in 
response to nutritional state (125,180,182,187,198,202). Minimal GFAP 
immunoreactivity was detected within the PVH, DMH or VMH. No coincidence of 
co-immunoreactivity of GFAP with TSPO was observed in the PVH nor the DMH. 
There was minor overlap of immunoreactivity observed within the VMH (Fig 
3.2.2.1). At first glance, TSPO and GFAP immunoreactivity appeared to overlap 
at the base of the Arc (Fig 3.2.2.1). However, at greater magnification the 
incidences of immunoreactivity are observed to be in apposition to each other.  
Potential occurrences of co-localisation between GFAP and TSPO were 
observed outside of the hypothalamus. Coincidence of immunoreactivity between 
GFAP and TSPO was identified within the SFO, but the majority of TSPO 
immunoreactivity did not co-localise with GFAP (Fig 3.2.2.2). There was 
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extensive GFAP immunoreactivity in the cortex, which did appear to coincide with 
TSPO (Fig 3.2.2.3). However, this was only visible if intensity of fluorescence was 
increased considerably compared to imaging of other brain regions. TSPO and 
GFAP immunoreactivity were also detected around vasculature throughout the 
brain, but with minimal co-localisation (Fig 3.2.2.3). 
Immuno-processing of brain sections with the secondary fluorescent antibodies, 
in absence of primary antibodies, confirmed their specificity for the TSPO and 
GFAP antibodies (Fig 3.2.2.4). 
 
3.2.2.2 TSPO in IBA1-positive microglia 
IBA1 is a cell marker for microglia. Its expression, as with GFAP, can be 
influenced by the reactive state of the cell (398,399). IBA1 is also specific to 
microglia, and labels cell bodies as well as projections.  
No co-localisation of TSPO and IBA1 immunoreactivity was detected in the PVH, 
DMH or VMH. IBA1-positive cells were abundant within the Arc and appeared to 
co-express TSPO, but at greater magnification the immunoreactivity was 
concluded to be in apposition (Fig 3.2.2.5). Specificity of secondary antibodies 
were confirmed with immuno-processing in absence of anti-TSPO and anti-IBA1 






Figure 3.2.2.1 TSPO and GFAP immunoreactivity in the hypothalamic arcuate 
nucleus and median eminence of a male C57BL/6J mouse brain. 
TSPO (ii; green) and GFAP (iii; red) immunoreactivity did not coincide in neither the 
hypothalamic arcuate nucleus nor median eminence (a-i; merge). Image taken at 20x 
magnification, and scale bars represent 100 μm. GFAP immunoreactivity was 
strongest in the arcuate nucleus around the median eminence (b). Images here were 
taken at 63x magnification, and scale bars represent 50 μm. 







Figure 3.2.2.2 TSPO and GFAP immunoreactivity in the mouse subfornical organ 
of tissue taken from a male C57BL/6J mouse. 
TSPO (ii; green) and GFAP (iii; red) immunoreactivity was detected within the 
subfornical organ (a-i). There appeared to be coincidences of immunoreactivity 
detected at higher magnification, as indicated by the white filled arrow versus the 
empty arrows, and insert of digital zoom image (b). Images taken at 20x (a) and 63x 








Figure 3.2.2.3 TSPO and GFAP immunoreactivity in the mouse cortex. 
TSPO (ii; green) and GFAP (iii; red) immunoreactivity were both observed in the 
mouse cortex (a-i; merge). Image captured at 20x magnification, and scale bar 
represents 100 μm. Co-localisation of immunoreactivity was detected in some GFAP-
positive astrocyte cells (b), as indicated by the white filled versus the empty arrows. 
Insert on merged image shows digital zoom of potential colocalisation. GFAP 
immunoreactivity was also observed around TSPO-positive immunoreactivity in the 
vasculature (c). Images here were captured at 63x magnification, with scale bar 








Figure 3.2.2.4 Immunohistochemistry in absence of TSPO and GFAP antibodies 
in the mouse brain. 
Figure from the Mouse Brain in Stereotaxic Coordinates (381) at -1.70 mm from 
bregma indicating the brain region from which the images are displayed (i). Image of 
the hypothalamic arcuate nucleus (outlined) showing secondary antibody non-specific 
binding (ii; merge) and DAPI nuclear staining (iii; blue) in the absence of TSPO (iv; 
green) and GFAP (v; red) antibodies. Images taken at 20x magnification and scale 
bars represent 100 μm.  






Fig 3.2.2.5 TSPO and IBA1 immunoreactivity in the hypothalamic arcuate 
nucleus and median eminence of a male C57BL/6J mouse. 
TSPO (ii; green) and IBA1 (iii; red) immunoreactivity were both detected within the 
arcuate nucleus of the hypothalamus (a-i; merge). There was coincidence of 
immunoreactivity detected at higher magnification, as depicted by the white filled 
arrows and the digital zoom insert (outlined) (b). The empty arrows indicate TSPO-
negative GFAP-positive cell. Images taken at 20x magnification (a) and 63x 
magnification (b), with scale bars representing 100 μm and 50 μm respectively.  







Figure 3.2.2.6 Immunohistochemical processing in absence of TSPO and IBA1 
antibodies in the mouse brain. 
Representative figure of -1.70 mm from bregma, taken from the Mouse Brain in 
Stereotaxic Coordinates (381), depicting the region in which the images were taken 
(i). Immunohistochemical processing in the hypothalamic arcuate nucleus as outlined 
by the white dashed line (ii; merge) with DAPI nuclear staining (iii; blue), in absence of 
TSPO (iv; green) and IBA1 (v; red) antibodies. Images taken at 20x magnification and 
scale bars represent 100 μm. 





3.2.2.3 TSPO in vimentin-positive tanycytes 
I used dual immunohistochemistry on forebrain sections from male C57Bl/6J 
mice; processing for TSPO and vimentin, a commonly used cell marker for 
tanycytes. Tanycytes are an ependymal-like cell that line the ventricles of the 
brain and are present in the circumventricular organs (153,400). Vimentin is a 
type-3 intermediate filament protein that is expressed in mesenchymal cells 
(401,402), and can also be expressed by mature astrocytes and ependymal cells 
(403). 
As expected, vimentin immunoreactivity was observed around the 3V throughout 
the brain in male and female mice (Fig 3.2.2.7-8). I found that TSPO 
immunoreactivity was mostly expressed in the 3V lining that is adjacent to the 
MBH compared to the level of the DMH (Fig 3.2.2.7). Co-localisation was also 
most prominent in the tanycyte layer next to the Arc (Fig 3.2.2.7c). There was a 
little co-immunoreactivity between TSPO and vimentin in the tanycytes at the 
base of the 3V (Fig 3.2.2.7d). Similarly, in the tanycytic layer adjacent to the DMH, 
no TSPO immunoreactivity was co-detected with vimentin (Fig 3.2.2.7b).  
Vimentin-positive cells were also identified around the 3V, further anterior in the 
mouse brain, at the level of the VOLT (Fig 3.2.2.8). As identified previously, this 
region has dense TSPO immunoreactivity and strong overlap of TSPO and 
vimentin immunoreactivity was observed across the region. 
Vimentin-labelled cells were also identified around the lateral ventricle (LV) of the 
mouse forebrain (Fig 3.2.2.9). Both TSPO and vimentin Immunoreactivity was 
only identified in the dorsal and lateral sides of the ventricles – where they 
appeared to co-localise. TSPO immunoreactivity was found throughout the LSN. 
Although it did not appear to extend from the ventricles, some vimentin 
immunoreactivity was identified in the LSN.  
The secondary antibody used in this immuno-processing was confirmed to be 






Figure 3.2.2.7 Vimentin and TSPO immunoreactivity coincide at the third 
ventricle adjacent to the hypothalamic arcuate nucleus in tissue from a male 
C57BL/6J mouse. 
TSPO (ii; green) and vimentin (iii; red) labelling occurred around the third ventricle in 
the hypothalamus (a-i; merge). There was minimal incidence of TSPO and vimentin 
co-immunoreactivity in the region adjacent to the dorsomedial hypothalamus (b), as 
denoted by the white filled arrows versus empty arrows digital zoom insert (outlined). 
There was considerably greater coincidence of immunoreactivity at the ventricle wall 
adjacent to the arcuate nucleus (c). There was little colocalisation of vimentin and 
TSPO above the median eminence (d). Images taken at 20x magnification with scale 
bars representing 100 μm (a). Images taken at 63x magnification and scale bars 
representing 50 μm (b-d). 




Figure 3.2.2.8 TSPO and vimentin immunoreactivity in the vascular organ of the 
lamina terminalis, in brain tissue taken from a male C57BL/6J mouse. 
TSPO (ii; green) and vimentin (iii; red) immunoreactivity were observed in the vascular 
organ of the lamina terminalis around the third ventricle (a-i; merge). The majority of 
immunoreactivity appeared to coincide (b), as noted by the white filled arrows versus 
empty arrows and the digital zoom insert (outlined). Images taken at 20x magnification, 
with scale bars representing 100 μm (a), and at 63x magnification with scale bars 
representing 50 μm (b). 






Figure 3.2.2.9 TSPO and vimentin immunoreactivity around the lateral ventricle 
in brain tissue taken from a male C57BL/6J mouse. 
TSPO (ii; green) and vimentin (iii; red) immunoreactivity were observed in the lining of 
the lateral ventricle (i; merge). The majority of immunoreactivity appeared to coincide 
at the wall adjacent to the lateral septal nucleus in the dorsal (a), intermediate (b) and 
ventral parts (c). Incidences of co-immunoreactivity are noted by the white filled arrows 
versus empty arrows, and the digital zoom insert (outlined). Images taken at 63x 
magnification with scale bars representing 50 μm. 






Figure 3.2.2.10 Immunohistochemical processing in absence of TSPO and 
vimentin antibodies in the mouse brain. 
Figure taken from the Mouse Brain in Stereotaxic Coordinates (381) indicating the 
brain region at  -1.58 mm from bregma in which the images were taken (i). 
Immunohistochemical processing at the median eminence (ii; merge) with DAPI 
nuclear staining (iii; blue), in the absence of TSPO (iv; green) and vimentin (v; red) 
antibodies. Images taken at 20x magnification and scale bars represent 100 μm. 
Key: Third ventricle (3V). 
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3.2.2.4 TSPO immunoreactivity in TRH-positive neurons 
I used dual immunohistochemistry to identify TSPO and GFP immunoreactivity in 
brain sections taken from TRH-eGFP reporter mice. Thyrotropin-releasing 
hormone (TRH) is synthesised primarily within neurons of the PVH, of which the 
axons project down to the ME. While TRH neurons are important in release of 
thyrotropin and prolactin from the pituitary gland, the interest of relevance to this 
study is their distribution within the PVH (87). As previously described, dense 
TSPO immunoreactivity was observed in the PVH which looked neuronal in 
appearance rather than glial (Fig 3.2.1.1). Furthermore, the characterised 
location of TRH-expressing neurons in the PVH matches with the pattern of 
TSPO immunoreactivity (87). TRH is also expressed in neurons outside of the 
hypothalamus, and has been shown to be expressed in reactive astrocytes (404). 
I identified a low level of co-localisation of TSPO immunoreactivity with that of 
GFP, a proxy marker of TRH neurons, within the paraventricular hypothalamus 
(Fig 3.2.2.11). TRH-eGFP immunoreactivity was mostly concentrated in the 
medial part of the PVH, while co-localisation was observed primarily in the lateral 
and dorsal regions of the PVH. The pattern of TRH-eGFP immunoreactivity 
formed mostly cell bodies and axons. TRH-eGFP immunoreactivity was noted 
within the medial zone of the ME (Fig 3.2.2.12). Surprisingly, this did not overlap 
with TSPO immunoreactivity, which was primarily contained within the external 
layer of the ME. TRH-eGFP immunoreactivity was, however, expressed in the 
DMH and this did coincide with TSPO immunoreactivity (Fig 3.2.2.13). TRH-
eGFP formed some cell bodies within the DMH, as well as processes.  
Other regions within the murine brain that both expressed GFP, as a proxy to 
TRH, and TSPO were the BNST and the SFO. Within the BNST, TRH-eGFP 
immunoreactivity took the form of processes rather than cell bodies – indicative 
of either dendrites or axons passing through these areas (Fig 3.2.2.14). Moderate 
coincidence of immunoreactivity was noted in the ventral portion of the BNST (Fig 
3.2.2.14). TRH-eGFP immunoreactive cell bodies and processes were observed 






Figure 3.2.2.11 TSPO and TRH-eGFP immunoreactivity are detected within the 
paraventricular hypothalamus of male mice.  
Both TSPO (ii; red) and TRH-eGFP (iii; green) immunoreactivity was detected in the 
paraventricular hypothalamus (a-I; merge). Image captured at 20x magnification, and 
the scale bar marks 100 μm. At 63x magnification (b), very little overlap of 
immunoreactivity was evident as depicted by the white filled arrows and the digital 
zoom insert versus the empty arrows. Scale bar represents 50 μm.  







Figure 3.2.2.12 TSPO and TRH-eGFP immunoreactivity at the arcuate 
hypothalamic nucleus of male mice. 
TSPO (ii; red) and TRH-eGFP (iii; green) immunoreactivity were both detected within 
the median eminence, but not the arcuate nucleus, of the hypothalamus (a-i; merge). 
Image captured at 20x magnification, with the scale bar representing 100 μm. No 
coincidence of immunoreactivity, as noted by the empty arrows, was detected in the 
median eminence at 63x magnification (b). Scale bars here represents 50 μm. 







Figure 3.2.2.13 TSPO and TRH-eGFP immunoreactivity in the dorsomedial 
hypothalamus of a male mouse. 
Dense TSPO (ii; red) and TRH-eGFP (iii; green) immunoreactivity was observed in the 
dorsomedial hypothalamus (a-i; merge). Image was taken at 20x magnification and 
the scale bar represents 100 μm. Incidences of potential co-localisation were observed 
and noted by the white arrows versus the empty arrows and the digital zoom insert 







Figure 3.2.2.14 TSPO and TRH-eGFP immunoreactivity in the ventral portion of 
the bed nucleus of the stria terminalis of a male mouse. 
TRH-eGFP immunoreactivity (ii; green) formed projection-like structures alongside 
TSPO (iii; red) immunoreactivity in the ventral bed nucleus of the stria terminalis (a-i; 
merge). There was a little overlap in immunoreactivity observed at high magnification, 
as noted by the filled arrows versus the empty arrows and the digital zoom insert 
(outlined) (b). Images taken at 20x (a) and 63x (b) magnification, with scale bars 
representing 100 μm and 50 μm respectively. 







Figure 3.2.2.15 TSPO and TRH-eGFP immunoreactivity within the subfornical 
organ of a male mouse. 
Both TRH-eGFP (ii; green) and TSPO (iii; red) immunoreactivity were observed in the 
subfornical organ (a-i; merge). No coincidence of immunoreactivity was observed as 
denote by the empty arrows (b). Images taken at 20x (a) or 63x (b) magnification with 
scale bars representing 100 μm and 50 μm, respectively. 
Key: Corpus callosum (cc). 
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3.2.2.5 TSPO immunoreactivity in CRH-positive neurons 
Corticotrophin-releasing hormone (CRH) is expressed within the parvocellular 
cells of the PVH, interspersed with TRH-expressing neurons. These neurons also 
project to the ME (87,405). CRH-positive neurons are important in regulating the 
neuroendocrine response to stress (405). CRH is also documented to be 
expressed in non-hypothalamic brain regions that are also associated with stress, 
such as the BNST and the amygdala (406,407). Furthermore, TSPO ligand Ro5-
4864 induces CRH production in ex vivo rat hypothalamic slices (408). I applied 
immunohistochemistry to forebrain brain tissue from mice that express eYFP in 
CRH-positive neurons to investigate co-immunoreactivity with TSPO. 
There was an overlap of immunoreactivity between TSPO and eYFP (labelled 
with GFP, as a proxy for CRH-expressing neurons) within the PVH (Fig 3.2.2.16). 
CRH-eYFP immunoreactivity formed mostly cell bodies in the parvocellular PVH, 
as expected, but processes were discernible in the dorsal portion of the PVH. 
TSPO immunoreactivity overlapped with that of CRH, albeit to a minor extent, in 
both the cell bodies and in the projections. TSPO immunoreactivity covered a 
greater area of the PVH than that of CRH-eYFP. 
Sparse CRH-eYFP labelled cell bodies were also observed in the DMH, though 
these did not contain any TSPO immunoreactivity. CRH-eYFP labelled 
projections were observed within the ME, which were dense within the external 
layer (Fig 3.2.2.17b). Images taken at 63x magnification indicated that TSPO and 
CRH-eYFP immunoreactivity were in apposition to each other at the external 
layer of the ME. 
There was coincidence of TSPO and CRH-eYFP immunoreactivity in the VOLT, 
immediately surrounding the 3V (Fig 3.2.2.18). The CRH-eYFP immunoreactivity 






Figure 3.2.2.16 TSPO and CRH-eYFP immunoreactivity in the paraventricular 
and periventricular regions of the hypothalamus of a male mouse. 
Dense CRH-eGFP (ii; green) and TSPO (iii; red) immunoreactivity was observed in 
the paraventricular hypothalamic nucleus (a-i; merge). Overlap of immunoreactivity 
was identified in the ventral portion of the paraventricular hypothalamus, as denoted 
by the filled arrows versus empty arrows and the digital zoom insert (outlined) (b). 
Images taken at 20x (a) and 63x magnification (b), with scale bars representing 100 
μm and 50 μm respectively.  







Figure 3.2.2.17 TSPO and CRH-eYFP immunoreactivity in the ventral part of the 
hypothalamus of a male mouse. 
CRH-eYFP immunoreactivity (ii; green) was detected alongside that of TSPO (iii; red) 
in the median eminence (a-i; merge). There were little incidences of co-localisation 
detected in the external layer of the median eminence, as noted by the filled arrows 
and digital zoom insert (outlined), but the vast majority of reactivity occurred in 
apposition – exemplified by the empty arrows (b). Images taken at 20x (a) and 63x 
magnification (b), with scale bars representing 100 μm and 50 μm respectively. 







Figure 3.2.2.18 TSPO and CRH-eYFP immunoreactivity around the third ventricle 
in the vascular organ of the lamina terminalis of a male mouse. 
CRH-eYFP (ii; green) & TSPO (iii; red) immunoreactivity were detected in the vascular 
organ of the lamina terminalis (a-i; merge). At higher magnification, a few incidences 
of co-reactivity were detected – defined by the white filled arrows versus the empty 
arrows and the digital zoom insert (outlined) (b). Images taken at 20x (a) and 63x 
magnification (b), with scale bars representing 100 μm and 50 μm respectively. 
Key: Third ventricle (3V). 
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3.2.2.6 TSPO immunoreactivity in GAD65-expressing neurons 
Glutamate decarboxylase (GAD) is an enzyme, expressed in both the CNS and 
in the pancreas, that catalyses the decarboxylation of glutamate to γ-
aminobutyric acid (GABA) and carbon dioxide (409). It exists as two isoforms, 
either GAD65 or GAD67, and each have distinct functions (410). GAD65 is 
primarily used in neuronal terminals and synapses of the neuroendocrine system, 
where it synthesises GABA for release as a neurotransmitter. Furthermore, the 
central benzodiazepine receptor is structurally similar to TSPO and has high 
affinity to GABA (411). TSPO ligands are also capable of modulating GABA 
secretion (412). To investigate TSPO expression in GAD65-positive neurons, I 
immunohistochemically processed brain sections taken from transgenic GAD65-
GFP mice for TSPO immunoreactivity. 
GAD65-positive neurons were identified within the DMH (Fig 3.2.2.19). These 
formed mostly cell bodies, and immunoreactivity did not coincide with that of 
TSPO. GAD65-GFP immunoreactivity was also observed within the Arc, but this 





Figure 3.2.2.19 TSPO and GAD65-eGFP immunoreactivity within the 
dorsomedial hypothalamus of a male mouse. 
TSPO (iii; red) immunoreactivity was detected around GAD65-eGFP-positive (ii; 
green) cell bodies in the dorsomedial hypothalamus (a-i; merge). No coincidence of 
overlap was detected at higher magnification, indicated by the empty arrows (b). 
Images taken at 20x (a) and 63x magnification (b), with scale bars representing 100 






Figure 3.2.2.20 TSPO and GAD65-eGFP in the hypothalamic arcuate nucleus of 
a male mouse. 
GAD65-eGFP (ii; green) and TSPO (iii; red) immunoreactivity was detected in the 
arcuate nucleus of the hypothalamus (a-i; merge). No coincidences of 
immunoreactivity were detected in the arcuate nucleus, as exemplified by the empty 
arrows (b). Images taken at 20x (a) and 63x magnification (b), with scale bars 
representing 100 μm and 50 μm respectively. 




3.2.3 Verification of immunoreactivity detected by rabbit anti-TSPO 
antibody in TSPO knock-out mice 
It was important to validate the antibody that targeted TSPO in order to confirm 
the distribution of TSPO in the mouse brain and the significance of the antibody’s 
immunoreactive product. This was performed by repeating the 
immunohistochemical process on brain sections obtained from TSPO wild-type 
(+/+) and knock-out (-/-) mice. Unfortunately, despite the antibody being knock-
out validated by its production company, I was still able to detect TSPO-positive 
immunoreactivity within the brain tissue from the TSPO -/- mice (Figs 3.2.3.2-5). 
Western blot analysis with the same antibody identified a band at 18 kDa, which 
corresponds to TSPO (Fig 3.2.1.6). Immunocytochemical processing of cortical 
primary astrocytes, cultured from litters of TSPO +/+ and -/- mice, confirmed 
absence of immunoreactivity in the astrocytes of TSPO -/- litters (Fig 3.2.3.1). In 
brief, these cultured cortical astrocytes were isolated as described by Schildge et 
al (413), seeded at 1 brain per flask and maintained in supplemented in 
Dulbecco’s modified Eagle Medium as described by Vlachaki Walker et al (414). 
For immunocytochemical processing, the mouse primary astrocytes were plated 
at a density of 1 x 105 cells per coverslip, fixed with 4% paraformaldehyde solution 
and permeabilised by lysine block prior to staining with rabbit anti-TSPO (Table 
2.7.1.1) and donkey anti-rabbit488 (Table 2.7.1.2) at the same concentrations and 
incubation times as described in this thesis. Considering the results obtained from 
these experiments, I consequently deduce that there is cross-reactivity between 
the TSPO antibody and an unknown antigen in mouse brain tissue – which is not 
present in primary astrocyte cell culture. I immunohistochemically processed 
forebrains from TSPO +/+ and -/- mice to investigate any differences in 
immunoreactivity identified by the TSPO antibody. 
First, it was important to look into the hypothalamic regions in which dense TSPO 
immunoreactivity was observed. Within the DMH, immunoreactivity was similar if 
not more intense in the TSPO -/- mice compared TSPO +/+ (Fig 3.2.3.2). 
Conversely, immunoreactivity within the Arc seemed to be reduced in TSPO -/- 
animals (Fig 3.2.3.2). This may have been due to the absence of TSPO 
immunoreactivity in the ependymal/tanycytes layer of the 3V in the TSPO -/- 
animals. There was no TSPO immunoreactivity that formed “tanycyte-like” 
projections away from the 3V in the TSPO -/- mice compared to that in TSPO +/+. 
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There was also reduced TSPO immunoreactivity within the ME, though not 
completely absent, in the TSPO -/- brains (Fig 3.2.3.2). 
Loss of TSPO-targeted immunoreactivity in circumventricular organs was 
observed in the TSPO -/- mice. In the VOLT, immunoreactivity was drastically 
reduced in brains from TSPO -/- animals compared to TSPO +/+ (Fig 3.2.3.3). 
However, immunoreactivity was not entirely absent and so expression of the 
unknown protein that cross-reacts with the antibody must also be present in the 
VOLT. Immunoreactivity was reduced in the SFO of TSPO -/- compared to TSPO 
+/+ mice (Fig 3.2.3.4). Within the choroid plexus, immunoreactivity was entirely 
absent in brains from TSPO -/- mice (Fig 3.2.3.5). The genotype of the mice, from 
which brain tissue was immunohistochemically processed, was confirmed using 






Figure 3.2.3.1 TSPO immunoreactivity in primary cultured astrocytes of TSPO 
+/+ and -/- mice. 
TSPO immunoreactivity was present in primary astrocytes, cultured from < 5 day old 
mouse pups, of TSPO +/+ (a) and -/- (b) litters. Channels are merged (i) from DAPI 
nuclear staining (ii; blue) and TSPO immunoreactivity (iii; green). Images captured at 
20x magnification, and scale bars represent 25 μm. Image courtesy of Dr. Josie Robb, 






Figure 3.2.3.2 TSPO immunoreactivity in the dorsomedial and mediobasal 
hypothalamus of TSPO +/+ and -/- mice. 
Figure taken from the Mouse Brain in Stereotaxic Coordinates (381), outlining the 
region at -1.70mm from bregma where the images were taken (a-i). TSPO 
immunoreactivity was lower in the mediobasal hypothalamus and in the layer of the 
third ventricle of TSPO -/- (a-iii) compared to TSPO +/+ mice (a-ii). Immunoreactivity 
imaged at 63x magnification in the dorsomedial hypothalamic nucleus (i), arcuate 
nucleus (ii) and median eminence (iii) of TSPO +/+ (b) and -/- (c) mice. Scale bars 
represent 200 μm at 20x magnification (a), 50 μm at 63x magnification (b, c). 





Figure 3.2.3.3 TSPO immunoreactivity around the vascular organ of the lamina 
terminalis of TSPO +/+ and -/- mice. 
A representative figure, taken from the Mouse Brain in Stereotaxic Coordinates (381), 
indicating the region in which the images were taken at 0.28 mm from bregma (a-i). 
TSPO immunoreactivity in the vascular organ of the lamina terminalis of TSPO +/+ (a-
ii) and -/- (a-iii) mice. Images taken at 63x magnification show high levels of 
immunoreactivity in TSPO +/+ tissue (b) compared to tissue taken from -/- mice (c). 
Scale bars represent 100 μm at 20x magnification (a) and 50 μm at 63x magnification 
(b, c). 






Figure 3.2.3.4 TSPO immunoreactivity in the subfornical organ (SFO) in TSPO 
+/+ and -/- mice. 
Figure of the mouse brain at -0.70 mm from bregma, taken from the Mouse Brain in 
Stereotaxic coordinates (381), indicating the region in which the images were taken 
(a-i). TSPO immunoreactivity in the brain tissue of TSPO +/+ (a-ii) and -/- mice (a-iii). 
TSPO-targeted immunoreactivity is reduced, but not absent, in the SFO in TSPO -/- 
mice (c) compared to TSPO +/+ mice (b). Scale bars represent 100 μm at 20x 






Figure 3.2.3.5 TSPO immunoreactivity within the choroid plexus of TSPO +/+ and 
-/- mice. 
Figure of the mouse brain at -1.22 mm from bregma, taken from the Mouse Brain in 
Stereotaxic Coordinates (381), indicating the region in which the images were taken 
(a-i). TSPO immunoreactivity is observed in the choroid plexus of brain tissue taken 
from TSPO +/+ mice (a-ii), but not TSPO -/- mice (a-iii). Images taken at 63x 
magnification show strong immunoreactivity in tissue from TSPO +/+ animals (b) which 
is absent in TSPO -/- tissue (c). Scale bars represent 100 μm at 20x magnification (a), 







Figure 3.2.3.6 Confirmation of genotype of TSPO +/+ and -/- mice used for 
antibody validation. 
A gel displaying the TSPO +/+ (i) and TSPO -/- (ii) alleles from tail samples of the mice 






3.3.1 Summary of findings and conclusions 
Uncovering the pattern of expression of proteins within an organ can help 
elucidate their role. In regionally heterogeneous organs such as the brain, this 
has been helpful to determine the roles of neuropeptides from the distribution of 
their expression. Using the hypothalamus as an example, novel peptides that are 
expressed in the Arc are likely (but not necessarily) to be involved in regulating 
feeding behaviour (77). TSPO is a mitochondrial protein that has been implicated 
in a variety of roles, as such linking its distribution to function may prove to be 
complex. In the clinical setting, non-invasive brain imaging such as PET is used 
to identify changes in TSPO expression in disease pathology. Techniques such 
as PET do not yet have the resolution to identify specific brain nuclei in which 
TSPO is highly expressed. There have been a few papers published which have 
characterised TSPO expression in the mouse brain, but these have all focussed 
primarily on the hippocampus and cortex (284). However, given that TSPO is 
expressed in other brain regions, this leaves potential CNS functions unresolved. 
Until very recently, there has been limited published work on TSPO expression 
and function in hypothalamic regions. There is good reason for hypothalamic 
TSPO expression to be investigated: TSPO is well-documented to be expressed 
in activated glia (172,284,294), and hypothalamic gliosis is known to be involved 
in the physiological response to high-fat intake (125,180,416). It seems sensible 
to expect that TSPO is expressed within the hypothalamus and, if not, this would 
remain interesting and provide evidence of glia heterogeneity. There are also 
non-hypothalamic regions that have been identified to be involved in appetite 
control and energy homeostasis. While the focus of this series of experimental 
studies in this chapter was in regions of the brain controlling energy balance, 
TSPO expression was also observed in these other brain areas.  
The purpose of this study was to identify regions in the mouse brain that contain 
detectable TSPO levels, even in absence of disease pathology and/or 
experimental intervention. This then has potential to provide a basis for 
understanding imaging of TSPO levels in the clinical setting; it is important to 
consider regional differences where high expression levels are considered 
normal or abnormal, and vice versa. 
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When using an antibody to investigate and describe protein expression in tissue, 
it is crucial to ensure that the antibody binding within the tissue is specific to the 
target antigen. Here, I performed the same immunohistochemical processing 
procedure in the brains of mice with a germline deletion of TSPO. The expectation 
was that the distribution of immunoreactivity, detected with the TSPO antibody, 
would be absent in the TSPO -/- mice. This was not the case, and the mice were 
confirmed as TSPO -/- using PCR and gel electrophoresis.  
I compared the immunoreactivity between TSPO +/+ and -/- mice, to investigate 
if there were any disparities in antibody binding. Differences in TSPO 
immunoreactivity between TSPO +/+ and -/- mice were noted in some 
circumventricular and secretory organs of the brain. These included brain regions 
where TSPO immunoreactivity co-localised with vimentin in TSPO +/+ tissue. 
This provides evidence that TSPO is relevant in some nuclei that are involved in 
– but not limited to – energy homeostasis. Furthermore, knock-out validated 
immuno-labelling was performed by immunocytochemistry in primary astrocyte 
culture.  These observations collectively indicate that there is likely specificity of 
the antibody in glia, tanycytes and ependymal cells.  
TSPO immunoreactivity was observed in the cell layer surrounding the 3V, which 
also co-localised with vimentin – a cell marker for tanycytes. These cells are 
essential for the communication of nutrients and signals from the cerebrospinal 
fluid  to the surrounding hypothalamic nuclei (153,155–157,160,161,163). A high 
level of expression in these cells indicates a potential role for TSPO in nutrient 
sensing. At the time of the experiments, there had been no mention in the 
literature of TSPO expression within tanycytes. Since the research was 
conducted, a study has been published which investigated the functional role of 
TSPO expression in β-tanycytes (301). The research I presented here agrees 
with the authors regarding the distribution of TSPO expression around the 3V: 
that TSPO expression is was mostly confined to the ventral portion of the 3V, 
adjacent to the Arc and ME, in the β-tanycyte cell layer. As well as proposing a 
role for TSPO in tanycytic integration of nutrient sensing to hypothalamic function, 
this restricted expression of TSPO in a sub-population of tanycytes is also an 
example of glial heterogeneity – a notion that is recently becoming acknowledged 
for its importance (417–419). Importantly, this study used the same antibody as 
was used in my work and also saw the same pattern of potentially “non-specific” 
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staining in the PVH and DMH; however, this was not noted as “non-specific” by 
the authors. 
In the studies described in this chapter, TSPO and vimentin immunoreactivity 
also co-localised in other areas of the mouse brain, in which was also validated 
by its absence in the TSPO -/- mice. Co-expression was observed in the VOLT, 
which surrounds the 3V anterior of the hypothalamus, and along the cell layer 
lining the lateral ventricles. TSPO expression in vimentin-positive cells of the 
ventricles may a play similar role to that in tanycytes despite differences in 
location of expression. 
3.3.2 Limitations of experimental approach 
Qualitative studies that rely on immunohistochemistry are limited by the quality 
and validity of the antibodies used. The validation of the TSPO antibody I 
performed as part of this study was purely for precautionary reasons; the antibody 
had been used and published by a variety of research groups and the reputable 
supplier of the antibody, Abcam, had performed in-house knock-out validation. 
Differences in antibody-antigen binding can be a result of technical approaches, 
and upon discussion with an Abcam representative I discovered such differences 
in our methods to validate the antibody. Abcam used peroxidase 
immunohistochemical labelling with an antigen-retrieval step – as recommended 
on the antibody product description. The advantage of using peroxidase activity 
to label immunoreactivity as opposed to fluorescence is that it negates obscuring 
positive-signal by autofluorescence in the tissue. That being said, I used 
secondary-only antibody labelling on tissue as an internal control for tissue 
autofluorescence and I did also perform peroxidase immunochemical labelling 
with the same antibody and observed the same pattern of immunoreactivity. At 
the time I did not see any need to perform antigen-retrieval as the immunoreactive 
signal was so strong, and the purpose of the retrieval is to unmask antigens. 
However, this technical difference may be useful to investigate further if the 
project were to continue. Furthermore, the “non-specific” TSPO labelling was 
identified in multiple laboratories and in a variety of mouse strains by myself and 
by colleagues. This also applied to multiple batches of the antibody. In addition, 
the pattern of immunoreactivity around the DMH and Arc has been included in 
published work (301). Consequently, it is unlikely that the “non-specific” 
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immunoreactivity occurred as a result of mouse strain genetics or histochemical 
techniques.  
A further point taken from the correspondence with a representative for Abcam is 
that the heterogeneity of TSPO expression must be considered when validating 
the targeting antibody. The images of the TSPO antibody validation provided by 
Abcam show a region of the hypothalamus, but with no labels so it is difficult to 
determine which nucleus of the hypothalamus is shown. As depicted in this 
chapter, while there is strong immunoreactivity within hypothalamic regions this 
is restricted to particular nuclei and there are some hypothalamic nuclei without 
any TSPO targeted labelling. One such example is the suprachiasmatic nucleus, 
which I think is the hypothalamic nucleus depicted in the Abcam image. During 
the correspondence, the Abcam representative also referred to a figure that used 
the antibody in Western blot analysis of a variety of tissues from both TSPO +/+ 
and -/- mice (420). However, there was no band indicating expression in brain 
tissue of either TSPO +/+ and -/- mice. On the contrary, I had identified TSPO 
expression in brain tissue of TSPO +/+ mice using the same antibody (Fig 
3.2.1.6). The key differences here were that the researchers used whole-brain 
tissue while I used micro-dissected hypothalamic tissue. This would influence the 
strength of the signal identified by the antibody, as it would be dampened by the 
inclusion of brain regions absent of TSPO in whole-brain tissue compared to 
hypothalamus only. Furthermore, the loading control of GAPDH is noticeably 
weaker in the lanes corresponding to the brain tissue compared to the other 
tissue samples taken (420). This indicates a lower level of protein was loaded 
from the brain compared to other samples, which would also reduce the antibody 
signal. I concluded that the antibody validation performed and sourced by Abcam 
were not adequate to rule out non-specific binding, especially in light of my 
immunohistochemical staining. However, my complaints were dismissed by the 
Abcam representative I spoke to.  
While the glial cell markers applied in this study are commonly used in 
immunohistochemistry and other applications, this does not mean that they are 
the most appropriate for this purpose. Both GFAP and IBA1 are regulated by their 
respective cellular active state (396,398,399). Consequently, it may be the case 
that these glial markers are not expressed to a substantial extent in the healthy 
brain limiting their detection using immunohistochemistry in this context. This 
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would influence the observations in coincidence of TSPO-targeted 
immunoreactivity with either cell marker. Another important note to consider in 
the case of astrocytes is that GFAP is a cytoskeletal protein. As a cytoskeletal 
protein, GFAP-immunoreactivity does not reveal the complete three-dimensional 
size and shape of astrocytes – which is more complex than the characteristic 
star-like shape (421). Therefore, we would not necessarily expect to see GFAP 
and mitochondrial proteins to co-localise. In addition, it is critical to make note of 
other cell types identifiable by the cell marker. GFAP is not specific to astrocytes, 
and so dual labelling around the vasculature is likely to have identified ependymal 
cells or tanycytes. In such cases, application of multiple cell markers could 
provide assurance to the cellular localisation.  
 
3.3.3 Future perspectives and outstanding questions 
Distribution of TSPO expression in the healthy mouse brain still remains to be 
fully understood. The studies outlined here would benefit from supporting data 
with additional methodologies. For example, employing different tissue 
acquisition and immunohistochemical processing approaches. This could be 
snap-freezing of dissected brain tissue to replace formaldehyde fixation, and 
peroxidase-labelled immunohistochemistry instead of fluorescence. The 
complete cellular localisation of TSPO is also still to be determined. 
Immunohistochemical co-labelling is an appropriate approach. However, 
considering the limitations mentioned above, for confidence that a protein is 
expressed within a particular cell type a more detailed sub-cellular approach may 
be beneficial – such as electron microscopy. 
The identity of the “non-specific” immunoreactivity could be informed by further 
examination of TSPO structure. There are proteins that are structurally similar to 
TSPO, namely TSPO-2 and TSPO-associated protein (422–424). It is possible 
that the “non-specific” antibody binding seen in the PVH and DMH is to an antigen 
expressed in neurons as the labelling, which formed a ‘projection’-like pattern and 
co-localised with neuropeptides, was still visible in TSPO -/- tissue. Therefore, 
the unknown antigen could be expressed in the neurons as identified in the dual-
immunohistochemistry experiments – namely TRH- and CRH-expressing 
neurons. These neurons are important regulators of neuroendocrine function, 
indicating a potential involvement of the unknown antigen. The company that 
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produced the antibody refused to disclose the antigen sequence used in its 
generation, so I was unable to pursue this further.  
Irrespective of the outcome of antibody validation, measuring differences in 
protein expression would benefit from additional approaches due to the 
qualitative nature of the methodology applied here. Western blot analysis of 
protein quantification is one prospect, but it alone lacks the spatial resolution of 
immunohistochemistry. In situ hybridisation is an alternative technique to assess 
distribution of expression, though of mRNA instead of protein 
 
To conclude, I characterised the distribution and cellular location of binding of a 
TSPO antibody in the mouse brain. Unfortunately, the majority of TSPO-positive 
immunoreactivity described in this study is likely a result of non-specific binding 
of the antibody to an unknown antigen. However, the techniques used provided 
information on the validity of the antibody. From comparison of immunoreactivity 
in TSPO +/+ and -/- brain tissue, I am confident that the TSPO-positive labelling 
at the walls of the ventricles is valid. Considering the insights of dual-
immunohistochemistry with TSPO and vimentin, I can conclude that the TSPO 
expression at the ventricles is contributed to by tanycytes of the 3V. Identifying 
the cellular location of TSPO has provided an insight to its function: that TSPO 
may be involved in nutrient sensing and communication between the 
cerebrospinal fluid (CSF) and the hypothalamus. This conclusion has since been 










Exposure to a high-fat and high-sugar diet is associated with widespread 
systemic low grade inflammation in rodents (122,123,125,367). Within the central 
nervous system, this is characterised by proliferation of glial cells 
(125,174,178,180,181,184); alterations in glial morphology (125,180); increased 
secretion of cytokines and reactive oxygen species (122,125,367,416,425–427); 
and infiltration of peripheral macrophages (123). Diet-induced gliosis is thought 
to occur in two separate temporal phases: the first following acute exposure, 
which then subsides but returns ensuing chronic high-fat diet intake (125). The 
reasons behind the temporal changes in gliosis are unknown – perhaps due to 
initial adaptation which becomes negated in chronic high-fat intake. Upregulation 
in glial mRNA, but not protein expression, is observable from one day of high-fat 
exposure (125). Excessive intake of energy-dense foods can lead to weight gain, 
if not balanced by energy expenditure. Obesity is a risk factor to other health 
problems, including cognitive deficits  and neurodegeneration (178,181,223,224) 
- both of which are also associated with neuroinflammation (428–432). 
Investigation of the inflammatory pathways that follow high-fat feeding and into 
obesity may unveil the mechanisms that invoke susceptibility to other 
neurological disease. 
In diet-induced obesity, excessive fat intake causes impaired lipid storage and so 
results in a higher level of free fatty acids (FFAs) in the circulation (119,433,434). 
Previous work has indicated that exposure to saturated fatty acids (SFAs) acts 
as a pro-inflammatory stimulus in glial cells (187). Attenuation of fatty acid (FA) 
signalling prevents FA-induced gliosis (435). Consequently, it is assumed that 
reactive gliosis in response to energy excess is in part caused by an increased 
level of circulating FAs.  
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Nutrient availability is not the only energy-associated signal that hypothalamic 
glia respond to. Interestingly, an increase in hypothalamic glial protein expression 
is observed after food deprivation in mice (202). Weight-loss in diet-induced 
obese mice also evokes hypothalamic reactive gliosis (182). This possibly 
indicates that reactive gliosis is triggered by a multitude of factors, and not 
restricted to excess nutrients. On the other hand, negative energy balance may 
cause release of free FAs (FFAs) from fat stores in the body – resulting in 
increased FFA availability and consequently hypothalamic gliosis. In cancer-
associated cachexia in mice, increased gliosis was observed in the mediobasal 
hypothalamus (MBH) (190). The gliotic response observed here was proposed to 
be beneficial and protective against cachexia and weight loss. Consequently, 
there is much yet to be understood in the glial reactive response to calorie deficit. 
The tanycyte cells – specialised ependymal cells that line the ventricles of the 
brain – of the third ventricle (3V) are key in sensing and communication of FFA 
availability (121,163). Ablation of these cells adjacent to the MBH exacerbates 
diet-induced obesity (191). Interestingly, disruption of lipid uptake in hypothalamic 
astrocytes also contributes to diet-induced obesity (218). Furthermore, there is 
recent evidence to suggest that tanycytes can mediate inflammatory-associated 
effects on food intake via the NF-κB pathway (436). This complements the 
previous finding that NF-κB signalling is essential in the reactive astrocytic 
response to diet-induced obesity (216). These collection of studies make it 
apparent that tanycytes are essential for reactive astrogliosis to occur in the 
hypothalamus in response to high-fat diet. 
The mitochondrial translocator protein of 18 kDa (TSPO) is expressed in glia, and 
upregulated in reactive gliosis (172,227,228,284,293–295,350,385,437). The 
importance of TSPO function in activated glia is not yet understood, but TSPO 
up-regulation is selective to cells in a pro-inflammatory phenotype (228,438). 
Nonetheless, there are temporal and cell-dependent effects in neural TSPO 
expression. In a rat model of brain damage in the hippocampus, reactive 
microglia did not upregulate TSPO until 14 days after damage was induced (172). 
Meanwhile, TSPO expression was increased in reactive astrocytes at all times 
during the experiment. Furthermore, TSPO up-regulation is detectable in pro-
inflammatory astrocytes in rat striatum even while nearby microglia remain in a 
resting state (227). These studies have focussed on striatal and hippocampal 
153 
 
regions, while less is known on TSPO up-regulation specifically in hypothalamic 
glia. 
There is little research to date that has examined TSPO expression and function 
in the context of diet-induced inflammation. Published work has shown TSPO 
expression to be moderately greater in the hippocampus and choroid plexus of 
the leptin-deficient ob/ob mouse compared to wild-type (439). However, a diet-
induced obese mouse model did not replicate this data (369). Regulation of 
hypothalamic TSPO in different states of energy balance is yet to be elucidated.  
The experiments in this chapter investigated the following hypothesis: changes 
in TSPO expression would be observed in hypothalamic regions of mice exposed 
to deviations in energy balance. This would be attributed to, in part, increases in 
hypothalamic glial fibrillary acidic protein (GFAP) expression – a marker for 
astrocytes – which indicates astrocytic proliferation and morphological changes 
(149,440). It is important to note that this hypothesis was formed and investigated 
before the problems with the TSPO antibody were realised. With this in mind, at 
the time of this study I anticipated that hypothalamic TSPO expression would be 
upregulated alongside that of GFAP. However, as diet-induced gliosis occurs in 
both positive (125,174,178,180,181,184) and negative (182,202) energy states it 
is possible that gliosis-induced up-regulation of protein is dependent on the 
stimulus rather than the activated state itself. Since there is a time-dependent 
effect on diet-induced gliosis as well as in TSPO up-regulation (125,172), the 
response to high-fat intake was examined in an acute and chronic scenario. 
The following questions were addressed in order to investigate the hypothesis 
above:  
 How are hypothalamic TSPO and GFAP regulated in response to acute high-
fat diet exposure? 
 Are hypothalamic expression of TSPO and GFAP influenced by acute food 
deprivation? 
 Does 3-month chronic high-fat exposure regulate hypothalamic expression 





4.2.1 Western blot analysis of TSPO and GFAP protein expression in the 
hypothalamus of mice exposed to positive and negative energy balance. 
The primary aim of the following experiments was to observe whether an acute 
manipulation of energy balance influenced hypothalamic TSPO expression 
alongside GFAP. The dorsomedial hypothalamic nucleus (DMH) and arcuate 
hypothalamic nucleus (Arc) – the latter of which also contained the median 
eminence (ME) - were micro-dissected from the brains of mice that were 
maintained on standard chow, or exposed to high-fat diet or food deprivation for 
12 hours. These brain regions were selected for study due to the dense TSPO-
targeted immunoreactivity, under the knowledge at the time regarding the 
antibody as described in Chapter 3, and as important regions in energy 
homeostasis. Protein expression was semi-quantified by Western blot analysis.  
To confirm that any changes in protein expression were due to energy intake, 
body weights and food intake of the mice were recorded. The weight of food 
pellets consumed was no different between mice fed high-fat diet or maintained 
on standard chow (Fig 4.2.1.1a; p = 0.1261). The high-fat chow pellets were more 
calorific than the standard chow, so even with a similar weight of food intake the 
high-fat fed mice consumed significantly more energy (Fig 4.2.1.1b; p < 0.0001). 
There were no differences in the body weights of the mice on the evening before 
dietary manipulation (Fig 4.2.1.1c; p = 0.1207).  
Samples containing the Arc and ME were collected in the coronal plane at the 
base of the 3V using a micropunch (Fig 4.2.1.2a).  These samples likely included 
a ventral portion of the ventromedial hypothalamic nucleus (VMH). TSPO 
expression within the Arc/ME samples was unchanged across dietary 
manipulation (Fig 4.2.1.2b; p = 0.8373). Meanwhile, there was a significant effect 
of dietary treatment on GFAP expression (Fig 4.2.1.2c; p = 0.0207) for which 
multiple comparisons analysis identified a significant increase in GFAP 
expression in Arc/ME tissue from high-fat fed mice compared to control (p = 
0.0335).  
The DMH samples were also micro-dissected from the coronal plane using the 
micropunch technique (Fig 4.2.1.3a). Due to the sampling technique, it is possible 
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that a portion of the paraventricular hypothalamic nucleus (PVH) or the VMH were 
also collected. DMH TSPO expression was decreased by dietary manipulation (p 
= 0.0384), with statistical significance achieved between the high-fat fed group 
with control (Fig 4.2.1.3b; p < 0.05). The appearance of double TSPO-positive 
bands in the Western blot indicated it to be in a dimeric or phosphorylated form 
(Fig 4.2.1.3e). GFAP expression in the DMH was not affected by dietary exposure 




Figure 4.2.1.1 There was no difference in body weights of mice that were 
randomly assigned to the standard chow, high-fat diet or food deprivation 
conditions. 
Mice that were provided with high-fat diet during the dark phase did not eat significantly 
more grams of food than the mice that were maintained on standard chow (a; p = 
0.1261, n = 6). However, the mice on high-fat chow did have a significantly greater 
calorie intake (b; p < 0.0001, n = 6). The body weights of the mice on the day prior to 
diet manipulation did not significantly differ across groups (c; F2,16 = 2.42, p = 0.1207, 
n = 6-7). Statistical analysis was conducted using unpaired Student’s t-test (a-b) or 






Figure 4.2.1.2 GFAP, but not TSPO, protein expression is altered in hypothalamic 
arcuate nucleus-containing samples from mice that were exposed to positive or 
negative energy balance. 
An image, taken from The Mouse Brain atlas (381), depicting the location at -1.70 mm 
from bregma at which the protein samples were taken (a). TSPO expression was not 
altered by exposure to high-fat diet nor fasting (b; p = 0.8373, F2,16 = 0.1795, n = 6-7). 
GFAP expression was statistically significantly affected by dietary manipulation (c; p = 
0.0207, F2,7 = 6.646, n = 6-7). Multiple comparisons indicated a significant difference 
of GFAP expression from mice fed high-fat diet compared to control (*, p = 0.0335), 
but not between fasted expression and control. Protein expression was quantified 
relative to total protein (d). The black filled arrows indicate the band from which GFAP 
and TSPO protein expression was quantified (e). The positive control was protein 
lysate from primary cultured mouse cortical astrocytes (d, e). Statistical analysis was 
performed by one-way ANOVA (b) or Welch’s ANOVA test (c) with Dunnett’s multiple 





Figure 4.2.1.3 TSPO, but not GFAP, protein levels in the dorsomedial 
hypothalamic area are influenced by energy state. 
An image, taken from The Mouse Brain atlas (381), depicting the location at -1.70 mm 
from bregma at which the DMH protein samples were taken (a). TSPO expression was 
statistically significantly altered by dietary manipulation (b; p = 0.0384, F2,12 = 4.328, n 
= 5-7). Multiple comparisons indicated statistical significance in TSPO expression of 
mice fed high-fat diet compared to standard chow (*, p = < 0.05). DMH GFAP 
expression was not affected by dietary manipulation (c; p = 0.3216, F2,7 = 1.393, n = 
5-7). Total protein was used to quantify relative expression of TSPO and GFAP (d). 
The black filled arrows indicate the bands from which protein expression was 
measured (e). Protein lysate from primary cortical astrocytes was used to confirm 
binding of the antibodies (d, e). Statistical analysis was performed using either one-
way ANOVA with Bonferroni’s multiple comparisons test (b) or Welch’s ANOVA test 




4.2.2 Immunohistochemical analysis of brain tissue from mice that were 
exposed to either high-fat diet or standard chow for 12 hours. 
To complement the protein quantification data acquired from Western blot, 
qualitative immunohistochemical examination was performed on hypothalamic 
sections from mice exposed to a high-fat diet for 12-hours. Male mice were fed 
either a high-fat diet or maintained on standard chow for a 12-hour period during 
the dark phase. Body weights and food intake were measured followed by 
euthanasia and transcardial perfusion for brain tissue collection.  
In mice of either dietary group, there was no difference in weight of food pellets 
consumed (Fig 4.2.2.1a; p = 0.4981). Since the high-fat pellets contain more 
calories per gram than standard chow, these mice consumed a significantly 
greater amount of energy (Fig 4.2.2.1b; p = 0.0011). Despite random allocation 
of mice to groups, the average body weight of mice in the control group was 
significantly higher than the mice in the high-fat group (Fig 4.2.2.1c; p = 0.012).  
Sections were immunohistochemically processed to examine TSPO and GFAP 
immunoreactivity (Fig 4.2.2.2). Semi-quantitative measures of TSPO 
immunoreactivity intensity in the Arc revealed no difference in TSPO expression 
between the two diet groups (Fig 4.2.2.3b; p = 0.709). The number of GFAP-
immunoreactive cells was also not influenced by acute exposure to high-fat diet 
(Fig 4.2.2.3c; p = 0.7336), nor was the number of processes on GFAP-positive 
cells (Fig 4.2.2.3d; p = 0.9172). Expression of TSPO at the 3V lining was also 
measured by intensity of immunoreactivity and number of TSPO-immunoreactive 
projections extending from the 3V into the hypothalamus (as discussed in 
Chapter 3). In both cases, there was no difference in measurements between diet 
groups (Fig 4.2.2.3e, p = 0.5029; 3f, p = 0.7973). 
Diet-induced inflammation in the DMH is not well characterised compared to the 
response within the Arc. However, as described in Chapter 3, dense 
immunoreactivity which was thought to bind to TSPO was detected in the DMH. 
TSPO and GFAP immunoreactivity was assessed in the DMH following acute 
exposure to high-fat diet (Fig 4.2.2.4). Measurement of TSPO immunoreactivity 
intensity indicated that TSPO expression was unaffected by acute high-fat diet 
feeding (Fig 4.2.2.5b; p = 0.2306). The number of GFAP-immunoreactive cells 
was also not different in the DMH of high-fat fed mice compared to control (Fig 
4.2.2.5c; p = 0.263). There was no difference between dietary groups in the 
160 
 
number of processes of GFAP-immunoreactive cells (Fig 4.2.2.5d; p = 0.7481). 
Semi-quantification of TSPO immunoreactivity in the wall of the 3V also revealed 
no differences between high-fat fed mice and control (Fig 4.2.2.5e, p = 0.6717; 







Figure 4.2.2.1 Mice that were exposed to high-fat diet for 12 hours consumed 
more energy in calories than their littermate controls. 
Mice that were provided with high-fat diet for 12 hours did not eat a greater mass of 
food compared to mice kept on standard chow diet (a; p = 0.4981). However, these 
mice consumed more energy due to the higher caloric density of the food (b; **, p = 
0.0011). The experimental cohort of mice randomised to the high-fat diet group was 
statistically significant lower in body weight compared to control mice (c; *, p = 0.012). 
N = 5-6. Statistical analysis performed using Student’s unpaired t-test. Data are 





Figure 4.2.2.2 TSPO and GFAP immunoreactivity in the hypothalamic arcuate 
nucleus of mice following acute exposure to high-fat diet. 
Images, taken at 20x magnification, indicating immunoreactivity for TSPO (ii; green) 
and GFAP (iii; red) in the arcuate nucleus of male mice fed either standard chow (a-i; 
merge) or high-fat diet (c-i) for 12 hours in the dark phase. Insets indicate TSPO and 
GFAP in the lining of the third ventricle following digital zoom. The same regions were 
captured at 63x magnification, for mice fed standard chow (b) and high-fat diet (d). 
Scale bars represent 100 μm in images taken at 20x magnification, and 50 μm in 
images taken at 63x magnification. 





Figure 4.2.2.3 TSPO and GFAP immunoreactivity in the male mouse 
hypothalamic arcuate nucleus was not influenced by a 12-hour exposure to 
high-fat diet. 
Image of coronal section (381), at -1.70 mm from bregma, indicating the region in 
which image analysis was performed (a). Semi-quantitative analysis of TSPO 
immunoreactivity intensity (b; p = 0.709) and number of GFAP-positive cells (c; p = 
0.7336) did not differ between diet groups. Morphological tracing analysis of GFAP-
positive cells did not show any difference following dietary manipulation (d; diet: p = 
0.9172, F1,9 = 0.0114; interaction of diet and radius: p = 0.966, F16,144 = 0.4489) TSPO 
immunoreactivity intensity (e; p = 0.5029) and number of TSPO-positive cell 
projections (f; p = 0.7973), in the ependymal layer of the third ventricle at the level of 
the arcuate nucleus, did not differ in mice exposed to high-fat diet for 12 hours 
compared to mice maintained on standard chow. N = 5-6 animals. Statistical analysis 
performed with Student’s unpaired t test (b, c, e, and f) and two-way ANOVA with 




Figure 4.2.2.4 TSPO and GFAP immunoreactivity in the dorsomedial 
hypothalamus of high-fat and standard chow fed male mice. 
Images taken at 20x magnification of TSPO (ii; green) and GFAP (iii; red) 
immunoreactivity in the dorsomedial hypothalamus from mice fed either standard chow 
(a-i; merge) or high-fat diet (c-i) for 12 hours overnight. Insets indicate digital zoom of 
TSPO and GFAP immunoreactivity at the third ventricle lining. The same regions were 
captured at 63x magnification in the mice fed standard chow (b) and high-fat diet (d). 
Scale bars represent 100 μm in images taken at 20x magnification, and 50 μm at 63x. 







Figure 4.2.2.5 TSPO and GFAP immunoreactivity in the dorsomedial 
hypothalamic nucleus was unaffected by acute exposure to high-fat chow in 
male mice. 
Image of coronal section (381), at -1.70 mm from bregma, indicating the region in 
which image analysis was made (a). Semi-quantitative analysis of TSPO 
immunoreactivity intensity (b; p = 0.2306, n = 4-5) and number of GFAP-positive cells 
(c; p = 0.263, n = 5-6) did not differ between diet groups. There was also no impact of 
dietary manipulation on morphological tracing analysis of GFAP-immunoreactive cells 
(d; diet: p = 0.7481, F1,9 = 0.1097; interaction of diet and radius: p = 0.732, F12,108 = 
0.7171, n = 5-6). TSPO immunoreactivity intensity (e; p = 0.6717, n = 4-6) and number 
of TSPO-positive cell projections (f; p = 0.316, n = 4-5) in the wall of the third ventricle 
did not differ with dietary manipulation. Statistical analysis performed with students’ 
unpaired t test (b, c, e, and f) and two-way ANOVA with repeated measures (d). Data 




4.2.3 Immunohistochemical analysis of brain tissue taken from mice that 
were exposed to 12-hour food deprivation compared to satiated mice. 
Cachexia or weight loss in obese mice can result in hypothalamic inflammation 
(182,190). Western blot analysis indicated that GFAP expression in the Arc was 
regulated by food deprivation (Fig 4.2.1.2). Therefore, I qualitatively examined 
immunoreactivity of TSPO and GFAP in hypothalamic brain regions of mice that 
were fasted for 12-hours compared with mice that were maintained on standard 
laboratory chow. There was no difference in body weights of mice randomly 
allocated to either the fasted or fed experimental group (Fig 4.2.3.1; p = 0.6702).  
Immunoreactivity of TSPO and GFAP were assessed within the Arc and the 
adjacent 3V wall (Fig 4.2.3.2). There was no difference in intensity of TSPO 
immunoreactivity in the Arc of the fed and the fasted mice (Fig 4.2.3.3b; p = 
0.0947), in the number of GFAP-positive cells (Fig 4.2.3.3c; p = 0.154) nor in the 
number of GFAP-immunoreactive projections (Fig 4.2.3.3d; p = 0.0893). 
Measurements of TSPO immunoreactivity in the 3V wall adjacent to the Arc 
revealed no impact of fasted status on TSPO-immunoreactivity intensity and cell 
processes (Fig 4.2.3.3.e, f; p = 0.0947, 0.1093). 
GFAP immunoreactivity increased within the DMH of food deprived mice, while 
TSPO immunoreactivity remained unchanged between experimental groups (Fig 
4.2.3.4). These observations were reflected in the semi-quantification of 
immunoreactivity. Intensity of TSPO immunoreactivity was not affected by 
overnight food deprivation (Fig 4.2.3.5b; p = 0.433). Meanwhile, the number of 
GFAP-positive cells were significantly greater in the DMH of fasted mice 
compared to fed (Fig 4.2.3.5c; p = 0.0217). However, the measurement of GFAP-
immunoreactive cell projections indicated no differences between experimental 
groups (Fig 4.2.3.5d; p = 0.9531). Semi-qualitative measures of TSPO 
immunoreactivity at the 3V wall, adjacent to the DMH, demonstrated no change 
in immunoreactivity intensity and in number of TSPO-immunoreactive cell 





Figure 4.2.3.1 There were no differences in body weight of mice prior to dietary 
manipulation.  
There were no differences in the body weight of mice randomly assigned to food 
deprivation or control groups (p = 0.6702, n = 3). Statistical analysis was performed 




Figure 4.2.3.2 TSPO and GFAP immunoreactivity in the hypothalamic arcuate 
nucleus of food deprived male mice. 
TSPO (ii; green) and GFAP (iii; red) immunoreactivity in the arcuate nucleus from mice 
fed either standard chow (a-i; merge) or food-deprived (c-i; merge) during the dark 
phase. Insets indicate digital zoom images of TSPO and GFAP staining in the layer of 
the third ventricle. Images taken at 20x (a, c) and 63x (b, d) magnification with scale 
bars representing 100 μm and 50 μm, respectively. 





Figure 4.2.3.3 TSPO and GFAP immunoreactivity in the hypothalamic arcuate 
nucleus is influenced by food deprivation in male mice. 
Image of coronal section (381), at -1.70 mm from bregma, indicating the regions in 
which image analysis was performed (a). Semi-quantitative analysis of TSPO 
immunoreactivity intensity did not differ between groups (b; p = 0.0947). The number 
of GFAP-positive cells was no different in the food-deprived compared to fed mice (c; 
p = 0.154). Morphological tracing analysis of GFAP-immunoreactive cells indicated no 
statistically significant difference in number of processes (d; diet: p = 0.0893, F1,100 = 
2.943; interaction of diet and radius: p = 0.0951, F24,100 = 1.472). TSPO 
immunoreactivity intensity (e; p = 0.0947) and number of TSPO-positive cell 
projections (f; p = 0.1093), in the third ventricle wall by the arcuate nucleus were not 
influenced by food deprivation. N = 3 animals per group. Statistical analysis performed 
by Student’s unpaired t test (b, c, e, and f) and repeated measures two-way ANOVA 





Figure 4.2.3.4 TSPO and GFAP immunoreactivity in the dorsomedial 
hypothalamic nucleus in satiated and food deprived male mice. 
TSPO (ii; green) and GFAP (iii; red) expression in the dorsomedial hypothalamic 
nucleus from mice fed either standard chow (a-i; merge) or food-deprived (b) during 
the dark-phase. Insets indicate digital zoom images of TSPO and GFAP staining at 
the third ventricle lining. Images taken at 20x (a, c) and 63x (b, d) magnification with 
scale bars representing 100 μm and 50 μm, respectively. 





Figure 4.2.3.5 GFAP, but not TSPO, immunoreactivity in the dorsomedial 
hypothalamic nucleus is influenced by acute food deprivation in male mice. 
Image of coronal section (381), at -1.70 mm from bregma, indicating the region used 
for image analysis (a). Semi-quantitative measurements of TSPO immunoreactivity 
intensity did not differ between dietary treatments (b; p = 0.433). The number of GFAP-
positive cells was significantly greater in the dorsomedial hypothalamic nucleus of 
food-deprived, compared to fed, mice (c; p = 0.0217). Morphological tracing analysis 
of GFAP-immunoreactive cells indicated no differences of GFAP-positive cell 
morphology in the dorsomedial hypothalamus of fasted or fed mice (d; diet: p = 0.9531, 
F1,4 = 0.0039; interaction of diet and radius: p = 0.9379, F11,44 = 0.4226). TSPO 
immunoreactivity intensity (e; p = 0.1884) and number of TSPO-positive projections (f; 
p = 0.1648), in the wall of the third ventricle adjacent to the dorsomedial hypothalamic 
nucleus, were no different in fasted mice compared to fed. N = 3 animals. Statistical 
analysis performed by students’ unpaired t test (b, c, e, f) and repeated measures two-
way ANOVA (d). Data are expressed as mean ± standard error. 
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4.2.4 Investigating the impact of diet-induced obesity on hypothalamic 
expression of TSPO and GFAP. 
The purpose of this experiment was to determine the effect of chronic high-fat 
diet intake on the expression of TSPO alongside that of GFAP. Male C57BL/6J 
mice (wild-type GFP-negative offspring of NPY-hrGFP mice on a C57BL/6J 
background) were provided with either high-fat diet or maintained on standard 
chow for a period of 12 weeks. The mice were then euthanised and transcardially 
perfused to collect brain tissue for immunohistochemical analysis.  
The body weight of mice in both groups did not significantly differ at the start of 
the experimental timeline. The mice fed high-fat diet gained significantly more 
weight than their littermate controls, which remained at a steady weight 
throughout (Fig 4.2.4.1a; p = 0.0003). Prior to euthanasia the body weights of the 
high-fat fed mice were significantly greater than that of the standard chow fed 
controls (Fig 4.2.4.1b; p = 0.0001). This confirmed diet-induced obesity in the 
mice provided with high-fat chow.  
TSPO and GFAP immunoreactivity were assessed within the Arc (Fig 4.2.4.2). 
TSPO immunoreactivity was no different in the mice that were diet-induced obese 
compared to control (Fig 4.2.4.3b; p = 0.2618). The number of GFAP-labelled 
cells (Fig 4.2.4.3c; p = 0.2062) and morphological tracing analysis of GFAP 
immunoreactivity (Fig 4.2.4.3d; p = 0.8995) were also not different between 
experimental groups. Measurements of TSPO immunoreactivity at the ventral 3V 
layer – intensity and number of TSPO-positive cell projections – were also 
unaffected by dietary manipulation (Fig 4.2.4.3e, p = 0.5955; 3f, p = 0.2584). 
TSPO and GFAP immunoreactivity was observed in the DMH of diet-induced 
obese and control mice (Fig 4.2.4.4). No differences in TSPO immunoreactivity 
were detected between diet groups (Fig 4.2.4.5b; p = 0.977), nor in the number 
of GFAP-positive cells (Fig 4.2.4.5c; p = 0.1070). There were also no differences 
in morphological tracing analysis of GFAP-immunoreactive cells between mice of 
the experimental groups (Fig 4.2.4.5d; p = 0.4454). No difference was measured 
in TSPO intensity in the 3V wall, adjacent to the DMH (Fig 4.2.4.5e, p = 0.5768; 






Figure 4.2.4.1 Mice with prolonged exposure to high-fat diet gained significantly 
more weight than their littermates that were maintained on standard chow. 
The body weights of the mice throughout the study, with Week 0 being the point at 
which dietary manipulation was commenced. There was a statistical significant 
increase in body weight of mice fed high-fat diet over the experimental timeframe (a; 
diet: p = 0.0003, F12,84 = 50.56; interaction of diet and time: p < 0.0001, F12,84 = 20.78). 
Multiple comparisons test indicated statistical significance at time points 2, 3 (*, p < 
0.05), 4, 5 (**, p < 0.01), 6 (***, p < 0.001) and 7 to 12 (****, p < 0.0001) weeks. The 
body weights between the mice in each treatment group were significantly different at 
the week of euthanasia (b; ***, p = 0.0001). N = 4-5 animals. Statistical analysis was 
performed with repeated measures two-way ANOVA with Sidak’s multiple 






Figure 4.2.4.2 TSPO and GFAP immunoreactivity within the hypothalamic 
arcuate nucleus of male mice fed standard chow or high-fat diet for 12 weeks. 
A representative image taken at 20x magnification depicting TSPO (ii; green) and 
GFAP (iii; red) immunoreactivity within the hypothalamic arcuate nucleus of male mice 
maintained on standard (a-i; merge) or high-fat chow (c) for 12 weeks. Insets show 
digital zoom images of TSPO and GFAP at the wall of the third ventricle. Images taken 
at 63x magnification display a similar pattern of immunoreactivity in brains from 
standard chow (b) and high-fat (d) mice. Scale bars represent 100 μm in images taken 
at 20x magnification (a, c), and 50 μm at 63x magnification (b, d). 





Figure 4.2.4.3 Chronic high-fat diet exposure did not alter TSPO or GFAP 
immunoreactivity in the hypothalamic arcuate nucleus of male mice. 
Image of coronal section (381), at -1.70 mm from bregma, indicating the region used 
for image analysis (a). Semi-quantitative analysis of TSPO immunoreactivity intensity 
did not differ in the arcuate nucleus of diet-induced obese compared to control mice 
(b; p = 0.2168). The number of GFAP-immunoreactive cells also did not differ between 
dietary manipulation groups (c; p = 0.2062; n = 5-6), and there was no difference in 
number of GFAP-immunoreactive cell processes between diet groups (d; diet: p = 
0.8995, F1,7 = 0.0171; interaction of diet and radius: p = 0.1625, F14,98 = 1.411, n = 5-
6). There was no difference between dietary manipulations in TSPO immunoreactivity 
intensity (e; p = 0.5955, n = 5-6) or in number of TSPO-positive cell projections (f; p = 
0.2584, n = 4) at the third ventricle layer beside the arcuate nucleus. Statistical analysis 
performed by Student’s unpaired t test (b, d, e, and f) and repeated measures two-way 





Figure 4.2.4.4 TSPO and GFAP immunoreactivity in the dorsomedial 
hypothalamic nucleus in diet-induced obese male mice compared to mice fed 
standard chow. 
TSPO (ii; green) and GFAP (iii; red) immunoreactivity in the dorsomedial hypothalamic 
nucleus in mice fed standard chow (a, b) and high-fat diet (c, d) for 12 weeks. Images 
were captured at 20x magnification (a, c) and 63x magnification (b, d). Scale bars 
represent 100 μm at 20x magnification, and 50 μm at 63x. 






Figure 4.2.4.5 Diet-induced obesity did not influence TSPO or GFAP 
immunoreactivity in the dorsomedial hypothalamic nucleus of male mice. 
Coronal image (381), take at -1.70 mm from bregma, depicting the dorsomedial 
hypothalamic nucleus in dotted lines where quantitative analysis was performed (a). 
Semi-quantitative analysis of TSPO immunoreactivity intensity within the dorsomedial 
hypothalamic nucleus did not differ with dietary manipulation (b; p = 0.977). The 
number of GFAP-immunoreactive cells in the dorsomedial hypothalamus of obese 
mice were no different to that of control mice (c; p = 0.1070). Analysis of GFAP-positive 
cell processes within the dorsomedial hypothalamus did not indicate any differences 
between mice of either dietary group (d; diet: p = 0.4554, F1,112 = 0.5611, interaction of 
diet and radius: p = 0.9987, F15,112 = 0.2342). TSPO immunoreactivity intensity (e; p = 
0.5768) and number of TSPO-immunoreactive projections (f; p = 0.2708), in the third 
ventricle wall adjacent to the dorsomedial hypothalamic nucleus, also did not differ in 
diet-induced obese mice compared to control. N = 4-5 animals. Statistical analysis 
performed by students’ unpaired t test (b, c, e, f) and two-way ANOVA with repeated 






 4.3.1 Summary of findings and conclusions 
The goal of this study was to investigate whether hypothalamic TSPO expression 
was regulated in the mouse brain by changes in energy balance, alongside 
GFAP, a common cell marker for astrocytes. TSPO regulation by diet has been 
documented in a few tissues: mouse adipose tissue, including adipose tissue 
macrophages (310), and in the human placenta (441). With regards to the brain, 
the leptin-deficient ob/ob mice show an up-regulation of TSPO in the 
hippocampus and choroid plexus (439). However, this has not been replicated  in 
high-fat fed mice (369). No attempts to identify regulation within the hypothalamus 
have been published. Consequently, this research is novel and its findings are 
important contributions to knowledge. 
TSPO expression in the DMH, as measured by Western blot, was downregulated 
in acute high-fat diet exposure. Although DMH GFAP expression was not 
regulated, this coincided with an upregulation of GFAP in the MBH - indicative of 
diet-induced gliosis. The acute high-fat fed group did not eat significantly more 
pellets by weight but did consume more calories than the standard chow-fed 
group. This suggests that the results observed were unlikely to be influenced by 
gastric stretch but are probably due to excess calories and nutrients of the high-
fat chow. The body weights of the mice were the same prior to dietary 
manipulation, so could not have been a confounding factor. However, the 
absence of specificity of the TSPO immunoreactivity in the mouse brain 
(described in chapter 3) is still a concern and further investigation is 
recommended. Furthermore, although only one band was quantified, the TSPO 
antibody identified two bands in Western blot at the relevant molecular weight in 
the DMH samples. This could be a result of TSPO existing in a dimeric form (442), 
or may be an artefact from the lack of specificity of the antibody.  
Complementary to the Western blot analysis, TSPO-immunoreactivity at the 3V 
wall was lower in fasted mice; this site of TSPO-immunoreactivity was validated 
in a TSPO-knockout mouse as specific in Chapter 3. However, the effect was not 
statistically significant, which could be due to lack of power in the sample size. 
The number of GFAP-positive cells in the DMH was higher in the fasted group. 
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This finding complements that of protein expression quantified by Western blot. 
If the sample number was increased, then a significant reduction of TSPO 
immunoreactivity may be observable at the 3V. This finding would be further 
enhanced by additional experimental approaches.  
In contrast to high-fat diet, the impact of food deprivation on glial reactivity is 
relatively under-studied; however, negative energy balance also induces reactive 
gliosis (202). While this initially appears contradictory, considering high-fat diet 
also induces gliosis, it is important to note that reactive gliosis is a process 
induced by a variety of stimuli. In addition, a role for TSPO in food deprivation 
has not previously been investigated. One possibility arising from this study is 
that downregulation of TSPO expression may reflect a modulation of metabolic 
flexibility. Upon reactive gliosis, cellular energetic requirements can change and 
this requires a shift in substrate use (226,443,444). Downregulation of TSPO 
could complement the energetic needs of the hypothalamic glia, in both positive 
and negative energy balance. Tanycytes are not known to be inflammatory cells, 
so tanycytic TSPO expression may serve a different purpose involving metabolic 
flexibility. Considering that tanycyte FA sensing is a key factor for diet-induced 
reactive astrogliosis (121,163,191), tanycytic TSPO expression may be important 
for nutrient sensing at the 3V and downregulated in nutrient deprivation. 
 
4.3.2 Limitations of the study 
I applied two experimental approaches in this study to assess protein expression: 
immunohistochemistry and Western blotting. Immunohistochemical visualisation 
of cells enables analysis of morphology and cell number as a proxy for glial 
reactivity. Morphological tracing analysis based on Sholl’s linear model – a 
method of quantifying neuronal morphology (384,445) - was performed to 
measure the ramification of GFAP-positive astrocytes (184). Semi-quantification 
of protein expression was performed by Western blot analysis. Unfortunately, 
after the study had been conducted it was realised that the TSPO antibody 
applied did not bind exclusively to TSPO in mouse brain tissue (see Chapter 3). 
This means that the majority of the TSPO analysis needs to be interpreted with 
extreme caution – with the exception of binding at the ventricle layers, which was 
validated in TSPO -/- brain tissue (see Chapter 3). Specificity of the antibody in 
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Western blot analysis has been validated in whole brain tissue (420), and also in 
primary cultured astrocytes and TSPO -/- astrocytes cells in our laboratory.  
There were inconsistencies in the results presented here, between 
immunohistochemistry compared to Western blot analysis. One such example 
was GFAP expression analysis in the Arc of high-fat fed mice. Western blot 
analysis indicated upregulation of GFAP in the MBH of high-fat fed mice, which 
is consistent with what is reported in the literature (125,180). 
Immunohistochemical processing did not identify any change in cell number or 
morphology, both of which can allude to increased GFAP protein levels in the 
tissue. There are a few potential reasons for this. Firstly, despite random 
allocation, the mice in the high-fat diet group were significantly lighter in body 
weight than the control mice. This could have masked any effect; the heavier 
weight of the control mice may have led to a higher number of resident astrocytes 
in the Arc. Nonetheless, diet-induced gliosis is attributed to diet rather than 
weight-gain: gliosis occurs before weight-gain in high-fat fed mice (125), and the 
obese ob/ob mouse model does not display increased Arc reactive gliosis unless 
fed a high-fat diet (446). Reactive gliosis is also associated with aging (447,448) 
and the mice of the immunohistochemical cohort were much older than those 
used for Western blot analysis (18-24 weeks versus 9-13 weeks old). Therefore, 
the basal level of astrogliosis in the older mice may have masked any effect from 
acute high-fat diet exposure in immunohistochemical analysis. 
Although not also quantified by Western blot, immunohistochemical analysis of 
GFAP immunoreactivity in diet-induced obese mice did not indicate any 
differences between experimental groups.  This finding also contradicts what is 
reported in the literature (125,180,181,184). The mouse cohort that was 
maintained on high-fat diet for 12-weeks gained significantly more weight than 
the standard chow fed mice, demonstrating that the diet-induced obese model 
was valid. A potential confounding factor that can underlie differences in results 
of studies investigating metabolism is the composition of the high-fat and control 
diet (449–452). However, this is unlikely to be the case here. I used a diet made 
consisting of 60% calories from fat – the same diet as used in the Thaler et al 
publication (125). Similarly, there were only small differences in diet composition 
in the other comparative studies (180,181,184). The discrepancy in my results is 
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most likely due to a different variable, such as duration of the experiment or age 
of the animals. 
The study presented here differed in time-points examined, compared to previous 
studies that investigated obesity on hypothalamic gliosis (125,180). In the study 
by Thaler et al (125), astrogliosis in response to diet-induced obesity declines 
after 3 weeks of exposure but returns by the 8 month mark. Elsewhere, 
hypothalamic markers of astrogliosis are observed after 2 months and 5 months 
of high-fat diet intake – depending on the study (174,176,177). It is clear that, 
even considering bimodal wave, markers of reactive gliosis in chronic high-fat 
feeding are observed at different time points by different research groups.  In my 
study presented here, 3 months of high-fat exposure may have not been sufficient 
to allow the second wave of diet-induced gliosis to occur. This would explain the 
absence of any differences in markers of astrogliosis in the diet-induced obese 
model used here. 
 
4.3.3 Future perspectives and outstanding questions 
Considering the lack of specificity of the common TSPO antibody, the 
experiments detailed here would benefit from additional methodologies to 
measure protein expression. For example, quantification of mRNA by in situ 
hybridisation is an alternative route for to confirm regulation of TSPO gene 
expression in response to dietary manipulation, including in the tanycyte layer of 
the 3V. Another approach to measure TSPO expression in this experimental 
scenario would be to use slice autoradiography with TSPO ligands. This study 
would also benefit with additional age-matched cohorts, and additional time 
points during high-fat exposure. For instance, changes in protein expression may 
be measurable at 3 to 7 days exposure and at 8 months as seen by Thaler et al 
(125) . It is important to consider the dynamic nature of glia through the lifespan, 
and how this may influence results. 
 
To conclude, this study (considering the assumption at the time that the TSPO 
antibody was specific) provides evidence to support the hypothesis that TSPO is 
regulated in the hypothalamus by energy imbalance. TSPO expression in the 
DMH, as measured by Western blot, was downregulated by acute high-fat 
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exposure. No effects were seen in the Arc. Down-regulation was also observed 
in TSPO at the 3V which, considering the findings of Chapter 3, is likely 
expressed by tanycytes. If these findings hold true with further experimentation, 
TSPO may promote metabolic flexibility in the different reactive states of glia. 
Furthermore, TSPO expression is unlikely to be solely related to reactive state of 
astrocytes as it was not co-regulated alongside GFAP in these studies. This study 
also supports previous work showing that negative energy balance can induce 
markers of reactive astrocytes (182,202). There may be a common downstream 









Experiments that used genetic and pharmacological manipulation of TSPO have 
indicated a potential role in metabolism 
(311,324,325,329,330,347,359,362,363,379,453). While in vitro experiments can 
provide useful insight into the molecular mechanisms underlying TSPO-mediated 
signalling, in vivo studies are needed to determine the physiological impact. As 
both approaches have their limitations, a combination of experimental 
methodologies is ideal for investigating protein function. In this chapter, I will 
present a series of data from different studies using pharmacological and genetic 
manipulation to investigate a potential role for TSPO in regulating systemic 
metabolism in C57BL/6 mice. 
Genetically manipulation of TSPO in cell culture reveals a role in mitochondrial 
metabolism. Knock-down of TSPO expression in cultured steroidogenic testicular 
Leydig cells increases fatty acid oxidation (FAO) (330) and alters lipid 
homeostasis (359). This indicates a shift in energy substrate preference from 
glucose to fatty acids. Furthermore, isolated microglia from TSPO knock-out (-/-) 
mice produce less ATP in culture than microglia taken from TSPO wild-type (+/+) 
controls (325). These studies demonstrate that alterations in TSPO expression 
can result in changes in cellular metabolism. 
Pharmacological targeting of TSPO in cell culture, on the other hand, has 
revealed varying effects on mitochondrial bioenergetics. Application of a range of 
TSPO ligands – XBD173, Ro5-4864 and PK11195 – enhances mitochondrial 
respiration in mouse BV-2 microglia cell culture (329). This was inconsistent, 
depending on the ligand, reflecting potential activation/inhibition actions. The 
same conclusions were drawn from human neuroblastoma (SH-SY5Y) cells 
(453). These studies suggest that exogenous TSPO ligands exert different 
functions depending on dose, and may exhibit non-specific binding. Moreover, at 
the doses used the off-target effects from these ligands were also observed in 
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TSPO knock-down BV-2 cells (329), therefore solid conclusions cannot be 
obtained from such studies.  
Studies in which TSPO expression is deleted in mice have strengthened the 
evidence from in vitro work that TSPO is involved in metabolism. Upon the 
discovery that global germ-line deletion of TSPO mice are viable (420), it has 
been determined that these mice appear to have normal growth rate, food intake, 
behaviour and blood composition  - at least when fed a standard chow diet (325). 
However, mice with targeted TSPO deletion in steroidogenic factor 1 (SF-1) 
positive cells display higher basal blood glucose levels than the control animals 
(363). This was only observed in male mice and no such alterations in resting 
blood glucose were seen in the females. Lipid storage was altered in both male 
and female SF-1 TSPO -/- mice, with increased storage in the gonads; liver; and 
testes (362). A comparison between these studies suggests a role for TSPO in 
mediating glucose homeostasis and lipid storage that is specific for its function in 
steroidogenic tissues. 
In addition to genetic manipulation, pharmacological targeting of TSPO in mice 
has also revealed effects on whole-body metabolism and glucose regulation. In 
food deprived C57BL/6 mice up-regulation of mRNA of metabolic enzymes is 
observed in the liver, an effect that is enhanced after treatment with the TSPO 
ligand PK11195 (347). The targets examined included glucose-6-phosphatase 
(G6p), carnitine palmitoyltransferase 1a (Cpt1a), and phosphoenolpyruvate 
carboxykinase 1 (Pck1) – which are all involved in glucose or lipid metabolism. 
Meanwhile, in diet-induced obese C57BL/6 mice, treatment with PK11195 was 
protective against  hyperglycaemia and also reduced hepatic steatosis (347). 
This study implies that TSPO is involved in compensatory responses to changes 
in energy balance – such as food deprivation and excessive nutrient intake. 
Administration of TSPO ligands can influence the role of TSPO in tissue 
metabolism (301,347), which may provide protection against the maladaptive 
effects of energy imbalance. However, further investigation along with replication 
of these observed effects is required before conclusions are made. 
Comparing the discoveries from genetic and pharmacological manipulation 
studies of TSPO highlights gaps in knowledge of its function. There are 
differences between in vivo investigations of TSPO function in whole-organism 
physiology that require clarity. For instance, SF-1 specific cell knock-out of TSPO 
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resulted in hyperglycaemia that was not observed in global knock-out mice 
(325,363). The SF-1 TSPO -/- mice also had altered lipid deposits (362), which 
was not investigated in the global knock-out mice and so comparisons are difficult 
to make. Pharmacological manipulation of TSPO in vivo hints at influence in 
physiological metabolic state in response to negative and positive energy 
balance. For example, in the case of energy excess, targeting TSPO signalling 
was protective in diet-induced obese mice (347). Meanwhile, TSPO knock-out in 
SF-1 cells resulted in a pre-diabetic phenotype irrespective of dietary 
manipulation (362,363). Regarding food deprivation, only gene expression of key 
metabolic enzymes was examined and so the physiological impact of targeting 
TSPO in negative energy states remains to be fully understood. Further 
experiments are required to answer these outstanding questions. 
The hypothesis underlying the study presented here is as follows: whole-body 
manipulation of TSPO-mediated signalling will alter the animals’ energy 
homeostasis. A shift in substrate preference for metabolism will occur in the 
affected cells, favouring fatty-acid oxidation as a fuel source over glycolysis. A 
change in energy substrate, due to absence of TSPO, will lead to a different 
physiological compensation to energy imbalance. I proposed that, in TSPO 
deficient mice, this will manifest as protection against the negative effects of 
chronic high-fat diet consumption: improved glucose tolerance; reduced body 
weight gain; and reduced markers of obesity-associated impairment in organs 
crucial for systemic metabolism. In regard to negative energy balance, as 
PK11195 induces upregulation of hepatic metabolic enzymes, this may be 
observed to reduce food-intake in fasted TSPO -/- mice. This study used both 
genetic global TSPO -/- mice along with pharmacological experiments with the 
TSPO ligand PK11195.  
The key questions used to investigate this hypothesis were: 
 Does absence of TSPO reduce food intake and body weight gain when 
mice are maintained on high-fat diet? 
 Does absence of TSPO protect against the negative effects of chronic 
high-fat feeding in mice? 
 Does modulation of TSPO signalling impact systemic glucose tolerance? 






5.2.1 Investigating differences in energy homeostasis in TSPO -/- mice 
The TSPO -/- and TSPO +/+ littermate control mice arrived at the biological 
services unit at ages 6-9 weeks old. Upon arrival, the mice were de-identified and 
randomised before being individually housed. Weekly measurements of food 
intake and body weight were made for 12 weeks. No measurements of food 
intake were taken in experimental week 5 due to the fasting intervention taking 
place. The investigators were blinded to the genetic identity of the mice for the 
entire study.  
The mice gained weight at a gradual and steady rate over this portion of the study. 
(Fig 5.2.1.1a & c). The male mice gained more weight than their female 
counterparts. The male TSPO -/- mice gained slightly more weight than their 
littermate controls over the experimental time-frame, which achieved statistical 
significance (Fig 5.2.1.1a; p = 0.0359). There was no difference between 
genotypes in body weight gain in the female mice (Fig 5.2.1.1c; = 0.3909). There 
was no genotypic influence in food intake in the male (Fig 5.2.1.1b; p = 0.3121) 
and female mice (Fig 5.2.1.1d; p = 0.3909). Food intake was also comparable 







Figure 5.2.1.1 Male TSPO -/- mice gained slightly more weight than TSPO +/+ 
controls, while growth of female mice and food intake of both sexes showed no 
genotypic differences. 
Male mice of both genotypes gained weight over the experimental time-course (a; 
Week: p < 0.0001, F1,45 = 399.1, n = 12-14) but TSPO -/- mice gained significantly more 
weight than their TSPO +/+ counterparts over the period (a; Interaction: p = 0.0359, 
F11,263 = 1.93). Post-hoc multiple comparisons analysis did not identify any statistical 
differences at any time point during the experiment. There was no significant impact 
of genotype alone (a; p = 0.2561, F1,24 = 1.354). There was no impact of genotype (b; 
p = 0.3121, F1,24 = 1.066, n = 12-14) nor interaction of genotype and time (b; p = 0.7472, 
F10,239 = 0.675) on weekly food intake in the male mice maintained on standard chow, 
but there was a significant effect of time (b; p < 0.0001, F5,131 = 10.01). In female mice, 
there was no effect of genotype (c; p = 0.3643, F1,25 = 0.854, n = 13-15) nor an 
interaction between genotype and time (c; p = 0.5288, F11,275 = 0.9124) on cumulative 
body weight gain between genotypes when kept on standard chow. Both genotypes 
gained weight over the experimental period (c; p < 0.0001, F2,50 = 173). There was no 
influence by genotype (d; p = 0.3909, F1,25 = 0.7624, n = 13-15), or an interaction with 
experimental time (d; p = 0.9587, F10,249 = 0.3698) on weekly standard chow food intake 
between female TSPO -/- and +/+ mice. There was a significant effect of experimental 
time on food intake in the female cohort (d; p < 0.0001, F5,139 = 10.55). Statistical 
analysis was performed using two-way ANOVA with repeated measures or mixed-




Pharmacological modulation of TSPO in fasted mice enhances the fast-induced 
up-regulation of mRNA for hepatic gluconeogenic enzymes and lowers blood 
glucose (347). This would likely cause homeostatic changes in food intake to 
recover the loss of energy. However, no such role of TSPO in homeostatic energy 
regulation has been published. To investigate this, I conducted a fast-induced re-
feeding experiment in TSPO +/+ and -/- mice. This produced two measurements: 
day-time food intake following the 12-hour overnight fast, alongside 
corresponding body weight changes in response to fasting and re-feeding. These 
measures reflect the homeostatic compensation for the food deprivation, and the 
ability of the animals to sense and recover body mass after state of negative 
energy balance. There was no impact of TSPO absence on the ability to retain 
body weight in the fasting period in the male mouse cohort (Fig 5.2.1.2a; p = 
0.2686), nor in cumulative food intake during the fast-induced re-feeding (Fig 
5.2.1.2b; p = 0.9414). Furthermore, no differences were observed in the loss of 
or recovery in body weights (Fig 5.2.1.2c; p = 0.3939) or in refeeding (Fig 
5.2.1.2d; p = 0.1064) between female TSPO +/+ and -/- mice. 
The loss of TSPO signalling on the response to positive energy imbalance was 
investigated by exposing the TSPO +/+ and -/- mice to an obesogenic diet. 
Following the 12 weeks on standard chow diet, mice were provided with high-fat 
diet (HFD; 60% calories from fat) as their only source of food, while their food 
intake and body weights were continued to be monitored. Daily measurements of 
food intake were taken during the first week, followed by weekly recordings in the 
weeks following. During this transition to a HFD, male TSPO -/- mice had 
significantly lower food intake than TSPO +/+ mice over the experimental period 
which came to a significant difference at day 7 (Fig 5.2.1.3a; p = 0.0078). The 
female TSPO +/+ and -/- mice displayed no significant differences in daily food 
intake during the initial exposure to the high-fat diet (Fig 5.2.1.3b; p = 0.2765). At 
day 7 of high-fat diet exposure, both cohorts of mice had increased their daily 
chow intake compared to previous days. However, both the female TSPO +/+ 
and -/- mice consumed more chow on day 7 than the male cohort. Greater 
variability in the female cohort was observed, due to the female mice shredding 






Figure 5.2.1.2 Absence of TSPO did not impact the homeostatic feeding 
response to negative energy balance. 
No differences in fasting induced body weight loss were observed in male TSPO -/- 
compared to TSPO +/+ mice (a; Genotype: p = 0.2686, F1,24 = 1.283; Interaction of 
genotype and energy state: p = 0.2201, F2,48 = 1.563, n = 12-14). Compensatory food 
intake of male TSPO -/- mice was no different to that of TSPO +/+ mice following 
refeeding after 12 hours of overnight food deprivation (b; Genotype: p = 0.9414, F1,120 
= 0.0054; Interaction of genotype and time: p = 0.9855, F4,120 = 0.0898, n = 12-14). 
There was no effect of genotype on body weight change from before to after fasting in 
female TSPO +/+ and -/- mice (c; Genotype: p = 0.3939, F1,26 = 0.7517; Interaction of 
genotype and energy state: p = 0.7115, F2,52 = 0.3426, n = 13-15). Fast-induced 
refeeding was also unaffected by genotype in the female TSPO +/+ and -/- mice (d; 
Genotype: p = 0.1064, F1,26 = 2.797; Interaction of genotype and time: p = 0.3089, 
F4,104 = 1.215, n = 13-15). Statistical analysis was performed with two-way ANOVA with 






Figure 5.2.1.3 High-fat diet intake in TSPO +/+ and -/- mice over 1 week. 
Male TSPO -/- mice ate a slightly, but significant, lower amount of high-fat chow than 
TSPO +/+ mice across the first week of high-fat exposure (a; Interaction of genotype 
and time: p = 0.0078, F3,72 = 4.272, n = 12-14). Sidak’s multiple comparisons test 
indicated a significant difference at experimental day 7 (**, p = 0.0093). However, there 
was no significant effect of genotype alone (a; p = 0.5245, F1,24 = 0.4172). Acute 
measurements of food intake in the first week of exposure to high-fat diet in female 
TSPO +/+ and -/- mice did not identify any genotypic differences (b; Genotype: p = 
0.2765, F1,25 = 1.238; Interaction of genotype and time: p = 0.5032, F3,75 = 0.7901, n = 
13-15). Statistical analysis was performed with two-way ANOVA with repeated 




The TSPO +/+ and -/- mice were maintained on high-fat diet for 6 weeks. The 
subtle difference in body weight of male TSPO +/+ and -/- mice observed when 
the mice were fed standard chow, was lost and there was no significant effect of 
genotype on body weight (Fig 5.2.1.4a; p = 0.5432). Food (Fig 5.2.1.4b; p = 
0.8045) and energy (Fig 5.2.1.4c; p = 0.8671) intake of the male mouse cohort 
displayed no genotypic differences. In both measurements, intake was lower at 
after 1 week of high-fat diet compared to standard chow (week 0) but had 
recovered and stabilised by week 3. Female TSPO -/- mice had a slightly lower 
rate of cumulative body weight gain than the TSPO +/+ littermates, but this did 
not reach statistical significance (Fig 5.2.1.4d; p = 0.061). In this portion of the 
study, both mouse cohorts gained weight and the sex difference in body weights 
reduced (Fig 5.2.1.4a & d). There was no influence of genotype in food (Fig 
5.2.1.4e; p = 0.7465) or energy (Fig 5.2.1.4f; p = 0.7587) intake in the female 
mice. Comparable to the male mouse cohort, the first week of high-fat diet 
exposure resulted in lower food and energy intake compared to week 0. However, 
the female mice consumed more food and energy by week 3 than observed in 
the male cohort – which then reduced and stabilised by week 4.  
Maintenance on an obesogenic diet leads to impaired glucose sensing and 
handling (46,119), which can be replicated in mouse models (374,454). This is 
reflected by reduced glucose clearance from the blood following an intra-
peritoneal bolus injection of glucose in a glucose tolerance test (GTT). The 
purpose of this experiment was to observe whether absence of TSPO alter the 
ability of the animals to clear glucose in the GTT in animals on a standard chow 
or high-fat diet. Accordingly, this procedure was performed prior to dietary 
manipulation and repeated following 5 weeks exposure to the high-fat diet. While 
maintained on standard chow, there was no genotypic difference in blood glucose 
levels in response to the GTT in the male mouse cohort (Fig 5.2.1.5a; p = 0.9521). 
Following exposure to high-fat diet, there was still no genotypic effect on blood 
glucose levels (Fig 5.2.1.5b; p = 0.2802). In both genotypes, basal blood glucose 
– as measured at time 0 (the time of injection) – was only slightly elevated 
following high-fat feeding (Fig 5.2.1.5b; mean = 13.8 mMol/L) compared to when 
maintained on standard chow (Fig 5.2.1.5a; mean = 11.8 mMol/L). Blood glucose 
of both high-fat fed mice did not return to basal measures during the experimental 
time-course (Fig 5.2.1.5b). Similarly, in the female mouse cohort, there were also 
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no genotypic differences on blood glucose levels of mice fed standard chow (Fig 
5.2.1.5c; p = 0.8032) or when fed high-fat diet (Fig 5.2.1.5d; p = 0.5259). In 
similarity to the males, blood glucose of high-fat fed female mice did not return to 
baseline levels during the experimental period. 
Female mammals are less susceptible to the negative consequences of 
consuming a high-fat diet than the males of the species, and female C57BL/6 
mice are no exception (386–388,455). The discrepancy between the sexes is 
likely due to differences in adipose mass and distribution, as well as differences 
in circulating sex hormones. The differences result in a lower rate of body weight 
gain and improved glucose tolerance, compared to male mice. To detect how 
sexual dimorphism influenced glucose handling in TSPO +/+ and -/- mice, the 
area under the curve was calculated for each graph in figure 5.2.1.5 and the data 
from both sexes were pooled together (Fig 5.2.1.5e). Comparisons of area under 
the curve of the changes in blood glucose levels during the glucose tolerance 
time-course test in both male and female mice indicated that, as expected, sex 
had a statistically significant effect on blood glucose levels during the GTT (Fig 
5.2.1.5e; p = 0.0006). The three-way analysis of the pooled data also indicated a 
statistically significant effect of dietary manipulation on blood glucose (Fig 
5.2.1.5e; p < 0.0001), and confirmed no effect of genotype (Fig 5e; F (1, 51) = 
0.02, p = 0.877). There were also no significant interactions between genotype, 





Figure 5.2.1.4 High-fat diet resulted in increased body weight and altered food 
intake compared to standard chow, but with no differences between genotype. 
Access to high-fat diet lead to a steady increase in body weight in both genotypes of 
male mice, compared to when mice were fed standard chow (Week 0) (a; p <0.0001, 
F2,53 = 320.9, n = 12-14). There was no interaction between genotype with regard to 
weight gain on high-fat diet (a; p = 0.5432, F6,143 = 0.8371, n = 12-14). Measures of 
food intake were also unaffected by genotype in male mice (b; p = 0.8045, F5,120 = 
0.4611, n = 12-14). Weekly energy intake was also no different between genotype (c; 
p = 0.8671, F5,120 = 0.3718, n = 12-14). Female TSPO -/- mice gained body weight at 
a lower rate than their TSPO +/+ counterparts while on high-fat diet, but this did not 
reach statistical significance (d; p = 0.061, F6,150 = 2.062, n = 13-15). In both genotypes, 
body weight did increase over time (d; p <0.0001, F3,75 = 226.4, n = 13-15). Weekly 
measures of high-fat chow intake did not differ between genotype in female mice (e; p 
= 0.7465, F5,124 = 0.5388, n = 13-15). Weekly energy intake of mice was also unaffected 
by genotype (f; p = 0.7587, F5,124 = 0.5227, n = 13-15). Statistical analysis was 
performed with two-way ANOVA with repeated measures or mixed-effects analysis as 






Figure 5.2.1.5 Exposure to high-fat diet resulted in reduced glucose tolerance in 
TSPO +/+ and -/- mice with a sex-dependent effect, but with no significant 
differences seen between genotypes. 
There was no difference in blood glucose levels over time, following an intra-peritoneal 
injection of 2 g/kg glucose at time 0, in male TSPO +/+ and -/- mice fed standard chow (a; 
Genotype: p = 0.9521, F1,14 = 0.0037; Interaction of genotype and time: p = 0.3683, F5,70 = 
1.1, n = 8). Following 5 weeks of high-fat feeding, blood glucose levels of TSPO -/- mice 
were slightly higher than that of TSPO +/+ mice but this did not reach statistical significance 
(b; Genotype: p = 0.2802, F1,11 = 1.29; Interaction of genotype and time: p = 0.3818, F5,55 = 
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1.08, n = 6-7). Similarly, there was no genotypic difference between standard chow fed 
female TSPO mice in blood glucose levels following a glucose challenge (c; Genotype: p = 
0.8032, F1,15 = 0.0644; Interaction of genotype and time: p = 0.8503, F5,75 = 0.3957, n = 8). 
After 5 weeks of high-fat diet, female TSPO -/- mice still exhibited no difference in blood 
glucose levels during the tolerance test compared to their TSPO +/+ littermates (d; 
Genotype: p = 0.5259, F1,11 = 0.429; Interaction between genotype and time: p = 0.9185, 
F5,55 = 0.2866, n = 6-7). Three-way comparison of area under the curve also indicated no 
effect of genotype on blood glucose (e; p = 0.8772, F1,51 = 0.0241, n = 6-7) while both sex 
(e; p = 0.0006, F1,51 = 13.28) and diet (e; p < 0.0001, F1,51 = 65.71) had a statistically 
significant influence on blood glucose levels. There was no statistically significant interaction 
between genotype and sex (e; p = 0.2619, F1,51 = 1.287) nor between genotype and diet (e; 
p = 0.745, F1,51 = 0.1069). Sidak’s multiple comparisons test indicated a significant difference 
in blood glucose area under the curve in comparisons of measurements taken before and 
after high-fat diet exposure in all cohorts (Male TSPO +/+: p = 0.0313, Male TSPO -/-: p = 
0.0002, female TSPO +/+: p = 0.0002, female TSPO -/-: p = 0.0064). Statistical analysis 
was performed with two-way ANOVA with repeated measures (a-d) and three-way ANOVA 
(e). Data are expressed as mean ± standard error. 





In the 6th week of high-fat diet exposure, the mice were euthanised and their 
primary metabolic tissues were extracted for analysis. Immunohistochemistry 
was performed on the peri-gonadal white adipose tissue (WAT) to investigate 
TSPO expression and the presence of macrophages – using the macrophage 
marker F4/80. In WAT extracted from male mice, TSPO immunoreactivity was 
expressed throughout TSPO +/+ tissue and absent in WAT from TSPO -/- mice 
(Fig 5.2.1.6). A low level of background fluorescence is visible in the green 
channel in tissue of TSPO -/- mice captured at 63x, but not 20x, magnification 
(Fig 5.2.1.6c & d). TSPO was localised to F4/80-positive macrophages in WAT 
of TSPO +/+, but not TSPO -/-, mice (Fig 5.2.1.6b & d).The absence of TSPO 
had no influence on the weight of WAT in the male mouse cohort (Fig 5.2.1.7a; p 
= 0.8421). Image analysis of immunoreactivity in the WAT of male mice did not 
indicate that there were genotypic differences in adipocyte size (Fig 5.2.1.7b; p = 
0.7493) nor the number of F4/80-positive macrophages identified in the tissue (Fig 
5.2.1.7c; p = 0.6182).  
Immunohistochemical staining of WAT dissected from female TSPO +/+ and -/- 
mice also exhibited TSPO immunoreactivity throughout the TSPO +/+ tissue (Fig 
5.2.1.8a-b). TSPO staining was absent in tissue from the TSPO -/- mice, though 
auto-fluorescent was again visible in images taken at 63x magnification (Fig 
5.2.1.8c-d). TSPO immunoreactivity co-localised with F4/80-positive 
macrophages in the TSPO +/+ tissue. The weight of the WAT dissected from 
female TSPO -/- mice did not differ from that taken from TSPO +/+ mice, although 
it did exhibit more variation between individuals (Fig 5.2.1.9a; p = 0.1829). 
Dissected WAT weight was also similar between sexes. There were no genotypic 
differences in average adipocyte size (Fig 5.2.1.9b; p = 0.6867) nor in the number 
of F4/80-positive cells (Fig 5.2.1.9c; p = 0.1747) per image within the female 
mouse cohort. The average adipocyte size was smaller in female mice compared 
to males, irrespective of genotype, while the average number of infiltrating F4/80-
positive cells was similar in both cohorts. 
The specificity of the secondary antibodies used in the WAT 
immunohistochemical analysis were assessed with the same procedure in 
absence of anti-TSPO and anti-F4/80. This was applied to WAT taken from 
female mice of the TSPO transgenic line that were fed standard chow (Fig 
5.2.1.10). Any observable fluorescence was either auto-fluorescence within the 
197 
 
tissue or by non-specific binding of the secondary antibodies. Both TSPO-
negative and F4/80-negative fluorescence was absent. Images were taken at 20x 
magnification only. 
Histology was assessed in the liver tissue dissected from the high-fat fed TSPO 
+/+ and -/- mice. The purpose here was to investigate lipid droplet accumulation 
in the liver tissue, which occurs in diet-induced obesity. It was previously reported 
that 5-weeks treatment with the TSPO ligand, PK11195, protects against hepatic 
lipid accumulation in diet-induced obese mice (347). Haematoxylin and eosin 
(H&E) staining was applied to identify vacuolarised (non-stained) areas within the 
tissue, as a proxy for presence of lipid droplets. No differences in liver weight at 
time of dissection (Fig 5.2.1.11a; p = 0.9021) nor average vacuolarised space 
(Fig 5.2.1.11b; p = 0.3286) were observed between high-fat fed male TSPO +/+ 
and -/- mice. Representative images of the H&E stained liver sections from male 
TSPO +/+ (Fig 5.2.1.11c) and TSPO -/- (Fig 5.2.11d) mice were captured with 
light microscopy. There were no genotypic difference in the weights of liver tissue 
extracted from female TSPO +/+ and -/- mice (Fig 5.2.1.12a; p = 0.3269). Liver 
weights of the female cohort were slightly lower than that taken from the males, 
which likely reflects the lighter body weight of the female mice. No differences in 
average vacuolarised area were observed between the female TSPO +/+ and -/- 
mice (Fig 5.2.1.12b; p = 0.7416). Average vacuolarised area was also similar 
between the female and male mice, regardless of genotype. Representative 
images of H&E staining of the liver were taken by light microscopy from female 





Figure 5.2.1.6 TSPO and F4/80 immunoreactivity in epididymal white adipose 
tissue taken from male TSPO +/+ and -/- mice fed high-fat diet. 
A representative 20x magnification image of white-adipose tissue from a TSPO +/+ 
mouse (a-i) - depicting DAPI-positive nuclear staining (ii, blue), TSPO (iii, green) and 
F4/80 (iv, red) immunoreactivity. The same tissue is displayed at 63x magnification 
(b). Adipose tissue from a TSPO -/- mouse confirms absence of TSPO 
immunoreactivity, at 20x (c) and 63x (d) magnification. TSPO +/+ (b) and TSPO -/- (d) 
F4/80-positive macrophages are shown in digital zoom in the inset images. Scale bars 






Figure 5.2.1.7 Absence of TSPO signalling did not impact adipocyte size or 
macrophage infiltration into epididymal white adipose tissue in high-fat fed male 
mice. 
The weight of peri-gonadal white adipose tissue did not differ between high-fat fed 
male TSPO -/- and +/+ mice (a; p = 0.8421, n = 11-13). The average size of adipocyte 
captured by microscopic image was also not distinct between genotypes (b; p = 
0.7493, n = 11-13). TSPO absence also had no genotypic effect on the number of 
F4/80-positive macrophages captured by image (c; p = 0.6182, n = 11-13). Statistical 
analysis assessed by Student’s (a, b) and Mann Whitney unpaired t test (c). Data are 
expressed as mean ± standard error.  






Figure 5.2.1.8 TSPO and F4/80 immunoreactivity in peri-gonadal white adipose 
tissue of female TSPO +/+ and -/- mice fed high-fat diet. 
A representative 20x magnification image of white adipose tissue from a female TSPO 
+/+ mouse (a-i) - depicting DAPI-positive nuclear staining (ii, blue), TSPO (iii, green) 
and F4/80 (iv, red) immunoreactivity. The same tissue is displayed at 63x magnification 
(b). Adipose tissue from a TSPO -/- mouse confirms absence of TSPO 
immunoreactivity, at 20x (c) and 63x (d) magnification. Digital zoom images of TSPO 
+/+ (b) and TSPO -/- (d) F4/80-positive macrophages are shown in the insets. Scale 





Figure 5.2.1.9 Absence of TSPO signalling did not impact adipocyte size or 
macrophage infiltration in the white adipose tissue of high-fat fed female mice. 
The weight of peri-gonadal white adipose tissue did not differ between high-fat fed 
female TSPO +/+ and -/- mice (a; p = 0.1829, n = 12-14). The average size of adipocyte 
captured by microscopic image was also no different between genotypes in female 
mice (b; p = 0.6867, n = 13). Female TSPO -/- also exhibited no difference on the 
number of F4/80-positive macrophages captured by image compared to TSPO +/+ 
controls (c; p = 0.1747, n = 13-14). Statistical analysis assessed by Mann Whitney test 
(a, b) and Student’s unpaired t test (c). Data are expressed as mean ± standard error. 







Figure 5.2.1.10 Non-specific immunoreactivity in peri-gonadal white adipose 
tissue of a female TSPO +/+ mouse. 
An image of non-specific secondary antibody immunoreactivity in sub-cutaneous white 
adipose tissue, in absence of primary antibodies, taken from a female TSPO +/+ 
mouse (a-i). DAPI nuclear staining (ii, blue) is still applied and visible, while TSPO (iii, 
green) and F4/80 (iv, red) immunoreactivity is absent. Images captured at 20x 







Figure 5.2.1.11 Male high-fat fed TSPO +/+ and TSPO -/- mice exhibited no differences 
in gross liver weight or histology were observed between. 
There was no difference in liver tissue weight taken from male TSPO +/+ and TSPO -/- mice 
that were fed high-fat diet for 6 weeks (a; p = 0.9021, n = 12-13). The average vacuolarised 
area was not different between the genotypes (b; p = 0.3286, n = 6-7). Statistical analysis 
was performed using Mann Whitney (a) and Student’s unpaired t test (b). Data are expressed 
as mean ± standard. Representative haematoxylin and eosin stained images of liver tissue 








Figure 5.2.1.12 High-fat fed female TSPO +/+ and TSPO -/- mice exhibited no 
differences were observed in gross liver weight or histology from. 
There were no differences in liver tissue weight taken from TSPO -/- mice compared to TSPO 
+/+ littermates following 6-week maintenance on high-fat diet (a; p = 0.3269, n = 13-14). The 
average vacuolarised area was not different between the genotypes (b; p = 0.7416, n = 6-
7). Statistical analysis was performed using Student’s unpaired t test. Data are expressed 
as mean ± standard error. Representative haematoxylin and eosin stained images of liver 
tissue structure from TSPO +/+ (c) and -/- (d) female mice, captured at 20x magnification. 




5.2.2 Investigating the effects of the TSPO ligand, PK11195, on feeding 
behaviour and analysis 
To complement the studies in TSPO -/- mice, I assessed the effect of a well-
studied TSPO ligand on energy homeostasis in a cohort of C57BL/6J mice. To 
first assess the impact of the drug on normal mouse feeding behaviour, two 
experimental protocols were performed. These consisted of measuring food 
intake in the nocturnal phase – when mice consume the majority of their daily 
energy intake - and at the beginning of the light phase when the mice are typically 
satiated and sleeping. Male and female mice were single-housed for at least a 
week prior to the experimental day. Intra-peritoneal administration of 1 mg/kg 
PK11195 had no impact on nocturnal (Fig 5.2.2.1a; p = 0.115) nor on satiated 
food intake in male mice (Fig 5.2.2.1b; p = 0.911). The same experiments were 
repeated in female C57BL/6J mice, where no effect of the ligand on nocturnal 
feeding was observed (Fig 5.2.2.1c; p = 0.1769). PK11195 treatment appeared 
to reduce food intake in the light phase, but this is likely a reflection of the scale 
of the graph axis and did not reach statistical significance (Fig 5.2.2.1d; p = 
0.0602).  
The same fast-induced refeeding protocol, that was applied to investigate the 
effect of negative energy balance in TSPO -/- mice, was repeated in C57BL/6J 
mice treated with PK11195. The published work prior to this experiment also used 
PK11195 at similar doses (347). Therefore, as well as accompanying the 
experiment performed in TSPO -/- mice, this portion of the study also acted to 
replicate previous findings. As with the TSPO -/- cohort, body weight prior to and 
after food deprivation was measured as well as post-fast food intake. Male and 
female mice were individually housed for at least one week prior to the 
experiment. The mice were food deprived for 12-hours, from onset of the dark 
phase, and treated with either 1 mg/kg PK11195 or vehicle as food was returned 
to the respective cages. Neither body weight change (Fig 5.2.2.2a-i; p = 0.3482) 
nor cumulative food intake (Fig 5.2.2.2a-ii; p = 0.1454) differed between the male 
mice administered 1 mg/kg PK11195 or vehicle. Although there was no impact of 
treatment on body weight change, the body weights of the PK11195-treated mice 
were slightly higher than that of the controls. Due to random allocation of the mice 
to the treatment group, this effect was likely due to chance. In the female mice, 
injection of 1 mg/kg PK11195 also had no influence on body weights (Fig 
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5.2.2.2b-i; p = 0.7726) or cumulative food intake (Fig 5.2.2.2b-ii; p = 0.2433). To 
determine whether the lack of any observed effect was related to the dose of the 
drug used, a greater dose of PK11195 at 5 mg/kg was given to an additional 
cohort of male mice. Change in body weights over the experiment were not 
influenced by PK11195 administration (Fig 5.2.2.2.c-i; p = 0.5993), as was the 
case with cumulative food intake (Fig 5.2.2.2c-ii; p = 0.2733). Here, the well-
defined TSPO ligand PK11195 did not influence homeostatic feeding behaviour 
in response to a negative energy state. 
As with the TSPO +/+ and -/- cohort of mice, glucose tolerance was also tested 
in male and female C57BL/6J mice treated with PK11195. However, in this study 
the protocol was only performed on standard chow fed mice and a small sample 
size that limited statistical analysis. In this experiment, mice received 5 mg/kg 
PK11195 or vehicle in the same intra-peritoneal injection as the bolus dose of 2 
g/kg glucose used for the GTT. There was no observable effect of drug treatment 
on peak blood glucose levels in either male (Fig 5.2.2.3a) or female mice (Fig 
5.2.2.3b). The response to the glucose tolerance test was not different in 
PK11195-treated male mice compared to vehicle (Fig 5.2.2.3a), nor in the female 







Figure 5.2.2.1 Pharmacological targeting of TSPO signalling did not disrupt 
normal feeding behaviour. 
Male C57BL/6J mice, administered with 1 mg/kg PK11195 at the start of the dark 
phase, did not display altered nocturnal feeding compared to vehicle injected mice (a; 
Treatment: p = 0.115, F1,8 = 3.127; Interaction of treatment and time: p = 0.6694, F6,48 
= 0.6762, n = 5). No difference in food intake was measured 90 minutes following intra-
peritoneal injection of 1mg/kg PK11195 or vehicle at the start of the light phase in 
satiated male mice (b; p = 0.911, n = 3-4).There was also no effect of 1 mg/kg PK11195 
administration in nocturnal feeding in female mice (c; Treatment: p = 0.1769, F1,7 = 
2.255; Interaction of treatment and time: p = 0.1102, F6,42 = 1.862, n = 4-5). Injection 
of 1 mg/kg PK11195 at lights-on induced a slight, but not significant, reduction in food 
intake in female mice compared to vehicle-injected mice (d; p = 0.0602, n = 4). 
Statistical analysis was assessed by two-way ANOVA with repeated measures (a, c) 






Figure 5.2.2.2 Pharmacological targeting of TSPO signalling did not impact the 
homeostatic response to acute food deprivation. 
Intra-peritoneal injection of 1 mg/kg PK11195 in male C57BL/6J mice had no effect on 
the recovery of body weight after fasting (a-i; Treatment: p = 0.3484, F1,25 = 0.914; 
Interaction of treatment and energy state: p = 0.6896, F2,50 = 0.3743, n = 13-14). 
Cumulative post-fast re-feeding was also not affected by PK11195 treatment (a-ii; 
Treatment: p = 0.1454, F1,175 = 2.139; Interaction of treatment and time: p = 0.941, 
F6,175 = 0.2902, n = 13-14). There was no influence of 1mg/kg PK11195 on post-fast 
body weight recovery (b-i; Treatment: p = 0.7726, F1,25 = 0.0853; Interaction of 
treatment and energy state: p = 0.4958, F2,50 = 0.7115, n = 13-14) or re-feeding (b-ii; 
Treatment: p = 0.2433, F1,245 = 1.368; Interaction of treatment and time: p = 0.9593, 
F6,245 = 0.2493, n = 13-14) in female C57BL/6J mice. A dose of 5 mg/kg PK11195 in 
male mice also did not impact body weight regulation (c-i; Treatment: p = 0.5993, F1,8 
= 0.2992; Interaction of treatment and energy state: p = 0.1427, F2,16 = 2.204, n = 5) 
or fast-induced refeeding (c-ii; Treatment: p = 0.2733, F1,116 = 1.212, Interaction of 
treatment and time: p = 0.36, F6,116 = 1.111, n = 5). Statistical analysis was performed 






Figure 5.2.2.3 Administration of the TSPO ligand, PK11195 (5 mg/kg), did not affect 
glucose tolerance in male or female C57BL/6J mice. 
There was no difference in blood glucose levels in either male (a; n = 2-3) or female (b; n = 
2) C57BL/6J mice after intra-peritoneal administration of 5mg/kg PK11195 with 2 g/kg 









5.3.1 Summary of findings and contribution to the literature 
The aim of the studies presented here was to characterise the whole-body 
metabolic response of TSPO -/- mice in response to deviations in energy balance. 
Previous research has examined the impact of loss of TSPO signalling on normal 
growth, but critically did not explore the potential effect of physiological challenge 
(325). Growth curves of TSPO -/- mice used in my studies did not deviate from 
that of TSPO +/+ mice, in both males and females. The data presented in this 
chapter confirms that of Banati et al (325), and complements the literature with 
measurements of weekly food intake. Furthermore, Banati et al reported no 
genotypic differences in basal blood glucose in either sex (325). The same 
observations were made in the study presented here, with additional 
measurements reflecting glucose tolerance in the animals when fed standard and 
high-fat chow. No influence of genotype was observed in either male or female 
mice, echoing the published work (325). Collectively these studies suggest that 
there is no role for TSPO in modulating normal body weight gain or blood glucose 
in male or female mice. I investigated whether there may be sex-specific functions 
for TSPO in female mice with regards to glucose handling, which would align with 
known sex-specific differences in metabolism (386–388,455), but my data 
supports the null hypothesis. 
The series of experiments presented here indicate that there is no role of TSPO 
in the whole-body homeostatic regulation of energy balance, at least using the 
approaches employed. This is a remarkably consistent conclusion amongst what 
is quite a controversial literature (301,325,347,363,379). The phenotypic 
characterisation of germ-line TSPO -/- mice to deviations in energy balance had 
not been explored before, and so this study is an important contribution to the 
literature. These findings are distinct from the results of previous studies, which 
used cell-type specific knock-outs (301,362,363). Using a germ-line/whole body 
deletion may result in developmental adaptation/compensation that mask some 
of the effects of deleting the gene from specific cell-types. This can be bypassed 
in future studies by use of inducible knock-out models.  
Glucose handling is sensitive to activity of the hypothalamic-pituitary-adrenal 
(HPA) axis, which is also a research area in which modulation of TSPO signalling 
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has been studied. A conditional TSPO -/- mouse line was recently generated 
where TSPO was deleted specifically from cells that produce steroidogenic factor 
1 (SF-1) (363). Consequently, the steroid-producing organs of these mice – the 
gonads and the adrenals – had a modest reduction in Tspo gene expression 
(362). The male TSPO -/- mice of the cohort had significantly higher basal 
glucose in serum samples compared to the TSPO +/+ mice, while no differences 
were exhibited in the female mice (363). Linking this study with that of Banati et 
al (325) and the experiments presented above, it can be concluded that TSPO is 
not directly involved in mediating glucose homeostasis. However, there are likely 
downstream effects on blood glucose levels via TSPO absence in steroidogenic 
organs. This may also explain the sex differences in blood glucose of the SF-1 
conditional TSPO -/- mice (363), which was not the case in my global TSPO -/- 
mouse line. The SF-1 TSPO -/- mice also have altered secretion of adrenaline 
and corticosterone (362,363), and adrenaline is known to raise blood glucose 
levels (456,457). The lack of an overall effect on glucose levels in the global 
TSPO -/- mice may be due to compensatory effects occurring across organs. 
While this research project was ongoing, a conditional TSPO -/- mouse line - with 
manipulation specific to the β-tanycytes of the third ventricle (3V) - was published 
(191). Similar to the study presented here and in the Banati et al (325) paper, 
there were no differences in body weight and cumulative food intake between 
TSPO tanycytic -/- and TSPO +/+ mice. However, when the mice were placed on 
a high-fat diet for 4 weeks, the TSPO tanycytic -/- mice gained less body weight 
and had reduced food intake compared to controls (191). In my study, while the 
male TSPO -/- mice did eat slightly less high-fat chow than controls in the first 
seven days of dietary manipulation, the general trends I observed contradicted 
with that of the tanycytic TSPO -/- mouse line. Differences in high-fat diet 
composition and genetic background of the mice cannot explain the contrast in 
results, as diet composition between studies is very similar and genetic 
background is experimentally controlled. Furthermore, tanycyte-specific TSPO -
/- mice also displayed no difference in glucose tolerance to that of TSPO +/+ mice 
even after high-fat diet exposure (191). This echoes that of the data described 
here in the global TSPO -/- mice. The β-tanycytes lie adjacent to the mediobasal 
hypothalamus (MBH), which contains the hypothalamic arcuate nucleus (Arc) 
and median eminence (ME). Consequently, any alteration in tanycytic function 
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would be immediately relayed to appetite and energy regulatory regions of the 
brain. Despite the tanycyte-specific TSPO -/- mice exhibiting subtle resistance to 
diet-induced obesity, the fact that they are not resistant to diet-induced glucose 
intolerance indicates a distinct role for TSPO in the tanycytes from the rest of the 
organism. This may be in nutrient sensing pertaining to fatty acids, but not 
glucose. 
The feeding studies with global TSPO -/- were replicated with a pharmacological 
intervention of intra-peritoneal injection with the TSPO ligand PK11195. This 
ligand is thought to act to oppose TSPO function (319,458–462). While the 
findings were consistent within my studies, they did differ to recently published 
work that also used PK11195 (301). Intra-cerebroventricular administration of 
PK11195 to mice resulted in a reduction in body weight and food intake when the 
mice were fed either standard chow or high-fat diet (301). The route of treatment 
is likely responsible for the difference in effects; intra-cerebroventricular injection 
will primarily target the TSPO-expressing tanycytes of the 3V. As described 
above, genetic modulation of tanycytic TSPO influences feeding behaviour (301). 
Meanwhile, although PK11195 in the periphery can cross the blood-brain barrier 
(BBB), its primary target will be TSPO-expressing organs such as the liver and 
the adrenal glands. The doses of PK11195 used in these studies was also 
different. My studies presented in this chapter used a greater dose of 1-5 mg/kg 
PK11195 than Kim et al administered to experimental animals with 2 nMol (301). 
This is also lower than the dissociation constant of PK11195 at 2.4 nMol. This 
considering, the greater dose of PK11195 administered via the peritoneum is 
likely to target TSPO in a wider range of tissues than intra-cerebroventricular 
injection at a lower dose.  
I also tested manipulation of TSPO-mediated signalling – through both genetic 
and pharmacological techniques – on recovery from negative energy balance. To 
date, no such research had been published. The reasoning behind these 
experiments followed those by Gut et al, who demonstrated an enhanced 
upregulation of gluconeogenic enzyme mRNA in fasted mice that were treated 
with PK11195 (347). In the study of Gut et al, intra-peritoneal PK11195 also 
lowered fasted glucose levels in the mice (347). Any impact on food intake in 
these mice were not reported, and so I anticipated that feeding behaviour would 
be reduced. I also sought to replicate the effect of PK11195 on fasted basal blood 
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glucose and extend these studies by performing intra-peritoneal glucose 
tolerance tests. My experiments involving the TSPO -/- and PK11195-treated 
mice did not reveal any effects on body weight, fast-induced refeeding or blood 
glucose levels. This may be explained by the duration of the fast; I exposed the 
mice to a 12-hour fast prior to refeeding and body weight measurements, which 
may not have been sufficient to induce hepatic gluconeogenesis. A 16- to 24-
hour fast is substantial to induce gluconeogenesis in mice (463,464). However, 
in the study by Gut et al, the mice were fasted for 8 hours which was sufficient to 
see enhanced transcription of the gluconeogenic enzyme mRNA and 24 hours 
for reduction in blood glucose levels (347). In my glucose tolerance test, mice 
were only fasted for 6 hours during the day. This would have minimal impact on 
hepatic gluconeogenesis, as the mice would not typically consume much food 
during the day. Consequently, a prolonged fast duration may be required for 
effects of PK11195 on food intake and response to a bolus injection of glucose 
to be observed. Daily treatment with PK11195 for 4 weeks also alleviated glucose 
intolerance in diet-induced obese mice (347). No effect was observed in glucose 
levels during my TSPO -/- experiments of this chapter. In both studies - the 
PK11195 treatment by Gut et al (347) and my TSPO -/- experiment - the mice 
were fasted for 6 hours, and so it is possible that the different experimental 
approaches resulted in disparity between results. 
As well as a role in metabolism, TSPO expression is upregulated in pro-
inflammatory states of multiple cell types (227,286,290,291,310,350,353). High-
fat feeding is associated with adipocyte expansion and macrophage infiltration 
into the WAT and lipid accumulation in the liver (3,57,64,66). Furthermore, 
increased TSPO expression in macrophages of WAT has been observed in 
obese mice compared to lean controls (310). In high-fat fed TSPO -/- mice, no 
phenotypic differences were observed in either the WAT or liver tissue compared 
to the TSPO +/+ mice in any of the parameters examined. These findings 
complement the absence of a genotypic effect on weight gain and glucose 
tolerance observed in vivo.  
 
5.3.2 Limitations of the study 
The studies presented in this chapter combined two experimental approaches to 
tackle the hypothesis that attenuation of TSPO-mediated signalling in mice will 
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alter their ability to maintain energy homeostasis. Comparison between the two 
approaches led to complementary findings: that systemic manipulation of TSPO-
signalling does not influence energy homeostasis in mice. The respective 
strengths and weaknesses of each experimental approach must be critiqued in 
reference to this study.  
The choice of mouse strain and its respective genetic background is important 
when comparing between studies that use more than one strain. The TSPO -/- 
mouse line used here was on the C57BL/6N subset, contrasting to the 
pharmacological studies that used mice on a 6J subset background. There are 
differences in metabolism identified between the N and the J subsets. In the case 
of the study presented here, both the genetic and pharmacological inhibition of 
TSPO signalling resulted in the same conclusions. In addition, appropriate 
controls were used in line with the difference in strain subset. Therefore, it is safe 
to assume that the differences in C57BL/6 mouse backgrounds used did not 
influence these results. 
Global germ-line deletion of a gene can result in compensatory effects, as key 
proteins can exhibit genetic robustness (465). Compensation can occur at the 
transcriptional or signalling level. For example, in global TSPO -/- models there 
may be an upregulation of proteins with a similar function and/or distribution. 
Alternatively, proteins that are involved in the same signalling network as TSPO 
may increase their activity in response to its loss (466,467). Use of conditional 
and or inducible knock-outs can overcome these effects. Phenotypes resulting 
from global deletion of a gene can differ to the phenotype of conditional knock-
out. For example, liver-specific deletion of sirtuin-1 (SIRT1) in mice leads to fatty 
liver while mice with global knock-out of SIRT1 exhibit healthy livers (468). A form 
of regulatory compensation is likely to have happened in the global TSPO -/- 
studies. This would explain the absence of a different response to high-fat feeding 
(reported in this chapter) compared with the subtle reduction in high-fat diet-
induced weight gain following tanycytic-specific TSPO ablation (301), as well as 
the lower basal blood glucose levels in the SF-1 conditional TSPO -/- mice that 
was not observed with the global TSPO -/- model (363). 
Observations resulting from pharmacological inhibition of a protein can be dose-
dependent; an administration of excess drug could have off-target or toxic effects, 
while a too low dose may be insufficient to detect any impact.  The dissociation 
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constant for PK11195 is 2.4 nMol. I used a dose (1-5 mg/kg) greater than the 
dissociation constant that was also in line with the experiments performed by Gut 
et al – which showed an effect of PK11195 on blood glucose levels (347). This 
dose is also compatible with other in vivo studies (233,281,292). Off-target effects 
have been seen in cell culture with treatment of 100 nMol PK11195 (283). Clearly, 
it is important to rely on not one technique with regards to TSPO function. My 
study here benefits from using genetic manipulation as well as pharmacological 
approaches. 
Route of administration of pharmacological agents can also lead to variability in 
results. For example, an intra-cerebroventricular injection will directly target the 
brain and may not reach the periphery. Meanwhile, an intra-peritoneal dose will 
reach the liver; spleen; and GI system and – depending on the drug – may not 
pass the blood-brain barrier. PK11195 was injected to the peritoneum in my 
experiments. Peripheral injection of PK11195 can cross the blood-brain barrier, 
as demonstrated by PK11195-radioligand binding for use in positron emission 
tomography (PET) (289,469–471). However, the drug would primarily target 
TSPO expression in peripheral organs such as the liver and adrenal glands. The 
integration of two or more experimental approaches, with critique and comparison 
of results, aims to bypass these listed problems and motivated the experimental 
design used for the experiments described in this chapter. 
 
5.3.3 Future perspectives and outstanding questions 
As covered in the limitations of this study above, some of the experiments 
described here would benefit from replication. For example, due to the potential 
off-target effects of PK11195 it would be insightful to repeat these experiments 
with another TSPO ligand. Conversely, it would also be useful to consider the 
impact of treatment with a ligand that is considered to enhance TSPO function, 
and whether it shows the anticipated effects based on the literature. TSPO 
pharmacology is an ever-developing aspect of the field, and crucial to approach 
TSPO experiments with the most appropriate ligand. 
There was data that was not included in this thesis, as analysis could not be 
sufficiently completed due to lockdown restrictions of the Covid-19 pandemic. 
These were to assess the same histological markers in liver and WAT tissue of 
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female TSPO +/+ and -/- mice which were maintained on standard chow. Since 
these experiments, data has been published from another group that shows lower 
lipid accumulation in liver tissue from standard chow-fed TSPO -/- mice compared 
to control (379). If replicable, then this suggests a role for TSPO in hepatic fatty 
acid metabolism outside of energy homeostasis. 
To unravel the role of TSPO across the organism, additional conditional knock-
out lines could reveal TSPO function pertaining to that specific tissue. Knock-
down of TSPO in hepatic cells could confirm a role of TSPO in glucose 
homeostasis at the level of the liver. In addition, the generation of inducible global 
TSPO -/- animal models may avoid any compensatory developmental effects. 
Regardless of model used, it is important to consider the results in accordance to 
what has been reported in the literature from other knock-out animals. TSPO is 
expressed throughout the body, and this should be appreciated accordingly. 
My studies presented in this chapter also leave questions for further investigation. 
For instance, to connect the published data from the SF-1-dependent TSPO -/- 
mice with that presented here (363), it would be of interest to measure the 
circulating levels of adrenaline in the global TSPO -/- mice. This would provide 
insight as to whether the effect of SF-1 TSPO -/- is maintained in the global TSPO 
-/- model. One of the actions of adrenaline is to enhance hepatic glucose 
production by gluconeogenesis (472,473). If adrenaline is higher in global TSPO 
-/- mice, then the action of adrenaline in the liver may have negated the effect of 
absent hepatic TSPO expression on lowering glucose production. Considering 
that SF-1 TSPO -/- also had differential effects on production of other steroid 
hormones – including sex-associated steroids – this sex-dependent influence 
may also be present and effective in the global TSPO -/- mice 
(135,386,387,474,475). A repeat comparison of glucose tolerance in male and 
female TSPO -/- mice would also benefit from increased power.  
 
In conclusion, this study combines genetic and pharmacological approaches to 
demonstrate that absence of TSPO signalling does not result in an altered 
response to energy imbalance. TSPO -/- mice were not protected against the 
negative consequences of diet-induced obesity in comparison to TSPO +/+ 
controls, nor did they display altered feeding in response to food deprivation. 
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These data were complemented with pharmacological targeting of TSPO in lean 
mice. The results observed here contrast with published findings from conditional 
TSPO -/- models (301,362,363,379). Therefore, this study provides novel insight 
to the importance of experimental approach to study TSPO function. It is likely 
that TSPO function differs between organs and that global inhibition results in 





Chapter 6: General Discussion 
 
6.1 Summary of findings and contribution to the 
literature 
 
The hypothesis underlying this project was that the mitochondrial translocator 
protein of 18 kDa (TSPO) is involved in cellular metabolic flexibility, and could be 
manipulated to influence energy homeostasis. Metabolic flexibility is crucial for 
function of certain cell types, such as immune-associated cells. In these cells, the 
transition in inflammatory states occurs alongside a shift in substrate utilization 
(476–481). Furthermore, nutrients for energy production - such as saturated fatty 
acids (SFAs) – may themselves trigger an inflammatory response 
(123,125,180,367,427,482). TSPO is implicated in both mitochondrial 
metabolism and pro-inflammatory phenotypes in different cell types 
(227,281,286,291,297,298,301,303,311,319,324,327,330,342,350,453,483). 
Henceforth, I investigated whether TSPO is involved in regulation in energy 
balance in the whole organism. 
 
6.1.1 Distribution of TSPO immunoreactivity in the healthy mouse brain 
The first study (Chapter 3) investigated the distribution of TSPO expression in the 
mouse brain, along with it its cellular localisation. This was important to 
investigate since TSPO upregulation in the brain is commonly used as a 
biomarker for neuroinflammation, both in research and the clinical setting 
(227,248,273,277,278,288,289,293,300,312,325,369,385,437,439,441,484–
495). Still, the distribution of TSPO in the healthy brain is relatively unknown 
(294,300,301,303). I observed and semi-quantified dense TSPO 
immunoreactivity in multiple brain regions, in the male and female mouse, that 
are known to be involved in energy homeostasis. However, upon comparison to 
brain sections taken from TSPO knock-out (-/-) mice, I confirmed the dense 
immunoreactivity was not specific for TSPO. The antigen for the off-target binding 
was unable to be identified due to being proprietary of Abcam. However, it 
appeared to colocalise with markers of neuroendocrine neurons such as 
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thyrotropin-releasing hormone (TRH). Intense immunoreactivity within the walls 
of the ventricles was suspected to be specific for TSPO, as it was absent in the 
TSPO -/- brain tissue. Following dual immunohistochemical analysis, this 
immunoreactivity colocalised with vimentin – a tanycytic marker. The low level of 
immunoreactivity throughout the brain was also absent in the TSPO -/- tissue.  
This study identified TSPO expression within tanycytes and ependymal cells of 
the brain ventricles, and provided evidence against the brain tissue specificity of 
a commonly used antibody against TSPO. This has implications for the extent of 
TSPO expression in healthy and diseased mouse brain tissue, as previously 
published research on this topic has relied on this particular antibody 
(296,306,322,325,362,369,379,420,496–511). While I confirmed that the 
antibody selectively binds to TSPO in mouse white adipose tissue (WAT) – and 
my colleagues confirmed specificity in cultured glia – we cannot rule out that there 
may be non-specific binding in other tissues and in other species. Furthermore, 
although I could not identify the antigen that causes the non-specific binding, it is 
possible that it is a protein structurally related to TSPO – such as TSPO-2 (422) 
or TSPO associated protein (424) – and remains of interest to research on 
hypothalamic control of energy balance. 
 
6.1.2 Regulation of hypothalamic TSPO by energy balance 
The second study of this thesis (Chapter 4) explored regulation of neural TSPO 
expression by energy state, alongside that of an astrocyte marker to confirm the 
presence of reactive gliosis. These experiments were conducted prior to the 
knowledge that the TSPO antibody lacked specificity in the mouse brain. Two 
methodologies were used, immunohistochemistry and Western blot, to provide 
both quantitative and qualitative measures. 
Western blot analysis identified downregulation of TSPO protein level in the 
dorsomedial hypothalamic nucleus (DMH) of high-fat fed male mice. Assessment 
of GFAP protein levels by densitometry confirmed presence of diet-induced 
changes in astrocyte number or morphology. This was also observed in high 
energy state and localised to the arcuate hypothalamic nucleus (Arc) of the mice. 
There are very few studies that report dietary regulation of TSPO – and none 
have considered negative energy balance (310,369,439,441). Published works 
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also focus largely on TSPO expression in hippocampal and cortical regions of the 
brain, not the hypothalamus.  
The downregulation of TSPO in positive energy states complements findings 
which indicate that knock-out of TSPO enhances fatty acid oxidation (FAO) and 
lipid catabolism (301,330) in cells. Following acute high-fat feeding, circulating 
fatty acids (FAs) would be elevated and so cells may respond with a shift in 
substrate utilisation from glucose to FAs. Therefore, expression of TSPO may be 
important for mitochondrial metabolic flexibility. Since TSPO is not expressed in 
all cells or tissues, if true, expression may be specific to cells that require such 
flexibility – such as inflammatory cells.  
This study also provided additional evidence that hypothalamic astrogliosis can 
also occur in response to an acute fast. This has been previously demonstrated, 
but with few published studies to confirm the findings (202). It at first seems 
paradoxical in relation to similar observations from animals fed a high-fat diet 
(125,174,180), given that one state represents an excess of energy availability 
and the other insufficient energy. However, both energy states can involve 
circulating levels of pro-inflammatory SFAs to increase (187). Furthermore, 
reactive gliosis is a response to a range of different stimuli so there may be 
multiple factors involved.  
The results from the immunohistochemical analysis of GFAP expression in diet-
induced obese mice in this study did not reflect what has been reported in the 
literature (125,222). The mice were exposed to high-fat chow for 3 months and 
gained substantial weight compared to the control mice, so this discrepancy in 
the findings was surprising. However, considering the bimodal response of 
inflammation to chronic high-fat diet (125), this points to the importance of 
exposure time and age of the animals in studies such as these. 
Considering the results and conclusions from this study, I propose that TSPO 
downregulation in the hypothalamus may be indicative of a role in mediating 
metabolic flexibility. Bearing in mind the non-specific immunolabelling of the 
antibody, the downregulation in the DMH may relate to a distinct but related 
protein. However, a report published since my studies were conducted has also 
identified a role for TSPO in tanycytic lipid metabolism at the 3V (301). In addition, 
glial physiology is dynamic and responsive to a range of factors – including 
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inflammatory stimuli, energy excess, and energy deprivation. Consequently, 
assessing gliosis in the setting of energy homeostasis requires control for or 
consideration to extraneous variables that can influence reactive gliosis. 
 
6.1.3 Inhibition of TSPO-mediated signalling 
The final part of this project (Chapter 5) looked to characterise the metabolic 
phenotype of mice with germ-line deletion of TSPO or pharmacological 
modulation of TSPO activity – including in response to both positive and negative 
energy states. This study, at the time of writing, was a novel and important 
contribution to the literature. The absence of differences in food intake, body 
weight, and blood glucose of TSPO +/+ and -/- mice when fed standard chow has 
been described previously (325). My work confirmed this, as well as providing 
new information regarding the physiological response to different levels of energy 
availability.  
Absence of TSPO in mice with germ-line deletions did not alter body weight or 
feeding behaviour of mice exposed to acute food deprivation, or to acute and 
chronic high-fat feeding. This was replicated in mice that received an intra-
peritoneal injection of the TSPO ligand, PK11195. Since I conducted these 
experiments, a paper was published demonstrating that both conditional TSPO -
/- in tanycytes and intra-cerebroventricular injection of PK11195 in the 3V subtly 
reduced food intake and body weight of diet-induced obese mice (301). This is 
an interesting difference to my data described here, which is likely explained by 
the types of animal models. While administration of PK11195 to the periphery - 
such as intra-peritoneal injection, as in my study - can enter the brain, multiple 
organs will be impacted including the liver, adrenals and gonads. Injection of 
PK11195 to the 3V is unlikely to affect these organs, and predominantly target 
the surrounding hypothalamic nuclei and other peri-ventricular brain regions. Kim 
et al also specifically knocked-out TSPO expression in the tanycytes adjacent to 
the MBH, which replicated their results from PK11195 treatment (301). I did not 
observe this in the global TSPO -/- mice, presumably due to compensatory effects 
not present in the tanycyte specific TSPO -/- model.  
In the study by Kim et al (301), glucose tolerance was not altered by tanycytic-
specific TSPO -/- or PK11195 treatment which – despite the difference in 
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methodologies - is consistent with the findings in my project. However, in a 
different study intra-peritoneal PK11195 reduces basal blood glucose in acute 
fasted mice and sub-cutaneous PK11195 improves glucose tolerance with 
repeated treatment in diet-induced obese mice (347). Furthermore, knock-out of 
TSPO in the adrenal cortex of mice induces hyperglycaemia (363). These studies 
suggest tissue-specific differences in TSPO function, which could explain an 
absence of effect in global TSPO -/- mice. 
I propose that TSPO function is tissue-specific, and this explains the discrepancy 
amongst the literature regarding its role in mitochondrial function. Consequently, 
with current technology the action of TSPO can only be studied in a snapshot. A 
global TSPO -/- model or peripheral administrations of ligands will target the 
different actions across the expressing tissues. Meanwhile, to distinguish the role 
of TSPO in different tissues, conditional knock-outs or localised drug 
administration will only highlight the roles of TSPO in the targeted tissues. A 
combination of and comparison between the above approaches will provide 
informed insight to the function of TSPO. 
 
6.2 Technical limitations of the study 
 
6.2.1 Limitations of immunolabelling methods 
There are a number of advantages, as well as limitations, to 
immunohistochemical processing to examine protein expression. This was used 
in Chapter 3 to characterise the expression distribution of TSPO in the mouse 
brain. The limitations of this approach became apparent with use of the TSPO 
antibody in brain tissue from TSPO -/- mice, as I found that the antibody had off-
target binding in the brain that had not been previously documented nor 
published. Consequently, this part of the project emphasised the need to validate 
use of antibodies independent of the supplier. Validation should be performed 
with the proposed technique and protocol for experimental use, using samples 
from an appropriate knock-out animal or cell-line or one with knock-down 
expression. In addition, tissue that is known to not express the protein of interest 
can be used as a negative control. For my studies, brain TSPO distribution could 
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also have be assessed/confirmed through a slice radioligand autoradiography 
binding study, although this method has limitations on its sensitivity. 
Immunohistochemistry was also applied to investigate colocalisation of protein 
expression markers to indicate co-expression. Confocal microscopy was applied 
here in order to discern between apposition and colocalisation. This is not a 
confirmative method, and use of more powerful tools such as electron microscopy 
can provide more conclusive evidence.  
Immunohistochemical labelling of astrocytes was used to assess astrogliosis in 
the hypothalamus of diet manipulated mice. This is a useful approach, in this 
scenario, to measure the number of astrocytes alongside the ramification of their 
morphology and could not be achieved by other methods. However, while GFAP 
is a common marker, heterogeneity amongst astrocytes has been identified and 
GFAP is not a universal marker of all astrocytes (512–514).  
Western blot densitometry analysis provides more reliable quantification than 
fluorescent immunohistochemistry. However, quantification is only reflective of 
the sample processed and does not provide additional detail such as morphology 
or location. I used micropunch dissection to target specific hypothalamic nuclei. 
However, this can lead to subtle variability in the precise regions captured 
between animals. While Western blot can provide an accurate representation of 
quantitative protein expression, the multiple steps required for sample processing 
can lead to variation in the results. 
 
6.2.2 Contrasts between animal models 
This project used multiple mouse strains and models, each with their own 
limitations. As discussed previously, both the 6N and the 6J sub-strain of 
C57BL/6 mouse were used – which have different phenotypes with regards to 
metabolism. This was appropriately controlled for within my experiments. 
However, since the 6J sub-strain is more prone to diet-induced obesity than the 
6N (371–373), generation of the global TSPO -/- mice on a 6J background might 
have yielded different results.  
There were also differences in the results obtained in this project compared to 
those published with regards to PK11195 manipulation. While PK11195 can 
cross the blood-brain barrier (BBB), intra-peritoneal administration of PK11195 
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may not enter the brain and be sequestered instead by the dense TSPO 
expression in peripheral organs. This could explain the differences in my results 
compared to intra-cerebroventricular injection of PK11195 (301). Furthermore, in 
vitro studies have suggested that PK11195 has off-target effects and that its 
action at TSPO could be concentration-dependent (283). In this study, in which 
progesterone secretion was measured from MA-10 Leydig cells with and without 
TSPO expression, the dose of PK11195 that gave off-target effects was much 
lower than its dissociation constant. In my experiments of this project I used a 
much higher dose of PK11195 than these in vitro studies, which reflects other in 
vivo work with PK11195 (347). The pharmacology, and route of entry, of a ligand 
are important considerations and can introduce variability when attempting to 
reproduce previous conclusions. 
Discrepancies in results obtained were found when comparing the global TSPO 
-/- mice of this study to those that used cell-specific knock-out models. The global 
TSPO -/- mice were generated by a germline deletion, which can result in 
compensatory effects during development. These could be avoided in future 
studies by the generation of mice with a global inducible TSPO deletion. For 
example, tamoxifen-inducible Cre-recombinase generated mouse models can 
allow for global and cell-type specific deletion of TSPO expression without 
developmental compensation. Injection of viral vectors expressing Cre-
recombinase also enable site-specific knock-out. 
 
6.3 Future perspectives & outstanding questions 
 
TSPO expression and distribution in the healthy brain is still unconfirmed. It 
appears to be widespread at a low level, but particularly strong in some 
circumventricular regions as well as in the ventricle walls. Nonetheless, 
considering the lack of antibody-antigen binding specificity in these studies, these 
data would benefit replication via additional techniques such as radioligand 
binding and/or in situ hybridisation. Electron microscopy could also confirm 
colocalisation of TSPO in tanycytes as well as astrocytes and microglia. To clarify 
regulation of TSPO by energy balance in tanycytes, Western blot analysis does 
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not have the spatial resolution but quantitative data could be acquired from in situ 
hybridisation.  
In these studies, the effect of modulation of TSPO-mediated activity on food 
deprivation and re-feeding was investigated. This was due to previous reports 
suggesting that hepatic gluconeogenic enzymes regulated by fasting are 
upregulated following PK11195 treatment (347). The same study demonstrated 
a PK11195-induced decrease in fasted basal blood glucose. I did not replicate 
this effect of PK11195 on either blood glucose levels or demonstrate an effect on 
fast-induced food intake, which may be due to differences in length of food 
deprivation used. Therefore, confirmatory measurement of the same 
gluconeogenic enzyme mRNA levels by quantitative PCR (qPCR) in PK11195-
treated mice fasted for the shorter duration would provide further evidence of a 
potential function of TSPO in the liver and regulation of hepatic glucose 
production.  
Global deletion of TSPO had no impact on mouse bodyweight or food intake 
when maintained on standard chow, but there may be differences in the structure 
of TSPO-expressing metabolic tissue. Recently, observations in another global 
TSPO -/- mouse strain were published which indicated a reduction in lipid droplets 
in the liver tissue of these mice maintained on standard chow (379). Whether a 
similar effect is seen in our TSPO -/- mice is yet to be shown. 
TSPO is strongly expressed in the liver and adrenal glands, which are both key 
influencers of energy homeostasis. Cell-specific knock-out of TSPO in the 
adrenal cortex results in elevated adrenaline production, which may explain the 
elevated basal blood glucose levels in these mice (362,363). Adrenaline induces 
glucose production via hepatic gluconeogenesis (472,473). Conversely, 
treatment with the TSPO ligand PK11195 lowers blood glucose levels (347). The 
effects on hepatic glucose production from these two studies are contradictory, 
and this may explain the absence of any effect in the global TSPO -/- mice. 
Measurement of blood adrenaline levels in the global TSPO -/- mice could 
potentially discriminate the role of TSPO in these two organs. Furthermore, 
measurement of hepatic gluconeogenic enzymes from global TSPO -/- mouse 
tissue would elude to whether the absence of TSPO influences blood glucose 
and enzyme expression despite potential elevated adrenaline levels. Generation 
and characterisation of additional conditional and inducible TSPO -/- mice, in 
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comparison to the global TSPO -/- mouse line, will also provide insight to the 
differential roles of TSPO within different tissue types. 
 
6.4 Conclusions of the study 
 
The conclusion of this research project is that the function of TSPO is tissue-
dependent (Fig 6.4.1). For example, in immune cells such as glia TSPO may be 
involved in mediating metabolic flexibility (286,310,318,324,326,484). This would 
then explain TSPO regulation in reactive gliosis (227,228,286), and also its 
potential downregulation in positive energy states within the hypothalamus (as 
reported in Chapter 4). Tissue-dependent function would result in a wide range 
of effects within the organism if pharmacologically targeted, including an overall 
null outcome from compensating actions in different tissues. Adrenal TSPO is 
involved in steroidogenesis (362,363) while hepatic TSPO regulates glucose 
homeostasis (347). These tissues have downstream effects on other functions – 
such as adrenal steroidogenesis impacting blood glucose – which complicates 
interpretation of the effects of TSPO manipulation. In addition, TSPO is unlikely 
to be an appropriate target for translational use clinically.  
As well as providing information regarding TSPO function, these studies provide 
new insight into limitations of experimental approaches to investigate TSPO. I 
propose that the function of TSPO is flexible and dependent on the dynamic 
environment in which it is expressed. Multiple endogenous ligands are shown to 
bind to TSPO (235,244,317), and so this likely influences its activity in response 
to the respective levels of such ligands in TSPO-expressing cells. Furthermore, 
mitochondria are also highly dynamic (194,515,516) and TSPO forms complexes 
with other mitochondrial proteins (517–519) – which are likely to show tissue-
dependent expression, such as the case with StAR (365,520,521). The access 
of the tissue to such ligands, and the tissue expression profile of mitochondrial 
proteins, may influence TSPO activity in a cell-type specific manner through 
tissue-specific binding or mitochondrial complex formation. This would explain 
the number of discrepancies within the TSPO literature regarding its function and 





Figure 6.4.1 Visual summary of proposed TSPO function. 
TSPO regulation in glia may reflect metabolic flexibility. Reactive glia utilise different 
energy sources compared to when in the resting state. Regulation of TSPO in relation 
to reactive gliosis may reflect this change in energy substrate preference (a). 
Reduction or absence of TSPO in the adrenal gland increases adrenaline secretion 
(b), which may in turn enhance gluconeogenesis in the liver (c). However, 
downregulation or knock-out of TSPO in the liver may reduce glucose production (c) – 










Appendix 1. Full representative immunoblots that were processed with anti-
TSPO and anti-GFAP for semi-quantification of diet-induced regulation. 
Blot showing total protein stain alongside ladder, of samples taken from the ventral 
portion of the hypothalamus of mice exposed overnight to high-fat chow or food 
deprivation or standard chow control (a). The same blot, but after total protein stain 
was washed off and instead probed with anti-GFAP and anti-TSPO (b). Blot showing 
total protein stain alongside ladder, of samples taken from the dorsomedial 
hypothalamic nucleus of the same mice exposed to overnight high-fat chow or food 
deprivation or control (c). The same blot, but after total protein stain was washed off 
and instead probed with anti-GFAP and anti-TSPO for analysis (d). In both blots, the 
positive control was protein lysate from primary cultured mouse cortical astrocytes. 
The black boxes represent the outline of the blot used in Figure 4.2.1.2 (a, b) and 
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